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Abstract  
 
Haemopoietic stem cells (HSC) maintain lifelong haemopoiesis through the monitoring 
and production of cells from multiple haemopoietic cell lineages. A key property of HSC is 
their ability to maintain quiescence. Quiescence refers to a state of inactivity in which the 
cell is not dividing and remains dormant. It is this property of the HSC that is thought to 
maintain genomic integrity and to allow the HSC to sustain haemopoiesis over the period 
of a lifetime. However, the regulation of quiescence in this context is not well understood. 
Numerous studies have aimed to understand the molecular mechanisms underlying HSC 
quiescence using high-throughput approaches. A previous microarray study by our group 
aimed to understand the transcriptional differences between quiescent and proliferating 
human HSC. Data from this microarray showed that the most up regulated group of genes 
in quiescent compared to proliferating human HSC were chemokine ligands, specifically 
within the CXC family. Although this was a novel finding at the time, the biological 
function of these chemokine genes was not studied until the current work presented here. 
In this thesis, we aimed to extend foregoing research and importantly, investigate the role 
of CXC chemokines in HSC properties, using both human and mouse systems. 
First, we validated the results from the microarray study using gene expression analyses to 
show that chemokine ligands CXCL1 and CXCL2 were significantly up regulated in 
quiescent HSC (CD34+CD38-) in comparison to more proliferative progenitors 
(CD34+CD38+). Focusing on CXCL1, we showed positive expression of the ligand protein 
in human stem/progenitor cells using immunofluorescence and western blotting on human 
primary CD34+ cells. In addition, we identified positive expression of receptor CXCR2 by 
gene and protein analyses on CD34+ cells, indicating the presence of an autocrine 
chemokine signalling loop. To determine the biological function of CXCL1/CXCR2 
signalling in human HSC, we used shRNA to reduce CXCL1 expression and a 
commercially available inhibitor (SB-225002) to block CXCR2 receptor signalling. 
Experiments on cell lines expressing CXCL1 and CXCR2 (HT 1080) showed that 
reduction of CXCL1 and over-expression reduced or increased cell viability and 
proliferation respectively. Experiments on human primary CD34+ cells revealed that 
reduction of CXCL1 induced apoptosis and reduced colony formation. Similarly, inhibition 
of CXCR2 signalling in CD34+ cells using SB-225002 induced apoptosis and reduced 
colony formation in a dose dependent manner. However, due to human sample availability 
and technical challenges, experiments need repeated in order for a valid conclusion to be 
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made and statistical analysis could not be carried out for some primary experiments. In 
addition, further experimental work is required to conclusively prove that human 
stem/progenitors express CXCL1 and CXCR2 as different techniques showed varying 
results. In summary, we provide some evidence that CXCL1 and CXCR2 is expressed by 
human HSC and may be an important survival pathway in normal human HSC which 
requires further experimental data to provide valid conclusions. 
In order to gain a deeper understanding of the biological function of chemokine signalling 
in HSC biology, we used an in vivo murine system. First, we examined mRNA transcripts 
of CXC chemokines in mouse HSC populations. We screened a small selected group of 
CXC chemokines using primitive mouse HSC and single cell quantitative PCR using the 
Fluidigm™ platform. Gene expression analyses identified that Cxcr2 and Cxcl4 mRNA 
transcripts were detected including in the most rare, primitive HSC fraction. To elucidate 
the mechanism of action, we used a transgenic reporter and knock out mouse models for 
both genes of interest. Analysis of a Cxcr2 null mice model (Cxcr2-/-) validated previous 
research in which animals lacking Cxcr2 show disrupted haemopoiesis with an expansion 
of myeloid cells in the haemopoietic organs. Interestingly, within the current work, 
analysis of steady state haemopoiesis revealed an expansion of the most primitive HSC in 
the BM of animals lacking Cxcr2 and enhanced mobilisation demonstrated by an increase 
in the stem/progenitor activity in the spleen and PB. HSC functional analyses using BM 
reconstitution assays with wildtype (WT) or Cxcr2-/- HSC showed that there was a trend 
towards a reduction in engraftment in animals transplanted with HSC lacking Cxcr2. 
However, this result was not statistically significant due to high sample variability and due 
to time constraints and the length of this assay, this was not repeated. The data suggests 
that Cxcr2 expressing HSC may be important for stem cell maintenance via a cell 
autonomous mechanism however experiments are required to be repeated to draw valid 
conclusions. 
Cxcl4-Cre transgenic mice containing a RFP construct under the control of the Rosa26 
promoter (Cxcl4-Cre) showed RFP expression in HSC and progeny. RFP expression in 
HSC populations was in accordance with Cxcl4 mRNA transcripts therefore suggesting 
RFP expression was correlated with endogenous Cxcl4 expression. Interestingly, flow 
cytometry analysis identified that not all (~50%) HSC showed positive expression for RFP. 
Flow cytometry sorting of positive and negative populations revealed that cells with 
enhanced colony formation potential reside within the RFP (Cxcl4) positive fraction. To 
extend this data, we aimed to knock out and reduce Cxcl4 expression and examine the 
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phenotype. Targeted deletion of Cxcl4 in vitro using a Cxcl4 shRNA vector demonstrated 
that Cxcl4 reduction in vitro diminished colony formation in primary and secondary 
replating assays. Since data for human CXCL4 mRNA were not conclusive from the 
original microarray, we reassessed the relevance of CXCL4 in the human system. Gene 
expression analyses showed that CXCL4 transcripts were indeed detected and furthermore, 
up regulated in primitive HSC (CD34+CD38-CD90+) compared with proliferative 
progenitors (CD34+CD38+). Collectively, the data indicates that CXCL4 may play an 
important role in mouse and human HSC biology, however further experimental work is 
required to address this. 
In summary, the data presented in this thesis demonstrate that several chemokines 
including CXCL1, CXCL4 and receptor CXCR2 may have key roles in HSC survival and 
maintenance, both in the mouse and human systems. However, increased biological 
replicates and further experiments are required to draw valid conclusions. Enhanced 
understanding of the regulation of stem cell properties is critical for improving our ability 
to manipulate normal stem cells in vitro and in vivo. Furthermore, understanding normal 
stem cell regulation is fundamental for the research of diseases such as leukaemia in which 
leukaemic stem cells are less sensitive to drug treatment. 
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1 Introduction 
1.1 The history of stem cells 
Homeostasis refers to the ability of a system to maintain a stable condition, even in 
response to perturbation. An excellent example of this is the human body, which is capable 
of continuously monitoring and regulating its conditions in order to maintain a constant of 
all variables. This is elegantly demonstrated when we consider the regulation of individual 
organs within an organism. For example, the haemopoietic system is responsible for 
producing cell types of all the blood lineages over the period of a lifetime. There is a 
constant turnover of large numbers of cell types under basal conditions, which is regulated 
in response to haemopoietic stress and injury. Importantly, it is now understood that stem 
cells are heavily involved in the production and regulation of all cell types in the biological 
system, including in haemopoiesis. 
The identification of stem cells marked an important discovery in the field of biology and 
medicine. The haemopoietic system represents an important component in the stem cell 
time line, beginning with a variety of observations including the acceptance of donor bone 
marrow (BM) into irradiated hosts in the mid 1900’s (Weissman and Shizuru, 2008). 
Subsequently, experiments by Till and McCulloch demonstrated that cells, when 
transplanted into irradiated mice, produced colonies in the spleen derived from a single cell 
(Wu et al., 1967, Becker et al., 1963, McCulloch and Till, 1960, Till and Mc, 1961, 
Siminovitch et al., 1963, Magli et al., 1982). These experiments implicated that there was 
an existence of cells with clonogenic activity within the BM which are now referred to as 
colony formation units-spleen (CFU-S) (Magli et al., 1982). These experiments led to 
translational research from 1968 onward in which the first human BM transplants were 
carried out. Collectively, these were the first studies that demonstrated that a specific type 
of cell had clonogenic activity and was capable of reconstituting a whole system. Stem 
cells from the haemopoietic system were subsequently identified and isolated, which 
provided a foundation for the understanding of stem cell biology (Weissman and Shizuru, 
2008). Over the following years, stem cells have been discovered in a variety of other 
organs and these discoveries have revolutionised our understanding of how biological 
systems function.  
Stem cells have been categorised into two main groups; embryonic stem cells (ESC) and 
adult stem cells (ASC) (Sylvester and Longaker, 2004). The main distinctions between 
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cells from these groups are in terms of residency and potency. An ESC is present at the 
beginning of development in the embryo and has the potential to produce cell types from 
all lineages of the embryo, which is described by the term ‘pluripotent’. In contrast, ASC 
are tissue specific and reside in particular adult organs. These cells are limited in their 
potential to produce cell types solely from a particular organ, which is described by the 
term ‘multipotent’. Although it is generally accepted that ASC have limited potential to 
particular lineages, recent studies have suggested there is an added ‘developmental 
plasticity’ of these cells (Korbling and Estrov, 2003, Wagers and Weissman, 2004). 
Indeed, there is evidence that purified HSC are capable of producing non-haemopoietic 
cell types, however this is thought to occur through fusion of haemopoietic and non-
haemopoietic cells and is suggested to only occur during stress/injury and is a relatively 
rare event (Nygren et al., 2008).  
The fusion of gametes results in the creation of a zygote which undergoes several rounds 
of cell division to generate a structure named the blastocyst, where the ESC reside 
(Donovan and Gearhart, 2001). ESC were identified and isolated from the inner cell mass 
of the blastocyst in mouse embryos in 1981 (Martin, 1981, Evans and Kaufman, 1981). 
This discovery was the beginning of a new area of research which would later prove to 
revolutionise the field of biology. ESC have been shown in vitro and in vivo to possess the 
ability to produce cell types of every lineage (Biswas and Hutchins, 2007). Over 
subsequent years, ESC have been used for several applications. To date (more than 30 
years after their initial discovery), ESC have been used in the generation of chimeric 
mouse models and as a model to understand the mechanisms of lineage differentiation 
(Smith, 2001). Understanding the development of different lineages provides the potential 
for the production of large numbers of particular cell types for pharmacological screening 
and to create cells to be used in the treatment of disease. This has been termed regenerative 
medicine and research within this field has expanded exponentially over the past decade. 
Although proven to be a useful tool, there were issues associated with the use of ESC in 
research. An ethical debate surrounded the use of ESC experimentally as this involved the 
destruction of embryos. Furthermore, the transplantation of cells from one origin to 
patients of a different origin raised concerns of tissue rejection. 
1.2 Regenerative medicine 
The concept of generating patient specific cells became a reality with groundbreaking 
research by Yamanaka and his team. The research involved the integration of several 
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transcription factors associated with pluripotency into mature somatic cells to 
reprogramme them into a pluripotent state (induced pluripotent stem cells, IPS) (Takahashi 
and Yamanaka, 2006). This technique facilitated the idea of generating patient specific 
cells for therapy and overcame the ethical issues of using ESC and the issue of tissue 
rejection. However, the methodology in the original study was controversial as viruses 
were used to integrate transcription factors into mature cells. More recently, groups have 
developed methods to overcome this (Okita et al., 2008). Alternative strategies have been 
developed to reprogramme cell types, including nuclear transfer of somatic nuclei into 
oocytes, or the fusion of somatic cells with ESC (Yamanaka, 2007). In addition, the 
generation of IPS cells from diseased individuals has opened a new avenue of research as 
these studies provided insight into the mechanisms of disease. To date, researchers have 
successfully generated IPS cells from diseased individuals (Dimos et al., 2008, Soldner et 
al., 2009). If we focus on the haemopoietic system, IPS cells have been generated from 
haemopoietic cells derived from normal and malignant patient samples (Kumano et al., 
2013). However, a key concern that still exists is the lack of understanding about the 
mechanisms of differentiation. ASC are studied to understand the pathways involved in 
differentiation. ASC, also referred to as tissue-specific stem cells are responsible for 
maintaining tissue homeostasis and producing the cell types required in particular organs.  
Haemopoiesis has been well studied and to date serves as a model for a well characterised 
adult stem cell system (Weissman and Shizuru, 2008). Haemopoiesis is a well understood 
hierarchical model which is controlled and maintained from a stem cell population, the 
haemopoietic stem cell (HSC).  
1.3 Haemopoiesis 
Haemopoiesis is a hierarchical organisation in which the HSC are responsible for tissue 
homeostasis. Simply, the HSC reside at the top of the hierarchy and produce a cascade of 
more committed progenitor cells, which in turn produce terminally differentiated mature 
cells of all the blood lineages. Before we consider how haemopoiesis is regulated by the 
HSC population, the true characteristics of a stem cell must first be discussed. 
1.3.1 Self renewal and differentiation 
The definition of a true stem cell is the ability to elicit three main functions; self renewal, 
differentiation and the capacity to reconstitute a tissue in vivo (Roobrouck et al., 2008). To 
understand self renewal and differentiation, cell division must be discussed. 
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Mitosis is the process of cell division in which two daughter cells are generated. HSC can 
undergo symmetric and asymmetric cell divisions, which ultimately decides the daughter’s 
cell fate (Morrison and Kimble, 2006, Domen and Weissman, 1999). Symmetric cell 
division involves the production of two identical daughter cells after mitosis. These 
identical cells can either be two HSC or two more differentiated daughter cells (Weissman 
and Shizuru, 2008). In this way, HSC can be produced which will either maintain the stem 
cell pool or more differentiated progeny can be produced which will ultimately provide 
mature cell types to replenish lost blood cells. In addition to symmetric cell division, HSC 
can also undergo asymmetric cell divisions in which progeny are produced that are not 
identical. Asymmetric division produces one stem cell and one differentiated cell. The 
combination of symmetric and asymmetric cell division is ultimately responsible for the 
maintenance of the haemopoietic system with the production of mature cell types when 
required while maintaining a functional stem cell pool (Figure 1-1) (Weissman and 
Shizuru, 2008).  
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Figure 1-1 Symmetric versus asymmetric cell division. 
HSC can undergo symmetric and asymmetric cell division in which identical progeny or 
two different progeny are generated respectively. Symmetric cell division can produce two 
identical HSC or more differentiated progenitors. Asymmetric cell division results in the 
production of one HSC and one progenitor. The combination of symmetric and asymmetric 
cell divisions ultimately controls haemopoiesis through the maintenance of a stem cell pool 
and the production of a cascade of more mature progenitors. 
The majority of research on asymmetric cell division has been carried out using 
developmental model organisms including the Drosophila melanogaster (Morrison and 
Kimble, 2006, Gomez-Lopez et al., 2013). Studies have shown that both intrinsic and 
extrinsic mechanisms govern cell division. As an example, cell polarity and the distribution 
of cell components/proteins occurs prior to cell mitosis and governs subsequent cell fate. 
This has been shown in stem cells including in HSC, in which several proteins were found 
to segregate differentially after cell division (Gonczy, 2008, Beckmann et al., 2007). In 
addition, external mechanisms also control cell division with evidence that cell location 
alters the ultimate cell fate (Morrison and Kimble, 2006). The decision of symmetric 
versus asymmetric division is important not only for cell fate in normal development, but 
also in disease as previous studies have highlighted that asymmetric divisions are 
deregulated in cancer (Morrison and Kimble, 2006, Gomez-Lopez et al., 2013).  
Self renewal is a fundamental property of HSC and it is thought that self renewal capacity 
is reduced as cell division occurs. Therefore more mature cells, including progenitor cells, 
show a reduced capacity to self renew. Differentiation is described as the production of a 
more mature, specialised cell down a particular lineage. HSC balance the processes of self 
renewal and multilineage differentiation to maintain a pluripotent HSC population poised 
to give rise to appropriate cell types when required including in response to blood loss, 
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infection or exposure to cytotoxic agents and oxidative stress (Seita and Weissman, 2010, 
Wilson et al., 2008).  
Self renewal and differentiation are key to HSC function and can be measured 
experimentally. For simplicity, mouse and human experiments will be discussed 
separately.  
1.3.1.1 Mouse 
Both in vitro and in vivo assays can be used to experimentally to examine self renewal and 
differentiation. In vitro colony formation assays (colony formation cell, CFC assay) are 
widely used. This assay involves the culture of cell populations with the addition of 
particular cytokines designed to drive proliferation and differentiation. Cells are cultured 
for a period of time and the resulting colonies formed can be scored based on enumeration 
and classification of colonies. This gives an indication of proliferation and differentiation 
capacity. This assay is considered an assay for more mature progenitor cells, however, the 
colonies derived from a primary plating assay can be replated into a secondary plating 
assay in which the growth of colonies can act as an indicator for self renewal capacity. 
However, a CFC assay is relatively short term and is therefore more indicative of 
progenitor cell activity. The long-term culture initiating cell (LT-CIC) assay allows the 
detection and enumeration of the HSC population (Woehrer et al., 2013). In this assay, 
cells are plated on a layer of stromal cells (designed to mimic in vivo conditions) which 
support the survival, self renewal and differentiation of HSC. These cultures are 
maintained long term to identify true HSC populations in comparison to shorter 
experiments which identify progenitor populations only. In addition, limiting dilution of 
cell populations are used to give an indication of the frequency of LT-CIC per population. 
The cobblestone area forming cell (CAFC) assay involves the culture of a test population 
on a stromal layer and particular areas of HSC growth termed ‘cobblestones’ are scored 
based on stem/progenitor growth over a period of time (Breems et al., 1994, de Haan and 
Ploemacher, 2002). 
However, in vivo experiments have provided unique insights into stem cell behaviour and 
are arguably more accurate in terms of quantifying HSC than in vitro assays (Domen and 
Weissman, 1999, Perry and Li, 2010). The CFU-S assays (as described previously) can 
provide an in vivo indication of stem/progenitor cell activity. The production of distinct 
colonies grown on the spleen of irradiated animals refers to the clonogenicity activity of 
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transplanted cells. Spleens are typically analysed on days 8 and 12 with the latter referring 
to a more primitive clonogenic cell than the former (Weissman and Shizuru, 2008). 
However, this assay is thought to involve more mature progenitor cells as opposed to stem 
cells due to the short time frame of the assay. The gold standard technique for assaying 
HSC function is the reconstitution of an ablated/diminished haemopoietic system 
(Harrison, 1980). A cell population can be transplanted into mouse models in which 
endogenous haemopoiesis has been ablated using irradiation or chemotherapy drug 
treatment. A true HSC will be capable of reconstituting the BM and providing progenitor 
and subsequent mature cells therefore rescuing haemopoiesis. Competitive repopulation 
involves the transplantation of donor test cells along with support BM cells which ensures 
host survival and markers can be used to elegantly track donor transplanted populations 
over time. Examples for host versus donor distinction are sex, expression of reporter genes 
or arguably the most commonly used, expression of cluster of differentiation (CD) cell 
surface markers including isoforms of CD45 (van Os et al., 2001, Domen and Weissman, 
1999). CD45 was originally known as the leukocyte common antigen as is expressed on all 
leukocytes (Trowbridge and Thomas, 1994). Two alleles of CD45 are available and mouse 
strains have been developed with each allele on a C57/BL6 background (van Os et al., 
2001). The generation of monoclonal antibodies against these alleles allowed for the 
distinction between donor versus host in competitive transplantation assays (Weissman and 
Shizuru, 2008). Limiting dilution experiments using a titration of the number of 
transplanted HSC are used and are more reliable in terms of quantifying the number of true 
stem cells in a population (Perry and Li, 2010). HSC transplantation assays not only give 
an indication of mutlilineage reconstitution, however self renewal can be experimentally 
examined through the ability of test populations to rescue haemopoiesis in secondary and 
tertiary recipient mice and these are the most stringent assays to report stem cell self 
renewal and therefore activity.  
1.3.1.2  Human 
Similar to in vitro assays described for mouse studies, the CFC, LT-CIC and CAFC assays 
can be used to assay human stem/progenitor behaviour (Domen and Weissman, 1999, Liu 
et al., 2013, Sarma et al., 2010, de Haan and Ploemacher, 2002). More recently, literature 
is emerging in which 3-dimensional structures are used to model the BM niche (Sharma et 
al., 2012). As discussed with the mouse in vitro assays, these assays are arguably not 
measuring true HSC activity.  
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The ability to transplant HSC into irradiated hosts and compare their differentiation and 
self renewal capacity has become a standard technique. However, studying human HSC is 
more complex. The use of immunocompromised mouse models as hosts for human HSC 
was a groundbreaking discovery in HSC research (Meyerrose et al., 2003). Original 
research showed that human haemopoietic tissue could engraft in immunocompromised 
(severe combined immunodeficient, SCID) mice which have a mutation resulting in 
defects in B and T cell development (Lapidot et al., 1992, Mosier et al., 1988). However, 
these mice still have natural killer cells which can attack foreign cells and therefore hinder 
the experiment. In order to study immune responses, there are other models available 
however further immune compromised mouse models have since been generated which 
work well as HSC xenograft models. Since this research, a variety of models have been 
described including non obese diabetic (NOD) SCID animals. These animals have 
additional defects in natural killer cell, macrophage and complement. Additional strains 
including, but not limited to, NOD/SCID/β-2-Microglobulin (β2M), NOD/SCID/IL-2R-γ-/- 
mice or RAG2-/- / IL-2R-γ-/- models are used which show more immunodeficiency than the 
NOD/SCID animals (Park et al., 2008, van der Loo et al., 1998, Wermann et al., 1996). 
Such models are commonly used in the literature and allow for the tracking of human HSC 
activity without the complications arising from  rejection of the foreign transplanted cells 
by the host immune system (Domen and Weissman, 1999). However, disadvantages of 
using these mice include a shortened lifespan and their extreme sensistivity due to their 
compromised immune systems (Meyerrose et al., 2003). A diagram is displayed in Figure 
1-2 for examples of the different assays available. 
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Figure 1-2 Commonly used methods for assaying HSC activity. 
Schematic is adapted from published literature and based on the literature described above 
(Domen and Weissman, 1999). Various techniques have been developed to assay HSC 
activity. In vitro techniques include the culture of cell populations in particular growth 
conditions in which resulting colonies can be identified to give an indication of 
proliferation and differentiation status (CFC). LT-CIC and CAFC assays monitor cell 
growth over a longer time period in a co-culture with stromal cells to assess more primitive 
HSC activity. In vivo techniques involve the transplantation of cells into irradiated 
recipients where colonies grown on the spleen (CFU-S) or the capacity for multilineage 
reconstitution is evaluated. Donor cell activity can be tracked using various methods to 
distinguish host versus donor cells. Self renewal activity can be examined using the serial 
transplantation of cells into secondary and tertiary irradiated recipients. Mouse models for 
the transplantation of human HSC involve various immunocompromised mouse models of 
which the most common are stated. (Dr Francesca Pellicano and Dr Arunima 
Mukhopadhyay should be acknowledged for the CFU-S and LT-CIC images respectively).  
1.3.2 The haemopoietic hierarchy 
Irving Weissman’s haemopoietic hierarchy hypothesis arose from work conducted in his 
laboratory beginning in 1998. This research was revolutionary and is now a generally 
accepted dogma (Weissman and Shizuru, 2008). The hypothesis was formed based on the 
stem cell activity of different mouse populations isolated using immunophenotypic cell 
surface markers. More specifically, cell sorting was used to isolate different cell types and 
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their activity was measured using BM reconstitution assays. These experiments identified 
that different populations of cells vary in terms of their ability to reconstitute the 
haemopoietic system. Furthermore, these experiments identified that certain cell types 
were capable of long term reconstitution (over a long period) while other cell types lost 
their potential for reconstitution over time. It was identified that a true HSC has a high 
capacity for multilineage differentiation and self renewal which allowed these cells to 
maintain haemopoiesis over a lifetime. 
Based on these assays, the hypothesis states that the HSC population resides at the top of a 
haemopoietic hierarchy with a distinct population known as the LT-HSC (long term 
repopulating HSC). Experiments using transplantation of different populations into 
irradiated hosts identified that different populations showed differences in 1. the ability to 
reconstitute haemopoiesis and 2. the ability to results in multilineage reconstitution long-
term (Weissman and Shizuru, 2008). The LT-HSC possess the ability to give multilineage 
reconstitution long term (at least 6 months) in a host with an ablated haemopoietic system 
(Weissman and Shizuru, 2008). Furthermore, these cells can be transferred to secondary 
hosts and will successfully maintain haemopoiesis. LT-HSC can give rise to a less 
primitive HSC population known as the ST-HSC (short term repopulating HSC) which has 
a reduced capacity for self renewal and repopulation i.e. cannot sustain haemopoiesis up to 
6 months post transplantation and will not rescue haemopoiesis in a secondary host. HSC 
populations give rise to cells termed multipotent progenitor (MPP) populations which have 
limited self renewal and reconstitution potential. Similarly, experiments identified that 
populations can only give rise to particular cell lineages, providing evidence that more 
mature lineage restricted progenitor populations exist (Weissman and Shizuru, 2008). 
These are now referred to as a common myeloid progenitor (CMP) and common lymphoid 
progenitor which are capable of producing cell types of the myeloid and lymphoid lineages 
respectively (CLP) (Akashi et al., 2000, Kondo et al., 1997).  Similarly, the CMP 
population gives rise to more mature progenitors in an intermediate stage named the 
granulocyte/macrophage progenitor (GMP) and megakaryocyte/erythroid progenitor 
(MEP) populations, which give rise to cell types of the myeloid lineage and which do not 
self renew. A simplified schematic of the haemopoietic hierarchy can be visualised in 
Figure 1-3.  
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Figure 1-3 The haemopoietic hierarchy. 
Schematic diagram adapted from published literature displaying the haemopoietic 
hierarchy as it is currently understood (Weissman and Shizuru, 2008). The haemopoietic 
system is a hierarchical system which is regulated and maintained by the HSC which reside 
at the top of a cell hierarchy. The LT-HSC are the most primitive cells which have the 
ability to reconstitute haemopoiesis in an ablated system and have a high capacity for self 
renewal. LT-HSC give rise to a more mature ST-HSC population which gives rise to a 
more mature progenitor population known as the MPP. HSC populations balance self 
renewal and differentiation to produce a cascade of more mature progenitor cells which are 
ultimately responsible for generating all of the diverse cell types of the myeloid and 
lymphoid lineages. The transition of HSC to mature cells results in a reduction in self 
renewal and long term repopulating capacity, which is associated with an increase 
differentiation.  
It is generally understood that the sequence of differentiation stemming from the LT-HSC 
through to terminally differentiated cell types is irreversible with the generation of more 
lineage committed cells at each stage (Bryder et al., 2006). For example, it is proposed that 
cells after the MPP stage are either lineage restricted CMP or CLP which are subsequently 
destined for myeloid or lymphoid status respectively (Akashi et al., 2000, Kondo et al., 
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1997). Some controversy over the potential of ST-HSC and MPP populations has arisen 
with the suggestion that priming for myeloid or lymphoid potential occurs at an earlier 
stage than previously proposed (Buza-Vidas et al., 2007). An alternative hypothesis has 
been put forward in which there is the existence of an additional lymphoid primed MPP 
(LPMPP) population. It is likely that the original Weissman hypothesis represents a 
simplified version of the haemopoietic system and there is additional complexity and 
plasticity involved. However, future research is required to address this in more detail. 
The identification and isolation of cell populations has facilitated our understanding of 
HSC biology. Since the original experiments were carried out by Weissman et al on the 
identification and isolation of mouse HSC populations, an abundance of literature has 
extended this research. New markers have since been identified which have selected for a 
more enriched, primitive HSC populations.  
1.3.3 HSC identification and isolation 
The study of stem cells requires the ability to identify and isolate these cells for 
experimental research. HSC are generally identified due to their lack of expression of 
lineage positive cell markers and low staining of side population using DNA and RNA 
stains which will be discussed in detail in this section.  
The discovery of HSC populations expressing particular cell surface markers has allowed 
for the identification and isolation of these populations (Wognum et al., 2003). There is 
some overlap between human and mouse HSC populations in terms of identification. For 
example, in both species HSC are identified through their lack of expression of lineage 
markers and low staining of DNA and RNA stains. HSC from both mouse and human are 
identified as existing in a population that are negative for staining of CD markers 
commonly expressed on mature lineage cells, including erythroid, granulocyte, B and T 
cells (defined from onwards as lineage negative). The addition of nucleotide stains, 
including RNA and DNA stains, has enhanced this population. As an example, Hoechst 
33342 was identified as marking HSC populations in 1996 and was subsequently referred 
to as the side population (SP). Experiments showed that the most primitive HSC effluxed 
the dye which identified Hoechst 33342 negative cells as stem cells (Goodell et al., 1996, 
Goodell et al., 1997). ABC/G2 transporters are selectively expressed on stem cell 
populations are thought to result in the efflux of Hoechst 33342 solely in stem cell 
populations (Zhou et al., 2001, Kim et al., 2002).  
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However, the species will be discussed in more detail separately due to differences in 
expression of cell surface markers between species.  
1.3.3.1 Mouse 
Animal studies have provided vast advances in the identification and isolation of HSC and 
progenitor populations. In 1986, cells which were negative for a cocktail of lineage 
markers were identified as a population enriched with mouse cells that had reconstitution 
potential (Muller-Sieburg et al., 1986). In 1988, cells which were additionally negative for 
CD90 and positive for Sca-1(ly-6 A/E) were shown to reconstitute haemopoiesis in a 
proportion of recipients with ablated BM with only the cells positive for Sca-1 having the 
capacity for in vivo reconstitution (Spangrude et al., 1988).  This research was extended to 
include c-Kit (CD117) as a positive marker for HSC, also known as the cell surface 
receptor which binds to stem cell factor (SCF) (Ogawa et al., 1991, Ikuta and Weissman, 
1992). The combination of lineage negative with Sca-1 and c-Kit positive markers (lineage 
negative, Sca-1+, c-Kit+; LSK) was identified as the population containing all the HSC 
activity (Uchida et al., 1994). However, this population is now known to be heterogeneous 
and contains a mix of stem cell populations with progenitor cells (Bryder et al., 2006). 
Subsequently after these initial investigations, research by the Weissman, Jacobsen, 
Nakauchi and Morrison laboratories collectively identified markers which allowed for the 
isolation of purer HSC populations. Interestingly, one of these markers, CD34, was found 
to be a negative marker of LT-HSC in contrast to evidence from the human studies. The 
addition of LSK with the negative selection of cell surface markers CD34 and Flk-3 was 
reported to give rise to long term haemopoiesis with the acquisition of these markers 
selecting for ST-HSC and MPP populations (Osawa et al., 1996, Christensen and 
Weissman, 2001). More recently and arguably most commonly used in the literature are 
the cell surface markers CD150 (more commonly referred to as SLAM), CD244 and CD48 
(Kiel et al., 2005). Currently LSKCD150+CD48- and LSKCD34-Flk-3- are the most 
commonly used sets of markers for LT-HSC identification in the mouse system. The 
former is arguably the most commonly used method for identification, due to the positive 
selection of marker CD150. Using this marker showed approximately 50% of the LT-HSC 
gave rise to BM reconstitution (Kiel et al., 2005). These studies bring us closer to 
identifying a HSC population capable of 100% BM reconstitution. This is the purest 
population currently available for mouse HSC to date. A figure with the most up to date 
mouse HSC hierarchy is displayed (Figure 1-4). Committed progenitor cell types are well 
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defined in the mouse system with a combination of cell surface markers including CD127, 
CD34 and CD16/32 (Doulatov et al., 2012). 
 
Figure 1-4 Mouse haemopoietic hierarchy. 
Schematic demonstrates the most recent mouse haemopoietic hierarchy. The boxes denote 
the cells used to identify human stem/progenitors in this study. The box marked in red 
identifies the LT-HSC (lineage-c-Kit+Sca-1+CD150+CD48-) used throughout in chapters 4 
and 5 and used widely in the literature to separate identify LT-HSC. The ST-HSC and 
progenitor populations used in this study are described more detail in the materials and 
methods chapter 2 and were used widely in the literature at the time of doing the 
experiments in this thesis. Information in this schematic is based on the literature discussed 
in section 1.3.3.1.   
1.3.3.2 Human 
Focusing on human studies, early experiments identified that positive expression of CD34 
marked a rare population of BM cells which were enriched for colony formation and 
capable of in vivo reconstitution of immunocompromised mice (Berenson et al., 1988, 
Sutherland and Keating, 1992, Civin et al., 1984, Andrews et al., 1989). Collectively, these 
studies suggested that CD34 marked a population of cells with stem/progenitor activity. In 
addition, the CD34 protein has also been shown to be expressed on endothelial cells (EC) 
and embryonic fibroblasts (Krause et al., 1996). To date, human HSC are now commonly 
identified in the literature as expressing CD34. It is a well known marker of a 
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heterogeneous stem/progenitor cell population (Stella et al., 1995). Experiments have 
detected stem cell activity in the CD34- fraction of human cells which indicated that CD34 
is not a marker of all stem and progenitor populations (Bhatia et al., 1998, Goodell et al., 
1997, Sonoda, 2008). Recently, a study has shown that this population in combination with 
additional marker CD93 does function as a HSC population and is more primitive than 
CD34+ cells suggesting CD34- cells are at the pinnacle of the haemopoietic hierarchy 
(Anjos-Afonso et al., 2013, Danet et al., 2002). However, this research is novel and to date, 
CD34 is widely used in experimental haematology and clinical haematology in which 
CD34+ cells are isolated and used for stem cell transplantation (Wognum et al., 2003). 
Interestingly, although CD34 is widely used as a human stem/progenitor marker, the 
function of the CD34 protein is not well understood. It is thought that this is due to a lack 
of data on functional assays on the protein as discussed in a detailed review (Nielsen and 
McNagny, 2008). As CD34+ cells are known to represent a heterogeneous population 
containing stem and progenitor cells, additional surface markers have been sought after in 
order to further enrich the human stem cell population. Additional marker CD133 has been 
reported (Yin et al., 1997). However, more recent evidence suggest CD133 does not mark 
only stem cells but also more mature cell types (Meregalli et al., 2013). CD38 is a cell 
surface marker known to play roles in immunity, cell adhesion and calcium signalling 
(Mehta et al., 1996). Experiments have shown that a small proportion of CD34+ cells 
express the CD38 protein (<10%) therefore representing a rare population of CD34+CD38- 
cells (Bhatia et al., 1997). The combination of CD34 with CD38 showed that the 
CD34+CD38- and CD34+CD38+ fractions differed in terms of cell cycle status and stem 
cell activity, including reconstitution into immunocompromised mice (Bhatia et al., 1997, 
Civin et al., 1996). These cell surface combinations are now widely used in studies with 
the CD34+CD38- fraction representing a more primitive subset of cells. However, further 
purification of this population can enrich the stem cell population, for example by using 
the combination of CD34 and CD38 with CD45RA and CD90 (Thy-1). In addition, 
rhodamine123 has been used as a dye to mark stem cells which are negative for the dye. 
Briefly, rhodamine123 is a dye that labels mitochondria with increasing intensity 
proportional to cellular activation (Kim and Broxmeyer, 1998). CD45RA is a member of 
the CD45 family that is highly expressed on naive T lymphocytes; whereas CD90 is 
commonly used to identify thymocytes, but has also been implicated in a variety of 
different processes (Streuli et al., 1987, McKenzie et al., 2007, Mayani et al., 1993, Baum 
et al., 1992). Recently the combination of markers was used to identify a population with 
stem cell activity (CD34+CD38-CD45RA-CD90+) however the population containing 
CD90- cells also showed engraftment in serial transplantation assays (Notta et al., 2011, 
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Majeti et al., 2007). More recently, the addition of CD49f was conclusively shown to be a 
specific HSC marker and it was shown that the MPP population lost expression (Notta et 
al., 2011). CD49f is a member of the integrin family which associates with either integrin 
β1 or β4 to form receptors for laminin and Kalinin. It is expressed on a monocytes, T cells, 
platelets, endothelial and epithelial cells, and is involved in adhesion or co-stimulation for 
T cell activation/proliferation (Hughes, 2001).  Although some controversy still exists, 
collectively CD34+CD38-CD45RA-CD90+CD49f+ cells represent the highest reported 
purity of human HSC to date and a figure is displayed in Figure 1-5. Humans have well 
defined cell surface marker expression committed progenitor cell types using CD135, 
CD10 and CD7 (Doulatov et al., 2012). Although human HSC identification has 
progressed, human markers of the stem and progenitor populations in haemopoiesis are not 
as well identified as in the mouse system.  
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Figure 1-5 Human haemopoietic hierarchy. 
Schematic demonstrates the most recent human haemopoietic hierarchy. The boxes denote 
the cells used to identify human stem/progenitors in this study. The boxes marked in red 
identify HSC (CD34+CD38-) with MPP (CD34+CD38+) used throughout in chapter 3 and 
used widely in the literature to separate HSC with more mature progenitor populations. 
The green boxes denote HSC (CD34+CD38-CD90+) with MPP (CD34+CD38-CD90-) and 
more committed progenitors (CD34+CD38+) used in chapter 5 which is used widely in the 
literature. Information in this diagram is based on the literature discussed in section 1.3.3.2.  
Due to the identification of cell surface markers expressed by human and mouse HSC 
populations, flow cytometry cell sorting has emerged as the best technique for the isolation 
of HSC populations. Cell sorting using flow cytometry allows for the isolation of 
individual cells which is ideal for stem cell biology in which these cells are so rare. This 
also allows for the study of the stem cell behaviour at a single cell level. The ability to 
identify and isolate HSC from their environment allows for their study and this approach 
has enabled us to understand their behaviour. 
1.3.4 HSC cellular fates 
In addition to self renewal versus differentiation, HSC can undergo alternative cellular 
decisions (Domen and Weissman, 1999). It is understood that the numbers of HSC are 
fairly constant over the period of a lifetime and it is thought that this is a tightly regulated 
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process. One of the mechanisms to ensure that HSC numbers are regulated over the period 
of a lifetime is programmed cell death. 
Apoptosis is understood to be a molecular mechanism which regulates numbers of cells 
within the haemopoietic system.  Known regulators of apoptosis in the HSC population, 
include members of the BCL family (Domen and Weissman, 1999, Domen et al., 2000). 
The over expression of BCL-2 in the HSC compartment was shown to result in altered 
HSC numbers and activity in competitive transplantation assays (Domen et al., 2000). In 
addition to members of the BCL family, other candidates are involved including the anti-
apoptotic protein MCL-1 (Opferman et al., 2005). 
When we discuss cell death it is also important that we consider not only programmed cell 
death, but other mechanisms. Autophagy is a key survival process in which cellular 
components are degraded to maintain cell survival at basal levels and in response to stress 
(Murrow and Debnath, 2013). Recent research has identified that autophagy plays an 
essential role in HSC maintenance (Mortensen et al., 2011a, Mortensen et al., 2011b). 
Further research identified autophagy as a mechanism which protected HSC from 
metabolic stress with forkhead family transcription factor member FOXO3a proven to be a 
key mediator of this process (Warr et al., 2013). 
The majority of HSC reside in the BM, however these cells can traffic into and out of 
circulation and home to sites of extramedullary haemopoiesis, which is termed as HSC 
mobilisation. Mobilisation plays important roles throughout development, with the 
migration of HSC to different sites of haemopoiesis and in the adult at basal levels. In the 
adult, the egress of HSC into the periphery is modulated in response to inflammation, 
stress or injury (Ratajczak and Kim, 2012). Furthermore, the administration of 
pharmacological agents has been found to increase HSC mobilisation. This process can be 
exploited with exogenous addition of particular cytokines which are shown to enhance 
mobilisation above basal levels.  Mobilisation through cytokine treatment is also routinely 
used in clinical therapy to mobilise the donor stem cells from BM to the PB so they can be 
more easily harvested prior to transplantation. The majority of understanding of HSC 
mobilisation is with the use of cytokine stimulation granulocyte-cell stimulating factor (G-
CSF) and chemokine receptor CXCR4 and ligand CXCL12 (Whetton and Graham, 1999). 
Although the mechanism of action is not clear, proposed mechanisms include the 
involvement of granulocytes, metalloproteinases (MMP) and proteolytic enzymes 
(Ratajczak and Kim, 2012). 
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The combination of the diverse cellular fates faced by the HSC allows the HSC population 
to be tightly regulated. As an example, when the HSC population becomes too large, 
apoptosis is induced and vice versa. Similarly, in response to haemopoietic injury or stress, 
differentiation is induced, ultimately leading to constant numbers of HSC and the stable 
production of a cascade of mature cell types. In addition to the cellular fates outlined 
above, HSC are known to exist in different stages of the cell cycle (Figure 1-6). As HSC 
face cellular decisions of self renewal versus differentiation it seems likely that the HSC is 
a dynamic, active population. However, surprisingly it is known that the majority of HSC 
exist in a quiescent state.  
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Figure 1-6 HSC cell fate decisions. 
Schematic diagram is adapted from published literature (Domen and Weissman, 1999). 
HSC face several fate decisions that are thought to be controlled by both intrinsic and 
extrinsic mechanisms. The majority of steady state HSC are quiescent, however they can 
also reversibly move into an active stage of the cell cycle (A) in which they can either self 
renew through symmetric cell division or differentiate through asymmetric or symmetric 
cell division (C). HSC can reside within the BM niche or they can migrate into the 
circulation, which occurs at low levels during steady state haemopoiesis, but may be higher 
in response to stress or haematological injury (B). HSC respond to external signals and 
balance survival with cell death by programmed cell death (apoptosis) or autophagy in 
order to maintain a constant size of the HSC pool (D).  
1.3.5 HSC kinetics 
When HSC are in an active state of the cell cycle they have the option to follow paths of 
self renewal or differentiation via asymmetric and symmetric cell division. However, 
studies examining the cell cycle status of HSC populations have identified that the majority 
of HSC are inactive and only a small percentage of HSC are actively proliferating. 
Quiescence is now known to be a common property in stem cells. It is this function that is 
thought to be crucial for the ability of stem cells to maintain homeostasis and the capacity 
to respond to stress or injury with regeneration over the period of a lifetime. In particular, 
it’s believed that the quiescent phenotype is to preserve genomic integrity and to ‘escape’ 
stress from external stimuli (Pietras et al., 2011, Li and Bhatia, 2011). it is generally 
A B 
C D 
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accepted that the majority of HSC are quiescent and are only induced to proliferate at low 
levels during basal haemopoiesis and at higher levels due to haematological stress (Li and 
Clevers, 2010). 
Quiescence refers to a cell in a state of dormancy or inactivity in which the cell is not 
dividing, therefore is in G0 phase of the cell cycle. Quiescence should not be misinterpreted 
with other processes in which cells are moved to G0, including senescence. Quiescence is 
viewed as a temporary state of inactivity in which cells are held in G0 but can re-enter the 
cell cycle in response to particular stimuli. Instead, senescence has been defined as a form 
of replicative cell death in which proliferation is irreversibly arrested (Campisi, 2013). 
Senescence is known to be induced in response to stimuli including DNA damage, 
epigenetic changes or activation of tumour suppressor genes. Although there is some 
literature to suggest senescence may not be completely irreversible, there is a distinction 
between quiescent and senescent cells and it is generally accepted that senescent cells do 
not re-enter the cell cycle. 
Experiments using the stem cell hair follicle system used dyes which were diluted upon 
cell division and identified that a proportion of cells were ‘label retaining’ (Cotsarelis et 
al., 1990). Similar observations were made in other systems containing stem cells, 
including the gut epithelium and epidermis (Cheung and Rando, 2013). Experiments in the 
haemopoietic system identified that adult HSC are mostly quiescent, with around 1-3% in 
cycle and 90% in G0 (Harrison and Lerner, 1991, Goodell et al., 1996, Bradford et al., 
1997, Cheshier et al., 1999). These cells were also shown to exhibit low RNA content and 
absence of markers involved in cell proliferation (Cheung and Rando, 2013). 
Haematological stress using chemotherapeutic reagent 5-fluorouracil (5-FU), results in the 
killing of mature, cycling cells and essentially depletes the BM system. Experiments found 
that the HSC population moved into an active cell cycle state in response to 5-FU 
treatment and replaced the haemopoietic system with the production of progenitors and 
subsequently mature cell types (Harrison and Lerner, 1991, Van Zant, 1984, Goodell et al., 
1996, Dixon and Rosendaal, 1981). A global gene expression analysis demonstrated that 5-
FU induced a proliferative signal in the HSC, which resulted in a preparative state in the 
HSC population. This was followed by active proliferation, before being re-introduced into 
quiescence depicted by distinct gene expression patterns at each stage (Venezia et al., 
2004). Collectively, these studies suggest that the majority of HSC are in a state of 
quiescence, allowing cells to be ‘poised’ for entering the cell cycle to give rise to mature 
blood cells when required, while maintaining a dormant stem cell pool.  The balance of 
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quiescence and proliferation is controlled for longevity and also for protection from genetic 
damage and stem cell exhaustion (Pietras et al., 2011). 
What are the molecular mechanisms which underlie cell fate decisions? Evidence has 
shown that a combination of both intrinsic and extrinsic mechanisms are involved which 
will be discussed below. 
1.3.6 Intrinsic regulation of HSC behaviour 
Intrinsic factors which regulate HSC behaviour are cell autonomous which are already 
embedded within the cell. Factors include gene and miRNA expression, epigenetics, 
metabolism and protein expression including post translational modifications. A brief over 
view of the mechanisms involved in the intrinsic regulation of HSC behaviour are 
discussed. 
The ability to identify and isolate rare HSC populations has allowed gene expression 
analyses. The identification of highly expressed genes in primitive HSC populations and 
studies using knock down or over expression has facilitated our understanding on their role 
in HSC maintenance. Genes previously identified include members of the Homeobox 
family (HOX) of genes, Polycomb (PCG) and Wnt families of genes (Eckfeldt et al., 
2005). As quiescence is fundamental to HSC behaviour, genes involved in cell cycle 
regulation have been identified to be essential for HSC maintenance, including the Cyclin 
family members (Pietras et al., 2011, Zon, 2008). Furthermore, studies have shown that 
signalling pathways fundamental to development are also essential for HSC maintenance. 
These include the bone morphogenetic protein (BMP) family members, Notch and 
Hedgehog signalling (Eckfeldt et al., 2005). In addition, genetic mutations involved in 
malignancies of the haemopoietic system have been reported to regulate normal HSC 
including Scl and Lmo2. Finally, chemical treatment has identified particular 
genes/pathways fundamental for HSC maintenance. Examples include retinoic acid and 
prostaglandin E2 which were found to alter signalling pathways involved in HSC 
maintenance including HOX and BMP pathways
 
(Zon, 2008).  
It is not solely gene expression which is fundamental for controlling HSC behaviour. In 
addition, there is the added complexity of protein expression and post translational 
modifications which can occur. Furthermore, transcription factors, epigenetics and 
microRNA (miRNA).are involved. Transcription factors including p53, Runx1, Cbp and 
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Gata2 have been identified to be essential for HSC maintenance (Pietras et al., 2011, Zon, 
2008). MiRNA are a class of small noncoding RNA that are involved in the regulation of 
gene expression. More recently, miRNA were identified to be fundamental for intrinsic 
HSC regulation (Zhao et al., 2013, Alemdehy and Erkeland, 2012). Finally, modifications 
of chromatin are involved and it has been shown that epigenetic regulators including E2H2 
and MLL are necessary for HSC self renewal (Zon, 2008).  
Experiments have identified that HSC reside in a location which is of low oxygen levels 
(Zhang and Sadek, 2013). Over the past several years, studies have shown that HSC have 
lower rates of oxygen consumption and master regulators of metabolism including 
hypoxia-inducible factors (HIF) have been shown to be essential for HSC maintenance. It 
has now been identified that various aspects of metabolism including mitochondrial 
respiration and oxidative stress are fundamental for HSC activity.  
It is clear that a complex network of gene, protein and other regulatory mechanisms are 
involved in the functioning of the HSC through intrinsic mechanisms. However, to add to 
this complexity, cell fate is not solely controlled by mechanisms intrinsic to the HSC. HSC 
behaviour is regulated by extrinsic factors which include growth factors (GF) and 
signalling pathways from within the BM niche where the adult HSC reside. 
1.3.7 BM niche 
There are distinct phases and locations of haemopoiesis which occur over the period of a 
lifetime. These can be divided into haemopoiesis during development in the early embryo 
and in the adult. 
Studies have aimed to identify and understand where and when the first haemopoietic cells 
appear in the early embryo. Studies on haemopoiesis in early development have been 
facilitated using the embryos of model organisms, including the zebrafish, chick and 
mouse. In the developing embryo, the first haemopoietic cells have been identified to 
appear in the yolk sac and blood islands of the chick embryo (Dzierzak and Speck, 2008). 
In terms of the first HSC, elegant transplantation studies collectively identified that the first 
HSC appear at embryonic day 10.5 (E10.5) in the aorta-gonad-mesonephros (AGM) region 
of the developing embryo (Ivanovs et al., 2011). Experiments using explants of particular 
regions identified that these cells at this stage and region were capable of long term, 
multilineage reconstitution of irradiated hosts (Dzierzak and Speck, 2008). Some 
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controversy exists about whether the first HSC can be found in the AGM region or exist at 
an earlier timepoint of development in the yolk sac (Samokhvalov et al., 2007). During 
mid to late gestation, HSC migrate to the fetal liver, which is an important site of 
haemopoiesis in early development and they subsequently migrate to the predominant site 
of adult haemopoiesis, the BM. 
Bone cavities are formed during early embryogenesis, the HSC migrate to the endosteum 
after birth and this remains the predominant site of haemopoiesis throughout adult life 
(Dzierzak and Speck, 2008). At the adult stage there are secondary sites of haemopoiesis, 
including the spleen, thymus and lymph nodes. In addition, HSC are capable of migrating 
to and from the BM into the periphery at low levels and is modulated in response to 
inflammation, stress or injury (Ratajczak and Kim, 2012). In this thesis, factors involved in 
adult haemopoiesis are investigated, therefore the BM and haemopoiesis in the adult 
system will be discussed onwards. 
The BM has been termed the adult haemopoietic ‘niche’ due to the complex signalling and 
interactions that occur between HSC and other cells within the structure. The term niche 
was first introduced in 1978 by Schofield and is now accepted and commonly used 
(Schofield, 1978). The concept of a stem cell niche is not unique to the haemopoietic 
system. An excellent example of this is demonstrated in experiments on germ stem cells 
(GSC) in the model organism Drosophila Melanogaster. GSC were found in close contact 
with accessory cells and their interaction was found to be fundamental for stem cell 
properties, including proliferation and differentiation (Eckfeldt et al., 2005). A dynamic 
niche has been well described for other stem cell systems, including the intestinal 
epithelium and epidermal structures such as the hair follicle (Moore and Lemischka, 2006). 
Collectively, these studies have identified a tight interplay between stem/progenitor cells 
with other cell types, which cooperate to ultimately maintain tissue homeostasis and 
function. Since the original proposal of a BM niche, an abundance of literature has 
emerged to show how diverse cell types within the niche affect HSC behaviour and 
maintain a functioning haemopoietic system (Moore and Lemischka, 2006, Weissman, 
2000). 
The BM niche is composed of several cell types including osteoblasts (OB), osteoclasts 
(OC), stromal cells, EC, macrophages, sympathetic nervous system neurons, glial cells as 
described in a recent review (Smith and Calvi, 2013). The evidence of how these cells 
regulate HSC behaviour and haemopoiesis is discussed below. The majority of research on 
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the BM niche has been carried out on mouse models, however more recently some human 
research has emerged. Mouse and human research will be discussed separately to avoid 
confusion. 
1.3.7.1 Extrinsic regulation of HSC behaviour 
1.3.7.1.1 Mouse  
 
MSC have been shown to play fundamental roles in haemopoiesis and have gained interest 
in the literature recently. Original experiments noted that individual cells derived from the 
BM could formed colonies of a fibroblast nature, which were colonies derived from single 
clonogenic cells (Friedenstein et al., 1968). These are now referred to as colony forming 
units fibroblast (CFU-F). In addition, these cells were known to exhibit self renewal and 
differentiation, indicating that these cells were of a stem cell origin (Friedenstein et al., 
1982). These cells were termed MSC and were subsequently identified and isolated. 
Although there is controversy regarding the exact molecular signature of these cell types, a 
recent review describes the most up to date phenotype in human and mouse systems 
(Frenette et al., 2013). MSC reside in the BM niche where they can produce stromal cells, 
adipocytes, chondrocytes and OB which have been implicated to play a role in HSC 
behaviour. The interactions occur through a variety of cell surface receptors, secreted 
ligands and GF (Krause et al., 2013). Experiments have identified that these cells and their 
progeny express proteins, including CXCL12, SCF, Angiopoietin-1, various adhesion 
molecules (for example, VCAM-1), VEGF, Wnt and Notch ligands (Ding and Morrison, 
2013). The receptors for these proteins are expressed by the HSC population and these 
interactions have been identified in the literature to play important roles in HSC properties, 
including quiescence, adhesion, maintenance and self renewal (Eckfeldt et al., 2005, Li et 
al., 2009, Yamashita et al., 2012, Reya et al., 2003, Kirito et al., 2005).  
In addition, various experiments using gene depletion and over expression noted that other 
cell types within the niche, macrophages, adipocytes, sympathetic nerve neurons 
adipocytes, extracellular matrix and glial cells altered HSC numbers or mobilisation 
(Krause et al., 2013, Smith and Calvi, 2013). The ECM is composed of collagens, 
glycoproteins which can influence a variety of HSC functions including adhesion, 
proliferation, survival and differentiation (Muth et al., 2013).  
Gene targeting studies have identified that a series of developmental signalling pathways 
are involved in HSC maintenance. Studies identified TGF-β, Wnt, Notch and Hedgehog 
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were essential for the extrinsic regulation of HSC behaviour (Pietras et al., 2011). A more 
in depth discussion is provided in the following paragraphs. 
Cells which have gained a lot of interest in the BM niche are OB and OC (Mansour et al., 
2012). OB and OC are involved in bone modelling and several studies have provided 
conclusive evidence that OB regulate HSC behaviour. It has been shown in mouse models 
that altering OB numbers alters the number of HSC (Visnjic et al., 2004, Calvi et al., 
2003). In the study by Calvi et al, transgenic mice with activated parathoid hormone (PTH) 
were used which increase OB number and consequently HSC numbers. In another study, 
complimentary findings were reported. Visnjic et al, used transgenic mice expressing 
herpes thymidine kinase under the collagen type I promoter (Visnjic et al., 2004). In these 
mice a bone loss was reported which resulted in a decrease in BM cellularity including 
mature cell types and the HSC population. A recent study also implicated the role of BM 
macrophages. Winkler et al, used transgenic mice (Mafia) to deplete macrophages and 
found a reduction in OB numbers which resulted in an increase in HSC mobilisation 
(Winkler et al., 2010). Furthermore, experiments inhibiting or activating OC has shown 
alterations in HSC mobilisation although there are some discrepancies between studies 
(Miyamoto et al., 2011, Kollet et al., 2006). It has been shown that increasing OC number 
alters HSC mobilisation. The study by Miyamoto et al used three different transgenic 
mouse models which reduced osteoclast numbers and showed no effect on mobilisation. 
However, pharmacological inhibition of OC was shown to increase HSC mobilisation 
(Miyamoto et al., 2011). Recently, a mouse model (Oc/Oc) resulting in loss of osteoclast 
activity resulted in HSC effects but also dramatic effects on the BM niche (Mansour et al., 
2012). Results showed increased MSC production and reduced osteoblast differentiation. 
Ultimately these niche changes resulted in a decrease in HSC homing. Further experiments 
identified a Notch signalling as a key signalling pathway in this process (Calvi et al., 
2003). Collectively, there is conclusive evidence from mouse studies that both OB and OC 
play a fundamental role in the regulation of HSC properties. As these cells are located in a 
particular region of the niche in close proximity to the bone tissue, it was hypothesised that 
there may be distinct regions within the niche important for HSC behaviour. 
Experiments have shown that cell types are located in particular areas of the BM niche 
which are essential for their development and maturation (Nilsson et al., 2001). To get an 
indication of the BM architecture and cell to cell interaction in vivo, studies on the BM 
niche have used histological analyses. These analyses have provided great insight into the 
location of particular cell types in the BM niche and indicated possible function. However, 
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histology provides only a two dimensional view of the niche, therefore more recently, 
intelligent imaging techniques, using intravital microscopy, have been employed to 
examine the niche with the intact three dimensional architecture in vivo. Studies have 
identified distinct areas within the BM niche in which HSC populations reside. More 
specifically, HSC have been identified to localise close to the endosteal surface of 
trabecular bone, endosteal niche which has been reported in HSC after transplantation 
(Nilsson et al., 2001, Lo Celso et al., 2009). The study by Nilsson et al used labelling of 
cells and transplantation into non ablated recipients. Stem cells were found to locate to the 
endosteal niche and more mature ‘lineage restricted’ cells were mostly located in the 
central marrow (Nilsson et al., 2001). Another study used an alternative technique of live 
imaging of transplanted, labelled cells in the calvarium and they noted that cells with 
varying maturity/differentiation located to different areas within the BM niche (Lo Celso et 
al., 2009). In addition, it was observed that HSC locate to the endosteal niche when 
required for expansion suggesting this area controls stem cell behaviour. In terms of a 
mechanism, a variety of studies have identified particular proteins involved, with calcium 
signalling as an example. HSC lacking a calcium sensing receptor were shown to have a 
defect in their localisation to the endosteal niche, which was shown to be disruptive to their 
function (Adams et al., 2006). Research has been conducted primarily on the calvarium 
which has been shown to be an ideal model for live cell imaging. However, differences in 
mouse models used, labelling of cells, exact cell populations studied and niche area studied 
will likely contribute to differences between studies. Indeed, a recent study has argued that 
different BM compartments are diverse and shown striking data in which heterogeneity in 
their structure and function is shown (Lassailly et al., 2013). 
Although there is a great body of evidence to suggest that the endosteal niche is 
fundamental to HSC function, a vascular niche exists which is also important. The vascular 
niche is located in the centre of the BM close to the blood vessels. It contains sinusoids 
which contain a layer of EC (Kopp et al., 2005).  It is proposed that different anatomical 
areas of the niche control different HSC behaviour with the general consensus that more 
mature progenitors reside in the vascular niche (Xie et al., 2009, Lo Celso et al., 2009). 
However, this is contradictory evidence in the literature and HSC have been reported to 
reside in the vascular niche with more mature progenitors located in the endosteal niche 
(Ding and Morrison, 2013). However, it has been suggested that experiments reporting that 
HSC reside close to the endosteum perhaps underestimate the vascular niche. There are 
also issues due to the close proximity of both niches and there are technical issues involved 
with the size of animal tissues (Doan and Chute, 2012). However, in spite of the 
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controversy in the literature regarding this issue, there is evidence that shows the vascular 
niche plays an important role in HSC behaviour (Eckfeldt et al., 2005). Studies have shown 
this involves blood vessels and the sympathetic nervous system. A study by Yamazaki et 
al, used TGF-β type II receptor null mice to confirm the role in HSC maintenance 
(Yamazaki et al., 2011). They found that non-myelinating Schwann cells were responsible 
for TGF-β expression through nerve cells. Furthermore, nerve denervation reduced 
Schwann cells and consequently decreased HSC cell number. Another study reported the 
function of EC in HSC function. Research by Winkler et al, used transgenic mice null for 
E-selectin and reported HSC proliferation and chemosensitivity was altered. In addition, 
pharmacological inhibition of E-selectin reduced HSC proliferation. E-selectin was found 
to be expressed in BM EC exclusively in the vascular niche (Winkler et al., 2012). This 
research supports the concept that HSC proliferation is important in the vascular niche and 
quiescence HSC reside in the endosteal niche (Kopp et al., 2005). CXCL12-abundant 
reticular cells (CAR) which express CXCL12 have been shown to play a role in 
maintaining the HSC quiescence pool through CXCR4. These cells have been reported in 
both the endosteal and the vascular areas within the BM niche in particular around the 
sinusoids in the vascular niche (Sugiyama et al., 2006).  
However, collectively these studies must be interpreted with caution as mostly these 
experiments use in vivo analysis of the BM niche typically after transplantation. 
Transplantation stresses the haemopoietic system and may indeed alter cell interaction 
dynamics, in comparison to behaviour that occurs in a normal, physiological setting.  
Studies examining oxygen sensing have identified that the BM niche is ‘hypoxic’, which 
refers to a state of low oxygen. Original experiments which used targeted deletion of 
essential hypoxic genes in the haemopoietic system found a reduction in HSC function and 
maintenance in response to deletion of these particular genes (Takubo et al., 2010). 
Furthermore, it has been proposed that particular HSC populations require distinct 
metabolic programs and require different oxygen levels according to their function (Warr 
et al., 2013). These signalling pathways are also related to DNA damage and oxidative 
stress and there is compelling evidence to show that these pathways are relevant to HSC 
and their niche (Moore and Lemischka, 2006). 
The studies outlined above clearly demonstrate that the BM niche is a complex interplay of 
several diverse cell types that work cooperatively to orchestrate haemopoiesis over a 
lifetime. Various studies have implicated the role of particular proteins in the regulation of 
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the haemopoietic niche, including BMP, Wnt and Notch signalling (Moore and Lemischka, 
2006). These signalling pathways are also known to be involved in several other stem cell 
niche systems and therefore a conserved stem cell signature common among several tissues 
has been proposed (Eckfeldt et al., 2005). Understanding niche interactions is fundamental 
to understanding HSC behaviour. In addition, haematological diseases are known to 
exhibit BM abnormalities. Recent evidence showed that the niche becomes modified in 
response to disease, which ultimately resulted in the protection of malignant HSC from 
apoptosis (Krause et al., 2013). 
1.3.7.1.2 Human 
Perhaps not surprisingly human studies on the BM niche are rare. Recently, a study by 
Guezguez et al. examined HSC location in xenograft mouse models and using histology of 
BM trephines (Guezguez et al., 2013). In this study, the authors characterise the location of 
HSC within human BM biopsy specimens and use human-mouse xenografts. In accordance 
with the majority of literature on mouse studies, human HSC were located in the trabecular 
bone area in an endosteal niche. Furthermore, OB and Notch signalling were found to play 
a role in HSC function. 
A collection of studies from both mouse and human models has shown that the BM niche 
is indeed complex and contains a variety of different cell types and signalling molecules 
which each play a fundamental role in regulating haemopoiesis. A summary of the main 
cell types with key molecules involved is presented in Figure 1-7. 
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Figure 1-7 Schematic diagram of components of the BM niche. 
The majority of research on the BM niche has been acquired from mouse studies. The BM 
niche is important for stem cell function and tissue homeostasis. The niche is a tight 
interplay of various components, cell types, GF, vessels, nerve fibres and matrices. Studies 
have highlighted that there are two distinct regions; the endosteal and vascular region 
which are both important for stem cell function. Although the majority of research has 
hypothesised that the endosteal region is where quiescent HSC are maintained and the 
vascular niche supports more mature, committed progenitor cells. HSC interact with the 
niche through adhesion molecules and gap junctions, cytokines/chemokines and GF and 
extracellular matrix. Schematic adapted from published literature (Ehninger and Trumpp, 
2011, Geiger et al., 2013, Eckfeldt et al., 2005).   
 
 
1.3.8 Methods for understanding HSC cellular fate decisions 
Several methods can be used to identify novel candidate genes/pathways involved in 
regulating a particular biological process including hypothesis and data driven approaches. 
Data driven approaches apply a non biased approach to identify candidates. As an 
example, data driven approaches including gene expression analyses on a high-throughput 
scale can be used as a tool to identify candidates involved in biological processes (Bryder 
et al., 2006, Eckfeldt et al., 2005). High-throughput screening analyses are not limited to 
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gene expression and studies have shown that epigenetic, protein and phospho-protein 
screens can be carried out. 
The experiments designed in this PhD thesis were based on a previous microarray study 
which aimed to identify transcriptional differences between quiescent and proliferative 
HSC populations. Although various previous studies have identified a variety of different 
factors which play a role in HSC quiescence, it is still not well understood (Li, 2011, Park 
et al., 2010, Liu et al., 2009). Several studies have aimed to identify novel transcriptional 
targets in quiescent HSC, however the literature is dominated by studies on mouse HSC 
(Cheung and Rando, 2013, Forsberg et al., 2010, Venezia et al., 2004, Passegue et al., 
2005). Understanding the molecular mechanisms underlying quiescence  in normal HSC 
can provide a foundation for when this becomes deregulated, for example in response to 
ageing and disease (Geiger et al., 2013, Li, 2011, Graham et al., 2002).  
1.3.9 Study rationale 
A previously published microarray study from our group aimed to use a high-throughput 
gene expression platform to identify candidates differentially regulated between quiescent 
and proliferative human HSC. This screen was carried out using human haemopoietic 
stem/progenitor populations sorted based on their cell cycle status with DNA and RNA 
flow cytometry markers (CD34+) (Graham et al., 2007).  Hoechst 33342 and Pyronin Y are 
widely used flow cytometry stains for the identification of populations with differential cell 
cycle status (Shapiro, 1981). In the previous study, viable CD34+ cells were sorted for G0 
and dividing cells (G1/G2/S/M) using Hoechst and Pyronin Y. The subfractions were sorted 
using flow cytometry with G0 defined as (CD34+, Hoechstlow, Pyronin Ylow) and dividing 
defined as (CD34+, Hoechstlow-high, Pyronin Yhigh). Global gene expression analysis was 
conducted and the published results from this screen identified that the most up regulated 
group of genes in G0 compared to dividing HSC were chemokine ligands including 
CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL10, CXCL11 and CXCL13. The genes 
reported with the greatest differentiation expression between populations were CXCL1, 
CXCL2, CXCL6 and CXCL13. The majority of these ligands bind to a communal receptor 
CXCR2 (CXCL1, CXCL2 and CXCL6), suggesting this common signalling pathway may 
play a role in stem cell properties, in particular quiescence. We therefore focused on these 
ligands in the human system and the rationale of this PhD thesis was to investigate their 
biological function. 
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Although global expression studies are useful and have increased our understanding of 
particular biological processes, candidates must be validated and their individual role 
should be deciphered. The main aim of this study was to validate expression data from the 
original array and extend this research by executing an investigation into the biological 
function of chemokines in terms of HSC behaviour.  
1.4 Chemokines 
Chemokines are a family of small molecular weight cytokines which are secreted and bind 
specific chemokine receptors to elicit their effects (Murphy et al., 2000). Chemokines are 
named due to their ability to induce directed chemotaxis in nearby responsive cells and due 
to their presence within the cytokine family. The majority of the literature is based on the 
ability of chemokines to attract and activate leukocytes (Baggiolini, 1998). An abundance 
of literature is now available showing that chemokines play roles in a diverse range of 
biological functions. It would be impossible to cover all aspects of chemokine function in 
detail in this thesis, therefore a brief overview of chemokine function is described. The 
primary topic of this thesis is HSC biology therefore a detailed description of chemokines 
in haemopoiesis is provided.  
1.4.1 Classification 
Chemokines were first discovered with the identification of proteins that could induce 
directed cell migration. After the discovery of the first chemokines, the identification and 
isolation of others quickly followed (Murphy et al., 2000). The accumulation of literature 
with the identification of novel chemokines resulted in a random nomenclature, although 
some proteins had similar structures and functions. In addition, several groups often 
identified the same protein simultaneously, but with different nomenclature, making the 
literature confusing. To overcome this issue, a classification system was devised and 
proposed in a keystone chemokine symposium with the strategy for the classification of 
chemokines according to their structure and function. In 2000, a nomenclature system for 
chemokine receptors was devised (Murphy et al., 2000). This was extended to include 
ligands and receptors (Zlotnik and Yoshie, 2000). This novel classification system created 
a standardised nomenclature for the naming of chemokines and grouping according to their 
structure. The classification system is logical, generally accepted and widely used. 
Although a few studies still quote chemokines using their alias, for simplicity, the naming 
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of chemokines in this thesis will be according to the standardised classification which can 
be observed in Table 1-1 (Zlotnik and Yoshie, 2000).  
Chemokines were named according to the presence and positioning of a cysteine residue in 
the N-terminus of the protein structure (Zlotnik and Yoshie, 2000) (Figure 1-8). 
Chemokines were classified into CXC, CC, XC and CX3C groups according to the location 
of the cysteine peptide with other peptides. The CXC family members contain two cysteine 
peptides with an amino acid separating them, the CC group contain two cysteine peptides 
in juxtaposition, the XC family members contain a single cysteine peptide which follows 
an amino acid and finally the CX3C group contain two cysteine peptides with the presence 
of three amino acids separating them. An identifying number was given for each individual 
chemokine. The standard nomenclature is used with the addition of L for ligand and R for 
receptor with numbering from 1 upwards for both (Table 1-1).  
It can be observed from the list of chemokines that there are many different known 
chemokines which have different functions. To add to this complexity, the existence of 
chemokines varies between human and mouse species (Zlotnik and Yoshie, 2012). For 
simplicity, the table shows a list of human receptors and ligands from a recent review 
which is based on human chemokines. Mouse homologs are known to exist and there are 
mouse chemokines that have high homology to the human chemokines. However, as 
described by Zlotnik et al in their recent review of the classification system there is not 
always a homolog between species (Zlotnik and Yoshie, 2000). There are chemokines 
found in mouse which have no clear human homolog and in contrast there are human 
chemokines which have no clear mouse homolog. In addition, for several chemokines, 
there are mouse chemokines available which have similarity to sequences of human 
chemokines, however the exact homolog is not clear. For simplicity, mouse homologs 
available are discussed in more detail for specific chemokines throughout the text. 
Furthermore, variants of particular chemokines have been found (Zlotnik and Yoshie, 
2012). These vary in terms of the protein structure, usually through the removal or addition 
of amino acids. These will be described in more detail for particular examples in the text. 
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Family Receptor Ligand 
CXC CXCR1 
CXCR2 
 
CXCR3A 
 
CXCR3B 
CXCR4 
CXCR5 
CXCR6 
Unknown 
CXCL6, CXCL8 
CXCL1, CXCL2, CXCL3, CXCL5, 
CXCL6, CXCL7, CXCL8 
CXCL9, CXCL10, CXCL11, 
CXCL13 
CXCL4, CXCL4L1 
CXCL12 
CXCL13 
CXCL16 
CXCL14, CXCL17 
CC CCR1 
 
 
CCR2A/B 
 
CCR3 
 
                               
                              CCR4 
CCR5 
 
 
CCR6 
CCR7 
CCR8 
CCR9 
CCR10 
CCL3, CCL3L1, CCL5, CCL7, 
CCL8, CCL13, CCL14, CCL15, 
CCL16, CCL23, CCL26 
CCL2, CCL7, CCL8, CCL13, 
CCL16, CCL26 
CCL3L1, CCL5, CCL7, CCL11, 
CCL13, CCL14, CCL15, CCL24, 
CCL26, CCL28 
CCL17, CCL22, 
CCL3, CCL3L1, CCL4, CCL4L1, 
CCL5, CCL8, CCL11, CCL14, 
CCL16, CCL26 
CCL20 
CCL1, CCL19, CCL21 
CCL1, CCL16 
CCL25, CCL27, CCL28 
CCL3L3, CCL4L2, CCL27, CCL28 
XC XCR1 XCL1, XCL2 
CX3C CX3CR1 CX3CL1 
 
Table 1-1 Chemokine classification system.  
Chemokines are classified into subgroups based on the presence and positioning of a 
cysteine residue in the N-terminus of the protein structure. Chemokine ligands are given 
the letter L and a particular number with receptors given the letter R. The table shows all 
chemokines in each subfamily with the known binding partners. The chemokine data is in 
reference to the most recent review of the chemokine superfamily by Zlotnik and Yoshie 
(Zlotnik and Yoshie, 2012).  
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Figure 1-8 Protein structure of chemokine families.  
Schematic is modified from published literature (Rollins, 1997). Schematic diagram 
demonstrates the protein structure of chemokine families. The chemokine protein structure 
contains an N-terminal loop connected with bonds between cysteine residues depicted by 
C. The tertiary protein structure of chemokines are very similar. Families are distinguished 
using the presence and positioning of amino acids (X) inbetween cysteine residues near to 
the N-terminus of the protein. Chemokines share a structured core consisting of three β-
sheets (β1, β2 and β3) with an α-helix at the C-terminal of the protein structure with 
disulphide bonds which stabilise the structure.  
1.4.2 Signalling 
Chemokine ligands are expressed by the cell and the majority are secreted as soluble 
factors which interact with their cognate chemokine receptors. Chemokine receptors are 
expressed selectively on particular cell types which mediate the chemokine signalling 
response. An interesting aspect of chemokine biology that is highlighted by Table 1-1 is 
the observation that several ligands can bind the same receptor and similarly that several 
receptors can bind the same ligand. This adds a complexity to chemokine signalling as it is 
known that a high level of redundancy and compensatory mechanisms between 
chemokines exist. An example is the CXC family, which plays a predominant role in the 
induction of leukocyte migration. It is thought that several chemokines share roles in this 
function to ensure robustness in cell recruitment during inflammation (Mantovani, 1999, 
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Remick et al., 2001). Another example is the availability of viable knock-out mouse 
models of particular chemokines. This suggests that shared chemokine function has 
developed in order that fundamental biological processes are not affected by the absence of 
individual chemokine genes (Mantovani, 1999). However, the concept of redundancy has 
been questioned and there is evidence against this theory (Schall and Proudfoot, 2011). 
Studies have shown that different binding partners to the same receptor can result in 
different receptor behaviour or kinetics. An example is CXCL8 which binds both CXCR1 
and CXCR2, however ligand binding shows different kinetics for each receptor (Holmes et 
al., 1991, Murphy and Tiffany, 1991). Furthermore, studies have shown that different 
ligands binding to the same receptor show different biological responses and there are key 
roles for specific chemokine interactions that are not shared between ligands. In addition, 
there are also specific ligand and receptor partners which are unique and have only one 
binding partner including CX3CL1 and CX3CR1. 
The majority of chemokine ligands function by binding and signalling through chemokine 
receptors which are 7 transmembrane domain spanning guanosine nucleotide binding 
protein (G protein) coupled receptors (GPCR). Briefly, an extracellular domain at the N-
terminus of the protein structure binds the target ligand and the intracellular domain at the 
C-terminus is responsible for signal transduction (Bockaert and Pin, 1999, Murdoch and 
Finn, 2000). The structure contains seven α helical transmembrane domains with three 
intracellular and extracellular loops. Receptor binding of the ligand results in receptor 
homodimerisation, internalisation, signal transduction and activation of downstream 
signalling pathways (Raman et al., 2011). The classical method of chemokine receptor 
signalling transduction is similar to that of alterative GPCR and involves signalling of 
heterotrimeric G-protein complexes as illustrated in Figure 1-9 (Bockaert and Pin, 1999, 
O'Hayre et al., 2008). Consequently to ligand/receptor binding, receptors are 
homodimerised and the G protein pathway is activated (Mellado et al., 2001). The G 
protein pathway includes activation of Gα, β and γ subunits which control the binding and 
hydrolysis of guanosine diphosphate (GDP) to guanosine triphosphate (GTP). In the 
inactive state, the Gα, β and γ subunits are bound with GDP. Ligand binding results in the 
activation of the receptor and the G protein subunits. GDP then dissociates from the Gα 
subunit which is replaced by GTP. The Gα-GTP complex dissociates from the receptor and 
from the Gβ and γ subunits. The process is demonstrated in Figure 1-9. These separate 
complexes then activate downstream effectors, which ultimately leads to a cellular 
response. The Gα and Gβ/γ sub units activate distinct signalling pathways, of which some 
overlap. Following prolonged exposure to a ligand, the receptor can become desensitised 
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(Murdoch and Finn, 2000). Consequently, the internalised receptor can be ‘recycled’ to the 
cell surface or be targeted for degradation which is thought to be important for monitoring 
the signalling response (O'Hayre et al., 2008, Cotton and Claing, 2009).  
To add to the signalling complexity, certain chemokine receptors have been shown to 
homodimerise or heterodimerise, a process which is thought to result in the activation of 
distinct signalling pathways and biological responses (Salanga et al., 2009, Mellado et al., 
2001). This has been observed for several chemokine partners including CCL3/CCL4, 
CXCL4/CXCL8, and CCL2/CCL8. It has been proposed that receptor dimerization 
involves the JAK/STAT signalling pathways and downstream transcriptional targets which 
are important for chemokine regulation in vivo. 
A series of downstream signalling pathways are activated in response to ligand binding 
which mainly involves the activation of protein kinases. The activation of signalling 
pathways is dependent upon the chemokine, the cell type which elicits the response and 
indeed the required biological response which is summarised in the comprehensive review 
by O’Hayre et al (O'Hayre et al., 2008). Briefly, signal transduction results in the 
activation of phospholipase C (PLC) which cleaves phosphatidylinositol (4,5)-biphosphate 
(PIP2) into iositol triphosphate (IP3) and diacylglycerol (DAG). This results in the 
activation of downstream signalling mediated by protein kinases. Migration and cell 
adhesion are mediated with phosphatidylinositide 3 kinase (PI3K) and tyrosine kinase 
(TK) activation as well as activation of Akt, Rac, Cdc42, Rho and Rho associated kinase 
(ROCK). Collectively, actomyosin is contracted and F-actin is polymerised which 
ultimately leads to cell motility. In addition, activation of Akt, PKC, TK, mitogen activated 
protein kinase (MAPK) and PI3K are thought to mediate the effects on survival and 
proliferation (O'Hayre et al., 2008).   
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Figure 1-9 Chemokine activation using the G protein pathway. 
In the inactive state, the receptor is free from ligand and the G subunits are bound. In 
response to ligand binding, G subunits are activated, recruited to the GPCR and facilitate 
the transfer of GDP to GTP. The Gα-GTP complex and the Gβ and γ subunit both 
dissociate and activate downstream signalling pathways to elicit the required response. 
Prolonged exposure to ligand binding to the GPCR results in phosphorylation of the C-
terminus tail. As a consequence arrestins including β-arrestin are recruited to the GPCR 
which blocks further interaction of the GPCR with G subunits. Schematic adapted from 
published literature (O'Hayre et al., 2008).  
An interesting aspect of chemokine biology is the presence of receptors which do not elicit 
a cellular response. These receptors are unique in terms of their function, are known as 
‘atypical’ receptors, and are thought to bind chemokine ligands without resulting in signal 
transduction (Balkwill, 2012). It has been proposed that the lack of signal transduction is 
due to the lack of a particular amino acid sequence which is found in all other chemokine 
receptors (Graham, 2009, Ulvmar et al., 2011, Nibbs et al., 2003). Atypical receptors are 
well studied and include duffy antigen receptor for chemokine (DARC), CCXCKR, 
CXCR7, CCRL2 and D6 (Graham and Locati, 2013). The random nomenclature reflects 
the fact that these receptors do not transduce a signal and were not considered as classical 
chemokine receptors. It is suggested that these receptors are involved in regulating 
chemokine activity, which is commonly referred to as ‘scavenging’. Arguably the most 
well studied and understood of the atypical receptors is D6. Studies showed that binding of 
CC ligands to the receptor does not activation signalling pathways commonly activated in 
response to GPCR activation (Hansell et al., 2011, Graham, 2009). Indeed, experiments 
60 
using CCXCKR and D6 have showed these receptors can bind ligands which are 
subsequently internalised and degraded (Graham, 2009). Recent evidence has shown that 
binding of ligands to atypical receptor D6 does not result in the activation of a classical G 
protein signalling pathway, but involves a β-arrestin dependent signalling pathway 
(Borroni et al., 2013). This pathway ultimately increases D6 protein at the cell surface and 
is essential for the scavenging activity. As examples for the physiological role of this 
process, D6 plays a central role in the modulation of inflammatory responses and CXCR7 
scavenging has been shown to regulate tumour cell survival (Lee et al., 2013, Graham and 
Locati, 2013, Hernandez et al., 2011). 
The method of ligand and receptor binding is referred to as the classical method of 
signalling, however this is not the only method of chemokine signalling. In addition, 
chemokines can interact with adhesion molecules and glycosaminoglycans (GAG) (Allen 
et al., 2007). Chemokine ligands CXCL16 and CX3CL1 are not secreted as soluble factors 
but are attached to the extracellular surface (Allen et al., 2007). However, there are cases in 
which these chemokines are cleaved and can also function as a soluble chemoattractants 
(Charo and Ransohoff, 2006, Laurence, 2006). More recently, extracellular ubiquitin has 
been implicated to bind chemokine receptors including CXCR4 (Saini et al., 2010) 
1.4.3 Function 
Although the classification system has grouped chemokines according to their structure 
and binding partner(s), these groups are not necessarily discrete in terms of function 
(Zlotnik and Yoshie, 2000). As an example, the CXC family contains members which 
contain a tri peptide motif with amino acids glutamate, leucine and arginine (ELR) 
between the N-terminus of the protein and the cysteine residue. The presence of this motif 
allows a distinction between members of the family with properties in leukocyte 
chemotaxis (Laurence, 2006). Members which contain this motif are produced in response 
to inflammatory factors and the presence of this motif allows the chemokines to attract 
neutrophils to inflammatory sites resulting in granule exocytosis and respiratory burst. As 
an example, CXCL4 does not contain the ELR motif and does not induce leukocyte 
migration. Experiments which have manipulated the structure of CXCL4 to include the 
ELR motif showed that this mutated protein structure was capable of leukocyte migration 
(Clark-Lewis et al., 1993). This ELR motif is also correlated with angiogenesis which is 
the process of blood vessel formation. ELR-CXC chemokines are proangiogenic and can 
stimulate EC chemotaxis. In contrast, those lacking the ELR motif are angiostatic (Strieter 
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et al., 2005). The pro and anti angiogenic chemokines separates the CXC family into 
discrete groups which signal through alternative receptors (Rossi and Zlotnik, 2000). 
Chemokines are known to play a variety of diverse roles throughout the biological system 
(Rossi and Zlotnik, 2000). The most recognised biological function in chemokine biology 
is in the direction of inflammatory cell types and consequently their role in the immune 
response. However, it is now clear that chemokines are also involved in development, 
organogenesis and homeostasis (Mantovani, 1999, Rossi and Zlotnik, 2000, Zlotnik et al., 
2011). For simplicity, chemokines are generally split into function according to their 
expression patterns and expression is thought to be either inflammatory or homeostatic. 
Inflammatory chemokines are induced in response to inflammatory conditions and are 
generally involved in leukocyte migration to sites of inflammation or injury. Homeostatic 
chemokines are constitutively active and direct trafficking of cell types under physiological 
conditions. Although this categorisation is useful when discussing function, chemokines 
are more complex and it is known that these functions overlap for some chemokines 
including CCL17, CCL20, CCL22, XCL1, XCL2 and CXC3CL1 (Zlotnik and Yoshie, 
2012). As the topic in the thesis is of chemokines in haemopoiesis and chemokine biology 
is complex, only a brief overview of the role of inflammatory and homeostatic chemokines 
is discussed below with particular examples. 
1.4.3.1 Inflammatory chemokines 
Inflammation occurs in response to tissue damage or infection and a step by step process 
occurs involving the immune system to deal with the insult (Ortega-Gomez et al., 2013). 
These processes are mediated by inflammatory chemokines which act as ‘molecular cues’. 
Inflammation is complex therefore a brief overview is provided with a few examples. 
Chemokines have a central role in leukocyte recruitment and leukocyte activation 
(Mackay, 2008).  Early studies identified chemokines as proteins in cellular supernatants 
that were capable of mediating directed chemoattraction of leukocytes using modified 
Boyden chamber assays (Ransohoff, 2005).  Inflammatory chemokines are up regulated in 
not only activated endothelial cells and smooth muscle cells, but also leukocytes, 
macrophages and monocytes (Balkwill, 2012). It has been shown that the inflammatory 
chemokine response varies on the type/cause of inflammation. The majority of 
inflammatory chemokines respond by an upregulation at the transcription level whereas 
other chemokines are stored in granules for immediate release when necessary. The 
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production of chemokines at the site of injury/infection is followed by the establishment of 
a chemoattractant gradient.  Chemokines present themselves on the endothelium of post-
capillary venules, resulting in the instantaneous activation of rolling leukocytes resulting in 
firm adhesion and diapedesis (Ransohoff, 2005).  
Acute inflammation is characterised by a predominantly neutrophil influx resulting in 
adema, redness and further recruitment of a large number of neutrophils, whereas chronic 
inflammation involves the sustained recruitment and activation of T cells and monocyte/ 
macrophages. Generally speaking, the CXC chemokine family are primarily implicated in 
the recruitment of polymorphonuclear leukocytes (neutrophils) to sites of acute 
inflammation, whereas the CC family of chemokines are primarily involved in the 
recruitment of MNC to sites of chronic inflammation (Ransohoff, 2005).  However, there 
is some overlap in the CC and CXC family and complexity involved. An example is helper 
T cells (Th1 versus Th2) which have been shown to respond to distinct chemokine 
signatures (Siveke and Hamann, 1998). The CXC members play a key role in wound repair 
as elegantly documented by studies using CXCR2 null mice (Charo and Ransohoff, 2006). 
As mentioned previously, the CXC family also play a pivotal role in the control of 
angiogenesis. 
The CC sub family are referred to as monocyte chemoattractant proteins as they are 
generally involved with the recruitment of monocytes to sites of injury including (but not 
limited to) to trauma and infection (Charo and Ransohoff, 2006). Key chemokines 
involved in monocyte recruitment include CCL2, CCL7, CCL8 and CCL13. Studies on a 
CCR2 knock out mouse model have identified that this receptor and its binding partners is 
essential for this process in inflammation (Daly and Rollins, 2003). CCR7 and ligands 
including CCL19 and CCL21 are involved in T cells and dendritic cell recruitment. A 
knock out mouse model lacking CCR7 has demonstrated the role of this signalling as these 
mice are deficient in T cell dependent immunity and show disorganised lymph node T 
zones (Charo and Ransohoff, 2006). 
Atypical receptors as described previously including D6 are thought to play key roles in 
inflammation, immune activation and anti-microbial resistance (Di Liberto et al., 2008).  
As an example, knocking out the D6 decoy chemokine receptor resulted in a higher 
susceptibility to tuberculosis infection compared to their wildtype counterparts regardless 
of bacterial load.  These D6 deficient mice harboured elevated levels of systemic 
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chemokines and other inflammatory cytokines, collectively implying that D6 belongs to a 
network of chemokines that limit excessive inflammatory responses in vivo.  
As an example of the role of chemokines in inflammation, chemokines have been 
demonstrated to be important in atherosclerosis, a chronic inflammatory disease process 
occurring in the arterial wall over a long period of time that results in angina, myocardial 
infarction and ischemic stroke (Weber et al., 2008).  Formation of atherosclerotic plaques 
is a process of on-going inflammation that is characterised by endothelial damage, MNC 
recruitment and vascular smooth muscle cell proliferation processes that can be driven by 
adhesion molecules, chemokines and their receptors (Weber et al., 2008, Zernecke and 
Weber, 2014). 
Chemokines have been implicated in some of these processes, such as development of 
atherosclerotic lesions (Weber et al., 2008).  Briefly, subsequent to endothelial cell damage 
and activation, chemokines are expressed and presented on damaged endothelium by 
binding to GAG. A chemokine gradient is created which attracts monocytes to enter the 
sub-endothelial space of the vessel and to differentiate into macrophages.  In particular 
CCL2 and CX3CL1 have important roles in recruitment of monocytes into the plaques.  
The role of these two chemokines, alongside their respective receptors CCR2 and CX3CR1 
were investigated by Saederup et al., who demonstrated that these two 
chemokine/chemokine receptor pairs have both individual and additive roles in the 
recruitment of macrophages to atherosclerotic plaques (Saederup et al., 2008).  In addition 
to macrophage recruitment, the retention of macrophages within the plaque aids in plaque 
progression. Indeed, Trogan et al., demonstrated that CCR7 expression and function are 
essential for emigration of macrophages from the atherosclerotic plaque (Trogan et al., 
2006). Chemokines also play a role in retention of monocytes in established atherosclerotic 
plaques.  As an example, a study by Baric et al., showed that when monocytes are exposed 
to oxidized lipids, pro-migratory chemokine receptor CCR2 levels decrease whilst pro-
adhesive chemokine receptor CX3CR1 levels are increased, aiding in plaque formation.  
Atherosclerosis is just one example of how chemokines function in an inflammatory 
disease, chemokines are also known to be involved in non inflammatory settings. 
1.4.3.2 Homeostatic chemokines 
Homeostatic chemokines are named due to their expression in normal organs in the 
absence of inflammatory stimuli or alternatively are expressed by cells not involved in 
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inflammation response (Baggiolini and Loetscher, 2000, Rossi and Zlotnik, 2000). 
Homeostatic chemokines are important for lymphocyte trafficking, B and T cell production 
and during development including in organogenesis and more specifically secondary 
lymph node organogenesis (Zlotnik et al., 2011). Studies on knock out mice of particular 
chemokines has formed the basis of the research including CXCR4, CXCL12 and CXCR5 
null mice (Locati and Murphy, 1999). 
 These chemokines are expressed at particular sites and bind to receptors that are expressed 
by lymphocytes (Baggiolini and Loetscher, 2000). Lymphoid cells including B and T cells 
are developed in secondary lymphoid organs, a process which is controlled by chemokines 
with main players CXCR4, CXCR5 and CCR7 involved (Baggiolini and Loetscher, 2000, 
Zlotnik and Yoshie, 2000). Most strikingly, CXCL12 null mice do not develop to 
adulthood and has been shown to have a defect in B cell lymphopoiesis (Nagasawa et al., 
1996). The CXCR4 and CXCL12 signalling axis is now also known to be involved in stem 
cell migration in early development and adult hood, and in the development of the central 
nervous system (Balkwill, 2012). Chemokines are also involved in the development of 
other organs including the thymus in which chemokines coordinate T cell trafficking 
(Rossi and Zlotnik, 2000).  
1.4.3.3 Chemokines in disease 
Due to the fundamental roles of chemokines in various biological processes, it is perhaps 
not surprising that chemokines are connected with disease. Chemokines have been shown 
to be associated with autoimmune disorders, vascular disease and viral disease (Allen et 
al., 2007). Briefly, chemokines are involved in inflammatory diseases included arthritis, 
asthma, psoriasis and atherosclerosis as used as an example in section 1.4.3.1 (Charo and 
Ransohoff, 2006). In terms of viral disease, an abundance of evidence is on human 
immunodeficiency virus (HIV-1) with the involvement of CXCR4 and CCR5 (Charo and 
Ransohoff, 2006, Mellado et al., 2001). Experiments have shown that CXCR4 and CCR5 
are required for mediating viral entry into host cells, with evidence that a polymorphism in 
CCR5 allows individuals to be resistant to viral infection, but more susceptible to West 
Nile virus (Glass et al., 2006, Mellado et al., 2001). Furthermore, HIV-1 replication is 
abrogated when CXCR4 and CCR5 are blocked (Moore et al., 2004).  
Chemokines were first implicated in cancer with the observation that high levels of 
CXCL1 were secreted by melanoma cells (Richmond and Thomas, 1986). Chemokine 
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signalling is now known to be directly involved in cancer development through different 
mechanisms. An interesting observation was that chronic inflammation predisposes 
individuals to cancer (Hanahan and Weinberg, 2011). In addition, a heightened 
inflammatory state was found in response to cancers (Balkwill, 2012). The main players 
involved include receptors CXCR1, CXCR2, CXCR2, CXCR4, CCR2 and CCR5 and their 
ligands. Currently, it is understood that chemokine signalling is important in various 
aspects of cancer development. The up regulation of chemokines, particular inflammatory 
chemokines results in the recruitment and activation of immune cells to the site. The 
chemokines act to promote angiogenesis, metastasis, tumour cell proliferation/survival and 
provide a protective microenvironment (Borsig et al., 2013, Zlotnik et al., 2011). As an 
example, deregulation of CXCR4 is well recognised in several cancers including breast, 
ovarian and prostate cancer (Teicher and Fricker, 2010, Furusato et al., 2010). This up 
regulation can have diverse effects including tumour progression, trafficking, angiogenesis 
and the prevention of apoptosis. Chemokines have also been shown to be down regulated 
in response to disease. In this way, malignant cells exploit chemokine signalling for 
disease development.  
Due to the abundance of literature on the role of chemokines in autoimmune disorders, 
viral disease and cancer development, chemokines have become popular as potential 
pharmacological targets. The best understood are CXCR4 and CCR5 in HIV-1, CXCR4 in 
cancers, CCR2 in atherosclerosis and CXCR1/CXCR2 in pulmonary disease (Charo and 
Ransohoff, 2006). 
The data discussed above highlights the complexity of chemokine signalling and the 
diverse range of roles they play throughout the biological system. In this thesis, 
chemokines CXCR2/CXCR2 binding ligands and CXCL4 are focused on. Therefore, the 
main function of these chemokines is discussed in more detail below. 
1.4.3.4 CXCR2 signalling 
As can be seen in Table 1-1, human CXCR2 binds ligands CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL7 and CXCL8. These chemokines are expressed on a variety of 
cell types including neutrophils, basophils, monocytes, macrophages, dendritic cells, 
natural killer cells and mast cells (Koelink et al., 2012). CXCR1 and CXCR2 were 
originally shown to be expressed on granulocytes when CXCL8 was shown to bind to two 
receptors with different affinity (Murphy and Tiffany, 1991, Holmes et al., 1991). CXCR2 
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shares structural similarity to CXCR1 with a 77% homology which can also bind CXCL6 
and CXCL8. There are differences between human and mouse CXCR2 signalling which is 
discussed for the later contents of this thesis. Mouse homologs have been identified against 
human CXCR1 and CXCR2 (Fan et al., 2007, Fu et al., 2005). CXCL1, CXCL2, CXCL3, 
CXCL5/6 and CXCL7 mouse homologs have been identified (Zlotnik and Yoshie, 2012). 
However, human CXCL1, CXCL2, and CXCL3 are structurally very similar and there is 
some controversy on the exact homolog for these ligands which can be confusing in the 
literature. Finally, to date a mouse homolog of human CXCL8 has not been identified. 
However, mouse cells can respond to human CXCL8 therefore it is suggested a chemokine 
with a similar sequence exists (Fan et al., 2007). 
CXCR2 signalling is involved in a variety of processes including leukocyte migration, 
wound healing, survival, proliferation, senescence and disease. CXCR2 signalling is 
predominantly involved in leukocyte trafficking and signalling through CXCR2 is essential 
for the migration of neutrophils to sites of inflammation (Devalaraja et al., 2000, 
Romagnani et al., 2004, Eash et al., 2010). Recently, CXCR2 signalling has been found to 
be important in cell senescence. Research has shown that chemokine signalling via 
CXCR2 reinforces senescence (Acosta et al., 2008). The results showed that senescent 
cells activate CXCR2 and its ligands including CXCL1 and CXCL8 reinforcing growth 
arrest. CXCR2 signalling has also been implicated in several models of cancer. It has been 
proposed that senescence prevents progression to a more malignant state that is bypassed 
with the acquisition of additional mutations which suppress these effects (Acosta and Gil, 
2009). In addition, studies have shown that CXCL8 is up regulated by tumour cells 
(Waugh and Wilson, 2008). More recently, CXCR2 ligands CXCL1 and CXCL2 were 
shown to induce inflammatory cell types to the tumour micronenvironment ultimately 
controlling cancer cell survival (Acharyya et al., 2012). CXCR2 is also involved in 
inflammatory disease and blocking agents are being tested (Busch-Petersen, 2006). In 
addition, CXCR2 is also known to be involved in cell proliferation and survival with 
ligand CXCL1 and CXCL8 in a variety of cell types (Tsai et al., 2002, Filipovic and 
Zecevic, 2008, Mockenhaupt et al., 2003).  
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1.4.3.5 CXCL4 signalling 
CXCL4 is one of the oldest members of the chemokine family and was discovered in 1977 
(Deuel et al., 1977). Dissimilar to other ligands within the CXC family, CXCL4 does not 
exhibit chemotactic activity for neutrophils and monocytes (Kasper and Petersen, 2011). 
Human and mouse CXCL4 share 64% identity (Watanabe et al., 1999). CXCL4 is 
predominantly produced in megakaryocytes and held in the α-granules of platelets where it 
released upon activation (Deutsch et al., 1955, Levine and Wohl, 1976). As seen in Table 
1-1, CXCL4 functions through binding to a spliced variant of CXCR3 (CXCR3B) which 
has been shown in EC (Lasagni et al., 2003, Mueller et al., 2008). However, the binding of 
CXCL4 to CXCR3B is not simply how CXCL4 functions. Studies have reported that cells 
respond to the ligand which lack the receptor therefore other mechanisms of action are 
involved (Kasper and Petersen, 2011). CXCL4 have been shown to bind to GAG with a 
high affinity and there is evidence that proteoglycans serve as a functional receptor for 
CXCL4 (Kasper and Petersen, 2011). Additionally, CXCL4 has been shown to interact 
directly and bind integrins on EC surface (Aidoudi et al., 2008). CXCL4 is also able to 
interact with GF including VEGF and inhibit their interaction with receptors 
(Gengrinovitch et al., 1995, Bikfalvi, 2004). CXCL4 can also form complexes with other 
chemokines as a co-factor in other chemokine responses (Kasper and Petersen, 2011). A 
variant of human CXCL4 (CXCL4L1) has been discovered and isolated from platelets and 
differs in terms of localization, secretion and behaviour (Struyf et al., 2004, Dubrac et al., 
2010, Lasagni et al., 2007). 
CXCL4 was initially reported to have anti heparin activity and the main physiological role 
of the chemokine is in coagulation regulation (Eitzman et al., 1994). Currently it is known 
to play a role in wound healing, chemotaxis, inflammatory cell activation, proliferation, 
survival, angiogenesis, differentiation inhibition, cancer development and atherosclerosis 
(Kasper and Petersen, 2011, Vandercappellen et al., 2011). It has a well documented role 
as a physiological inhibitor of megakaryocytopoiesis and and angiogenesis (Lambert et al., 
2007, Maurer et al., 2006). This thesis focuses on the role of chemokines in haemopoiesis, 
therefore previous published literature in this field is discussed in more detail below. 
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1.4.4 Chemokines in haemopoiesis 
Chemokines play vital roles in haemopoiesis with their main roles including cell migration, 
proliferation, differentiation and survival. A summary of the role of chemokines in 
haemopoiesis is provided below with a focus on the literature involving the chemokines in 
this study.   
Chemokines have been shown to positively and negatively regulate haemopoietic cell 
proliferation in vitro (Broxmeyer, 2001). In 1989, CCL3 and CCL4 were shown to increase 
myeloid colony formation, however under particular growth conditions they inhibited 
proliferation of early progenitors, both in culture and in vivo (Broxmeyer et al., 1989). A 
variety of studies have been carried out to show that CCL3 suppresses myelopoiesis, CFU-
S, cell cycling and HSC/progenitor cells numbers (Broxmeyer, 2001). After the original 
pioneering research, several other chemokines were tested for myelosuppressive activity 
and it was identified that several chemokines displayed inhibitory activity against 
immature haemopoietic cells in vitro and in vivo including CC and CXC family members 
(Broxmeyer and Kim, 1999). Due to the high number of chemokines which were found to 
effect haemopoietic cell growth, targeted deletion of particular receptors was examined. 
Investigation of a Cxcr2-/- mouse model identified that signal transduction via this 
chemokine receptor is involved in negatively regulating myeloid growth (Broxmeyer et al., 
1996). CCR2 has also been implicated in this process, with studies using a Ccr2-/- mouse 
model and there is evidence that signalling mediated by CCR2 is regulates apoptosis in 
these populations (Reid et al., 1999, Boring et al., 1997). 
Chemokines have also been found to support HSC/progenitor survival. Specifically in the 
CXC group, CXCL4, CXCL8 and CXCL10 were shown to support the viability of myeloid 
progenitor cells in culture and to protect them from cytotoxic induced cell death (Han et 
al., 1997). Experiments have shown that HSC respond to CXCL8 and, in turn, CXCL8 can 
be detected in human HSC populations (Behringer et al., 1997). 
Focusing on CXCL4 as this is a key player in this thesis, an abundance of research is 
available on the role of this chemokine on haemopoietic cells including 
megakaryocytopoiesis inhibition and cytoprotection, survival and adhesion of primitive 
stem/progenitor cells. CXCL4 has been shown to offer a protective effect on haemopoietic 
cells (CD34+) treated with cytotoxic compound 5-FU in culture and in vivo (Aidoudi et al., 
1996, Xi et al., 1996). It was reported that CXCL4 could increase the recovery of cells 
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following 5-FU treatment including the most primitive haemopoietic cells, the stem cells. 
In addition to viability, studies have shown that CXCL4 also promoted proliferation in 
addition to viability in stem/progenitor cells in response to 5-FU treatment.  A similar 
protective effect on haemopoietic cells was found with other chemotherapeutic compounds 
also (Han et al., 1997). In addition, experiments have shown that culture of CD34+ cells 
derived from human BM or CB with CXCL4 resulted in an increase in cell viability and 
numbers of the primitive sub population (CD34+CD38- cells) (Huang et al., 2000, Han et 
al., 1997). In addition to the effects of CXCL4 on primitive haemopoietic cell survival, it 
has been shown to alter other properties. CXCL4 has also been shown to alter cell adhesion 
with an enhancement of adhesion of stem/progenitor cells to EC (Zhang et al., 2004, 
Dudek et al., 2003). It was also noted that CXCR4 expression was increased following 
culture with CXCL4, suggesting a possible mechanism of increased adhesion. Another 
report found that CXCL4 increased CD34+ cell adhesion to EC and also stromal cells. The 
enhancement of adhesion by CXCL4 is thought to be mediated via CXCL8 and a link 
between CXCL4 and CXCL8 has been previously proposed (Pelus et al., 2002, Dudek et 
al., 2003).  
Chemokines in haemopoiesis cannot be discussed without describing a well defined 
chemokine interaction, that of CXCL12 and CXCR4. Their interaction is responsible for a 
variety of diverse roles, including fundamental roles in haemopoiesis controlling the 
survival and migration of HSC. The first identification of a role for these genes in 
haemopoiesis came from studies on Cxcr4-/- and Cxcl12-/- embryos, which were shown to 
be embryonic lethal (Zou et al., 1998, Ma et al., 1998, Nagasawa et al., 1996). CXCL12 
was shown to exert survival enhancing effects and to improve engraftment on human and 
mouse HSC and progenitor cells (Broxmeyer et al., 2003). CXCL12 was identified as a 
chemoattractant for CD34+ positive cells and present in BM derived stromal cells (Aiuti et 
al., 1997) (Ponomaryov et al., 2000, Peled et al., 1999, Imai et al., 1999) and CXCR4 was 
shown to be expressed by CD34+ HSC and progenitor cells (Viardot et al., 1998, Kim and 
Broxmeyer, 1998, Mohle et al., 1998). Although originally the CXCR4/CXCL12 axis was 
considered to be monogamous, CXCL12 has been shown to bind CXCR7. CXCR7 is 
expressed on HSC and possibly functions as a scavenging receptor (Pelus and Fukuda, 
2008, Sun et al., 2010). In the adult BM, CXCR4/CXCL12 controls HSC 
homing/mobilisation and an inhibitor against CXCR4 (AMD3100) induces the release of 
HSC and progenitor cells from the BM into the periphery which synergises with G-CSF 
(Zlotnik and Yoshie, 2012, Broxmeyer et al., 2005). A study by Sugiyama et al, used 
targeted deletion of CXCR4 which severely reduced HSC numbers without altering 
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progenitor frequency suggesting that CXCR4-CXCL12 signalling also maintains the 
quiescent HSC pool (Sugiyama et al., 2006). 
In addition to the CXCL12/CXCR4 axis, a role for other chemokines have been 
documented in haemopoietic cell mobilisation (Pelus et al., 2002). CXCL2 is a member of 
the CXC family ofchemokines which functions through binding to receptor CXCR2. A 
study published by reported that exogenous treatment of CXCL2 to mice resulted in the 
mobilisation of HSC from the BM into the circulation (King et al., 2001). An N-terminal 
truncated form of the protein (SB-251353) was also found to show the same effect on HSC 
mobilisation. This phenomenon was noted in mice in non-human primates (rhesus 
monkeys) (King et al., 2001). In addition, in comparison to mobilisation agent G-CSF, 
HSC mobilised into the periphery with CXCL2 and SB-225353 were reported to show 
increased homing and engraftment after transplantation of the cells in addition to a higher 
proportion of mobilised primitive cells (Pelus and Fukuda, 2006).  Studies have aimed to 
examine the molecular mechanism, however this is not well understood. Research 
indicated the involvement of MMP including MMP-9 (King et al., 2001). An increase in 
MMP-9 in the plasma was noted prior to HSC mobilisation and MMP-9 blocking 
antibodies showed this was an essential component of the mobilisation. It is thought that 
MMP are involved in other mechanisms of mobilisation including G-CSF as a defect in 
HSC migration has been reported in MMP-9 null mice (Heissig et al., 2002). Furthermore, 
a study showed that mobilisation mediated by CXCL2, SB-251353 and G-CSF is 
dependent on proteases secreted from neutrophils (Pelus et al., 2004). Mobilisation by 
CXCL2 has been shown to require neutrophils from studies using antibodies against GR-1 
(Pelus et al., 2004). Results for CXCL2 mediated mobilisation have also indicated the 
involvement of receptor CXCR2, however, the characterisation of cell types that are 
involved and the function of CXCR2 in HSC mobilisation signalling remains poorly 
understood (Pelus, 2008). It has been noted that the mobilising agent G-CSF up regulates 
expression of CXCL2 in BM neutrophils and it is proposed that granulocytes and 
monocytes are required to mediate mobilisation via CXCR2 and G-CSF (Nguyen-Jackson 
et al., 2010, Ratajczak and Kim, 2012, Semerad et al., 2002, Levesque et al., 2003, Pelus, 
2008, Liu et al., 1997). In addition to CXCL2, another CXCR2 binding ligand, CXCL8 has 
been shown cause mobilisation of mouse HSC into the circulation (Laterveer et al., 1996). 
A study aimed to examine the molecular mechanism of CXCL8 mediated mobilisation and 
implicated neutrophils in the process by showing mobilisation did not occur in neutropenic 
mice (Pruijt et al., 1999). In addition, CXCL8 mobilisation was reported to be dependent 
on MMP as reported with CXCL2 mediated mobilisation. A summary of role of CXC 
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chemokines in stem cell properties is provided in Figure 1-10. Due to the complexity of 
chemokine signalling, the schematic focuses on CXCL2, CXCL4, CXCL8, CXCL12 and 
CXCR4. 
 
Figure 1-10 Chemokine regulation of HSC. 
Schematic diagram shows a summary of the known role of CXC chemokines CXCL2, 
CXCL4, CXCL8, CXCL12 and their receptors in HSC properties. CXCR4 is expressed on 
HSC and responds to CXCL12 secreted by BM stromal cells and various other cells within 
the BM niche. This interaction regulates HSC migration to and from the niche and also 
quiescence. CXCR7 is also expressed on HSC and is thought to act as a scavenger receptor 
for CXCL12. CXCR2 ligands CXCL2 and CXCL8 can induce the mobilisation of HSC 
into the circulation which is thought to involve CXCR2 expressing neutrophils and MMP 
molecules. CXCL4 and CXCL8 have been shown to alter HSC survival, proliferation and 
adhesion however the molecular mechanism is not well understood. 
Similarly to the evidence outlined above with chemokines in cancer, chemokines are 
known to be deregulated or to have roles in malignancies of the haematological system. 
CXCL8 and CCL25 have been identified as pro-survival or proliferative factors in various 
subtypes of chronic lymphocytic leukaemia (CLL) (Laurence, 2006). Due to their roles in 
normal haemopoiesis, it is perhaps not surprising that CXCL12 and CXCR4 are involved 
in haematological malignancies. CXCR4 is decreased and signalling impaired in response 
to oncogene BCR-ABL in chronic myeloid leukaemia (CML) and current therapy has been 
shown to alter CXCR4 signalling, leading to accumulation of CML cells in the niche and 
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potential protection through stromal cell interaction (Dillmann et al., 2009, Geay et al., 
2005, Jin et al., 2008). Based on this research, inhibition of CXCR4 using small molecule 
inhibitor AMD3100 has shown promise in a leukaemic model in vivo (Weisberg et al., 
2012). Multiple myeloma cells have been documented to express various chemokine 
ligands and receptors which play roles in cell homing, growth of tumours and disease 
progression (Aggarwal et al., 2006). Chemokines known to be expressed by acute myeloid 
leukaemia (AML) cells include CXCL1, CXCL6 and CXCL13 however the biological 
function is not clear (Bruserud et al., 2007).   
Collectively, chemokines control fundamental process in haemopoiesis. Chemokines are 
continuing to be found to confer important properties in haemopoiesis. A recent study 
showed that CCL28 enhanced cell survival, cycling and long term repopulation in human 
HSC (Karlsson et al., 2013). Although there is a great body of work on the role of 
chemokines in haemopoiesis, the work in this thesis aims to build on results from a 
previously published microarray in which CXC chemokines were implicated in HSC 
biological properties with a particular focus on CXCL4 and CXCR2 signalling (Graham et 
al., 2007). Although there is some literature available on these chemokines, the data are not 
conclusive, in particular the data on their expression and functional roles. 
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1.5 Thesis aims 
The following thesis is an investigation into the role of CXC chemokines in HSC 
properties, including survival, self renewal, differentiation and cell cycle status. The aims 
can be broken down as follows: 
1. Examine CXC ligand and receptor expression on quiescent and proliferating human 
HSC populations. 
It is fundamental that the results from the previously published microarray are validated. 
The expression of key CXC chemokine ligands from the original array (CXCL1, CXCL2 
and CXCL6) were examined at the gene expression level between quiescent and 
proliferating human HSC populations. To ensure the protein was translated, protein 
expression analysis using multiple techniques was assessed. Furthermore, it was not clear 
from the previous research whether CXCR2 was expressed on HSC populations. The 
expression at the gene and protein level of CXCR2 was examined. 
2. Investigate the effect of modulating expression of CXC ligands and receptor and the 
resulting biological effect on human HSC properties. 
To elucidate the biological function, experiments were designed to modulate chemokine 
expression and examine the effect on human HSC properties. In this section of the thesis, 
chemokine ligand and receptor CXCL1 and CXCR2 were focused on due to the high 
expression in preliminary data and evidence in the literature. Experimental techniques 
included the use of over expression and knock down vectors against CXCL1. To 
compliment this, an inhibitor against CXCR2 signalling was used.  
3. Examine the effect of CXCR2 signalling on haemopoiesis using a Cxcr2-/- mouse model. 
Due to the presence of complex in vivo signalling involved in the haemopoietic system, it 
is possible that niche interactions of CXCR2 signalling may play a role in stem cell 
properties. Key experiments understanding chemokine function have used targeted deletion 
of the proteins, in particular the receptor. A mouse model in which Cxcr2 has been deleted 
is viable and it was decided to use this model to examine if Cxcr2 signalling is 
fundamental to stem cell properties. Haemopoiesis was examined in a Cxcr2-/- background. 
Experimental techniques involved the examination of steady state haemopoiesis, in vitro 
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stem cell functional assays and the effect of the haemopoietic system in response to stress, 
including ageing and BM reconstitution assays. 
4. Examine which CXC ligands and receptors are expressed in mouse HSC populations 
and investigate their biological function. 
There is limited literature of the role of chemokines in mouse haemopoiesis. Furthermore, 
the previous microarray study was carried out on human HSC which may not translate to 
the mouse system. A range of CXC chemokine ligands and receptors were examined for 
expression by single cell gene expression analysis on mouse HSC populations. Based on 
the expression, the biological function was investigated using a combination of transgenic 
mice, including a reporter model, examination of knock out mouse models and knock-
down using shRNA in vitro.
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2  Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
Cell line Origin 
HEK293 Human embryonic kidney 
HT 1080 Human fibrosarcoma 
PC-3 Human prostate cancer 
Table 2-1 List of cell lines.  
 
Details of the cell lines used in this study and their origin are listed in Table 2-1. HT 1080 
and HEK293 cell lines were available ‘in-house’. PC-3 cell lines were a kind gift from Dr 
Hing Leung. HT 1080 and PC-3 cells express high levels of CXCL1 and CXCR2 therefore 
were an ideal model for optimisation of techniques prior to the use of precious primary 
samples. HEK293 cells were used for lentiviral particle production.  
2.1.2 Plasmids 
Plasmids were used in this study to over express and knock down the expression of 
proteins of interest. Lentiviral transduction was designated as the appropriate technique as 
primary samples (human and mouse) are difficult to transduce due to their non-
proliferative status. For knock down experiments, plasmids encoding a shRNA hairpin for 
human CXCL1 (Cat No. RHS4533-NM_001511) and mouse CXCL4 (Cat No. RMM4534-
NM_019932) were purchased in a pLKO.1 vector containing a puromycin (puro) 
resistance cassette (pLKO.1-puro) (Thermo Fisher Scientific Inc., Hertfordshire, UK). 
Each shRNA construct was designed to contain a hairpin of 21 base paired (BP) stem 
separated by a 6 BP loop designed to target the gene of interest. ShRNA hairpins of 
interest were subcloned into the pLKO.1 plasmid containing a green fluorescent protein 
(GFP) tag (pLKO.1-GFP) as described in section 2.3.6.9.1. A plasmid encoding a shRNA 
hairpin with a sequence designed as non-targeting was used as a control (pLKO.1-Scr). 
CXCL1 cDNA for over expression studies was cloned into a plasmid with a GFP tag 
(CXCL-PRRL) as described in section 2.3.6.9.2. Packaging plasmids were required to 
provide the accessory proteins required for the transcription and packaging of an RNA 
copy of the expression construct into recombinant pseudoviral particles. PLKO.1-GFP, 
pLKO.1-Scr and PRRL plasmids were kindly donated by Dr Kamil Kranc. Packaging 
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plasmids pCML-VSV-G and HIV-1 were kindly donated by Professor John Rossi and 
Professor Paolo Salomoni respectively. 
2.1.3 Small molecule inhibitors 
SB-225002 is a potent and selective antagonist of CXCR2 for the inhibition of ligands 
binding to the CXCR2 receptor (Figure 2-1) (Catusse et al., 2003, White et al., 1998). SB-
225002 was purchased commercially (Cat No. 559405, Molecular Weight 352.1) (Merck 
Chemicals Ltd, Watford, UK). SB-225002 was solubilised in dimethyl sulfoxide (DMSO) 
at a stock solution of 1mg/mL, aliquoted and stored at -20ºC for long-term storage. A 
working concentration of SB-225002 was made fresh and diluted to the appropriate 
concentration as documented in the text, with a DMSO treated control as a vehicle control. 
 
Figure 2-1 Chemical structure for SB-225002. 
Image shows chemical structure for SB-225002 (chemical name N-(2-Bromophenyl)-N-(2-
hydroxy-4-ni-trophenyl)urea).  
2.1.4 Tissue culture supplies 
Company Product 
Baxter Healthcare, Nottingham, UK Sterile Water 
Biolegend, London, UK Mouse recombinant IL-3  
Mouse recombinant IL-6  
Mouse recombinant Stem Cell Factor (SCF) 
Chugai Pharma, London, UK Human recombinant G-CSF 
Gilson, Bedfordshire, UK Yellow and blue tips 
Greiner, Bio-One, Gloucestershire, UK Cryotubes 
Pipettes (5mL, 10mL and 25mL) 
Tissue culture flasks (25cm2, 75cm2 and 
175cm2) 
Tissue culture plates (6-well, 12-well, 24-
well and 96-well) 
Invitrogen, Paisley, UK 2-mercaptoethanol (2-ME) 
Dulbecco’s modified eagle medium 
(DMEM) 
Dulbecco’s phosphate buffered saline 
(PBS) 
Foetal calf serum (FCS) 
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Isocove’s modified Dulbecco’s medium 
(IMDM) 
L-glutamine (200mM) 
Miltenyi Biotec, Bisley, UK c-Kit microBead™ kit mouse 
CD34 microBead™ kit human 
CliniMACS CD34 reagent 
CliniMACS microBead™ kit 
CliniMACS PBS/ 
ethylenediaminetetraacetic acid (EDTA) 
buffer 
Nalgene Labware, Roskilde, Denmark 25cm2 and 75cm2 non-adherent tissue 
culture flasks 
Cryo freezing container ‘Mr Frosty’ 
Vacubottles 
Peprotech, London, UK Human recombinant FLT-3L 
Human recombinant granulocyte 
macrophage-colony stimulating factor 
(GM-CSF) 
Human recombinant CXCL1 
Human recombinant IL-3 
Human recombinant IL-6 
Human recombinant SCF 
Human recombinant TPO 
Sartorius, Hannover, Germany Minisart 0.2µM sterile filters 
Minisart 0.45µM sterile filters 
Scottish National Blood Transfusion, 
Glasgow, UK 
20% Human serum albumin (ALBA) 
4.5% Human albumin solution 
Sigma-Aldrich, Dorset, UK 5-azacytidine (5-AZA) 
Bovine serum albumin (BSA) 
Carbonate-bicarbonate buffer 
DMSO 
Gelatin 
Hank’s buffered salt solution (HBSS) 
Histopaque®-1077 
Histopaque®-1119 
Hydrochloric acid (HCl) 
Magnesium chloride (MgCl2) 
Polybrene® 
Potassium chloride (KCl2) 
Puro 
Sodium azide 
Trisodium citrate 
Trypan blue 
Trypsin-EDTA 
StemCell™ Technologies, Grenoble, 
France 
Ammonium chloride solution (NH4Cl) 
Bovine pancreatic deoxyribonuclease 
(DNase) 1mg/mL 
BSA/insulin/transferrin (BIT) 
Low density lipoprotein (LDL) 
Methocult (human) H4434+ 
Methocult (murine) M3434× 
Serum substitute 
Sterilin Ltd, Hounslow, UK Disposable pipettes (5mL, 10mL and 
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25mL) 
Pastettes 
Sterile plastic falcon tubes (15mL and 
50mL) 
+ Human Methocult contains SCF, GM-CSF, IL-3 & erythropoietin (EPO) 
× Mouse Methocult contains SCF, IL-3, IL-6 & EPO  
Table 2-2 Tissue culture supplies. 
 
2.1.5 Molecular biology supplies 
Company Product 
Applied Biosystems, Foster City, CA, 
USA 
96 and 384 well plates 
High capacity complimentary DNA 
(cDNA) reverse transcription (RT) kit 
SUPERase-In™ 
TaqMan® probes 
TaqMan® universal polymerase chain 
reaction (PCR) master mix 
Bioline, London, UK Crystal 5X DNA loading buffer blue 
HyperPAGE prestained protein marker 
ISOLATE II Genomic DNA kit 
MangoMix™ 
α-select competent cells (gold and silver 
efficiency) 
Bio-Rad Laboratories Ltd, Sussex, UK Combs 
Gel casting trays 
Immuno-Blot™ polyvinylidene fluoride 
(PVDF) membrane 
Immuno-Star™ WesternC™ Kit 
Cambridge Bioscience, London, UK Transdux™ 
Cell Signaling Technology®, New 
England Biolabs, Hitchin, UK 
100 BP DNA ladder 
1kiloBP DNA ladder 
Anti-goat IgG horseradish peroxidise 
(HRP) linked secondary antibody 
Anti-rabbit IgG HRP linked secondary 
antibody 
BamHI restriction enzyme (RE) 
EcorI RE 
HindIII RE 
NdeI RE 
Rabbit anti-human β-Tubulin antibody 
Shrimp alkaline phosphatase (SAP) 
SnabI RE 
SpeI RE 
T4 DNA ligase 
Chemical Store, University of Glasgow, 
UK 
Ethanol 
Isopropanol 
Methanol 
Clontech, Saint-Germain-en-Laye, 
France 
Retronectin™ 
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Eurofins MWG Operon, 
Wolverhampton, UK 
PCR primers 
Invitrogen CellsDirect™ One-Step PCR kit 
Miller’s Luria Broth (LB) base® 
Super optimal broth with catabolite 
repression (SOC) medium 
SYBR®Safe 
Tris EDTA (TE) buffer 
Qiagen, West Sussex, UK HiSpeed® plasmid maxi kit 
QIAamp DNA blood mini kit 
QIAquick gel extraction kit 
QIAshredder kit 
RNeasy micro kit 
RNeasy mini kit 
SG Wasseraufbereitung und 
Regenerierstation GmbH, Barsbuttel, 
Germany 
Ultra pure water system 
Sigma-Aldrich 4-(2-hydroxyethyl)-1-
piperazinethanesulfonic acid (HEPES) 
Agarose 
Ammonium persulfate (APS) 
Boric acid 
Calcium chloride (CaCl2) 
EDTA 
Formaldehyde solution (36.5%) 
Microagar 
Sodium chloride (NaCl) 
Sodium docedyl sulphate (SDS) 
Tetramethylethylenediamine (TEMED) 
Tris base 
TWEEN 20 for electrophoresis 
Thermo Fisher Scientific Inc. Bicinchoninic acid (BCA)™ protein assay 
kit 
Table 2-3 Molecular biology supplies. 
 
2.1.6 Flow cytometry supplies 
Company Product 
BD Biosciences, Oxford, UK Annexin-V Allophycocyanin 
(APC)/Fluorescein isothiocyanate (FITC) 
Anti-human CD34 APC monoclonal 
antibody 
Anti-human CD38 Peridinin chlorophyll 
(PerCP) monoclonal antibody 
Anti-human CD90 Phycoerithrin (PE)-Cy5 
monoclonal antibody 
Anti-human Ki-67 FITC 
Ant-mouse CD4, CD5, CD8a, CD11b, 
GR1, TER119 & B220 biotinylated 
antibodies 
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Fluorescent activated cell sorting (FACS) 
flow/ FACS clean 
IgG APC 
IgG FITC 
IgG PE-Cy5 
IgG PerCP 
Biolegend Anti-mouse B220 PE-Cy5 
Anti-mouse CD11b PE 
Anti-mouse CD11b PE-Cy7 
Anti-mouse CD150 APC 
Anti-mouse CD16/CD32 APC-Cy7 
Anti-mouse CD19 APC-Cy7 
Anti-mouse CD34 FITC 
Anti-mouse CD34 PE 
Anti-mouse CD45.1 FITC 
Anti-mouse CD45.2 Pacific Blue™ 
Anti-mouse CD48 PE 
Anti-mouse CD4 PE 
Anti-mouse CD8a APC 
Anti-mouse CD8a PE 
Anti-mouse c-Kit APC 
Anti-mouse c-Kit APC-Cy7 
Anti-mouse Gr-1 APC 
Anti-mouse Gr-1 APC-Cy7 
Anti-mouse Sca-1 PE-Cy7 
Anti-mouse TER119 FITC 
Streptavidin PerCP 
R&D Systems, Abington, UK Anti-human CXCL4 PE monoclonal 
antibody 
Anti-human CXCR2 FITC monoclonal 
antibody 
Invitrogen Streptavidin Pacific Blue™  
Sigma-Aldrich 4’6-Diamidino-2-phenylindole 
dihydrochloride (dapi) 
Table 2-4 Flow cytometry supplies. 
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2.1.7 Primers 
2.1.7.1 PCR primer sequences 
Primer Sequence 
Human CXCL1 Forward ATGGCCCGCGCTGCTCTCTCCGC 
Human CXCL1 Reverse GCAGGGCCTCCTTCAGGAACAGCC 
Mouse Cxcl4 Forward GGTACCACACCGGCAGATGATAG 
Mouse Cxcl4 Reverse CACTATGTTGAGCCCCCTTCCTG 
Neomycin Forward TTTTGTCAAGACCGACCTGT 
Neomycin Reverse TGCGCTGCGAATCGGGAGCG 
pLKO.1 Backbone Forward GACTATCATATGCTTACCGT 
pLKO.1 Backbone Reverse AAACCCAGGGCTGCCTTGGAAAAG 
Table 2-5 PCR primer sequences. 
 
2.1.7.2 TaqMan® probes+ 
Probe Catalog number Spans exons 
Human Cell Division Cycle 6 
(CDC6) 
Hs00153374_m1 Yes 
Human CD34 Hs00990732_m1 Yes 
Human CD38 Hs01120071_m1 Yes 
Human CXCL1 Hs00236937_m1 Yes 
Human CXCL2 Hs00601975_m1 Yes 
Human CXCL4 Hs00427220_g1 Yes 
Human CXCL6 Hs00605742_g1 Yes 
Human CXCR2 Hs00174304_m1 Yes 
Human Glyceraldehyde 3-
Phosphate Dehydrogenase 
(GAPDH) 
Hs02758991_g1 Yes 
Mouse CCL19 Mm00839967_g1 Yes 
Mouse CCR7 Mm01301785_m1 Yes 
Mouse CXCL1 Mm00433859_m1 Yes 
Mouse CXCL13 Mm00444533_m1 Yes 
Mouse CXCL2 Mm00436450_m1 Yes 
Mouse CXCL3 Mm01701838_m1 Yes 
Mouse CXCL4 Mm00451315_g1 Yes 
Mouse CXCL5/6 Mm00436451_g1 Yes 
Mouse CXCR2 Mm00438258_m1 Yes 
Mouse CXCR5 Mm00432086_m1 Yes 
β2M Mm00437762_m1 Yes 
+ All Taqman® probes were purchased from Applied Biosystems.  
Table 2-6 Taqman® probes. 
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2.1.8 Immunofluorescence supplies 
Company Product 
Abcam, Cambridge, UK Mouse IgG isotype control 
BD Biosciences Golgistop™ 
Carl Zeiss, Jena, Germany AxioVision software 
Fisher Scientific, Leicestershire, UK Multi-spot microscope slides 
Invitrogen Alexa Fluor® 488 goat anti-mouse IgG 
Alexa Fluor® 594 donkey anti-goat IgG 
R&D Systems Goat IgG isotype control 
Mouse anti-human CXCR2 monoclonal 
antibody 
Santa-Cruz Biotechnology, Inc, CA, USA Goat anti-human CXCL1 polyclonal 
antibody 
Sigma-Aldrich Poly-L-lysine 0.1% (w/v) 
Triton-X-100 
Vector Laboratories Ltd, Peterborough, 
UK 
VECTASHIELD® hardest mounting 
medium with dapi 
Table 2-7 Immunofluorescence supplies. 
 
2.2 Medium and Solutions 
2.2.1 Tissue culture 
 
2.2.1.1 DMEM 
DMEM     440mL 
FCS      50mL 
L-glutamine (200mM)   5mL 
Penicillin/streptomycin solution  5mL   
(10,000UmL-1/10,000gmL-1) 
 
2.2.1.2 DMEM+ 
+DMEM as prepared in section 2.2.1.1 with the addition of 20% FCS for viral production. 
 
DMEM     390mL 
FCS      100mL 
L-glutamine (200mM)   5mL 
Penicillin/streptomycin solution  5mL   
(10,000UmL-1/10,000gmL-1) 
 
2.2.1.3 IMDM 
IMDM      440mL 
FCS      50mL 
L-glutamine (200mM)   5mL 
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Penicillin/streptomycin solution  5mL   
(10,000UmL-1/10,000gmL-1) 
 
2.2.1.4 IMDM+ 
+IMDM prepared as in section 2.2.1.3 with the addition of cytokines for mouse culture. 
 
IMDM      50mL 
Mouse SCF (10µg/mL)   200µl (40ng/mL) 
Mouse IL-3 (10µg/mL)   100µl (20ng/mL) 
Mouse IL-6 (10µg/mL)   100µl (20ng/mL) 
 
2.2.1.5 PBS 2%FCS 
PBS      490mL 
FCS      10mL 
2.2.1.6 DAMP solution 
DNase I     2mL 
MgCl2      1.25mL 
Trisodium citrate (0.155M)   53mL 
ALBA      25mL 
Dulbecco’s PBS    418.75mL 
 
2.2.1.7 Serum free medium (SFM) 
BIT      25mL 
L-glutamine (200mM)   1.25mL 
Penicillin/streptomycin solution  5mL   
(10,000UmL-1/10,000gmL-1) 
2-ME (50mM)    250µl 
LDL (10mg/mL)    500µl 
IMDM      97.25mL 
 
2.2.1.8 SFM supplemented with a 5 GF cocktail+ 
 
SFM      50mL 
Human IL-3 (50µg/mL)   20µl (20ng/mL) 
Human IL-6 (50µg/mL)   20µl (20ng/mL) 
Human G-CSF (20µg/mL)   50µl (20ng/mL) 
Human FLT-3L (50µg/mL)   100µl (100ng/mL) 
Human SCF (50µg/mL)   100µl (100ng/mL) 
 
+The solution was filtered through a 0.2µM filter to sterilise the solution before use. 
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2.2.1.9 20% DMSO/4.5% ALBA 
DMSO      20mL 
4.5% ALBA     80mL 
 
2.2.1.10 Freezing media 10% DMSO FCS 
 
DMSO      5mL 
FCS      45mL 
 
2.2.1.11 PBS/0.1% BSA 
 
PBS      50mL 
BSA      0.5g 
 
 
 
2.2.2 Western blotting 
2.2.2.1 2X SDS sample buffer (Laemmli) 
1.5M Tris-HCl, pH6.8   10mL 
Glycerol     30mL 
20% (w/v) SDS    6mL 
Bromophenol blue    15mL 
dsH20      up to 100mL 
 
2.2.2.2 10X TBS buffer+ 
 
NaCl      876.6g 
Tris      121.1g 
dH20      10L 
 
 
+A 1X solution was made using 100mL of the 10X solution with the addition of 900mL of 
dH20 supplemented with 10mL of Tween-20. 
 
2.2.2.3 Homemade gels 
2.2.2.3.1 15% Resolving gel 
 
dsH20      2.3mL 
30% Acrylamide    5.0mL 
1.5M Tris (pH8.8)    2.5mL 
10% SDS     0.1mL 
10% APS     0.1mL 
TEMED     0.01mL 
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2.2.2.3.2 Stacking gel 
 
dsH20      1.4mL 
30% Acrylamide    0.33mL 
1.0M Tris (pH6.8)    0.25mL 
10% SDS     0.02mL 
10% APS     0.02mL 
TEMED     0.01mL 
 
2.2.2.4 10X Running buffer+ 
Glycine     144.1g 
Tris      30.3g   
SDS      10g 
dH20      up to 2L 
pH 8.3 
 
+A 1X solution was made using 100mL of the 10X solution with the addition of 900mL of 
dH20. 
 
2.2.2.5 10X Transfer buffer+ 
Glycine     144.1g 
Tris      30.3g 
dH20       to 2L 
pH 8.3 
 
+A 1X solution was made using 100mL of the 10X solution with the addition of 700mL of 
dH20 and 200mL of methanol. 
 
2.2.2.6 5% BSA/TBST blocking solution 
1X TBST     100mL 
BSA      5g 
 
2.2.3 Flow cytometry 
 
2.2.3.1 Dapi+ 
 
Dapi      50mg 
dsH20      1mL 
 
+The stock solution was diluted 1 in 50 in PBS to make a 1000X solution. Aliquots were 
stored at -20ºC and immediately prior to use a 1X solution was made using PBS result in a 
final concentration of 1µg/mL. 
 
2.2.3.2 Annexin-V 
 
Annexin-V APC/FITC   5µl 
HBSS supplemented with dapi  95µl      
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2.2.4 Immunofluorescence 
 
2.2.4.1 3.65% Formaldehyde 
 
36.5% Formaldehyde solution  5mL 
PBS      45mL 
 
2.2.4.2 0.25% Triton-X-100 
 
Triton-X-100     125µl 
PBS      49.875mL 
 
2.2.4.3 5% BSA blocking solution  
 
BSA      5g 
PBS      100mL 
 
2.2.5 PCR 
 
2.2.5.1 10X TBE+ 
 
Tris base     108g 
Boric acid     55g 
EDTA     9.3g 
dsH20      up to 1L 
 
+A 1X solution was made using 100mL of the 10X solution with the addition of 900mL of 
dH20.  
 
 
2.2.5.2 2% Agarose TBE+ 
 
1X TBE     125mL 
Agarose     2.5g 
 
+The solution was boiled using a microwave until the agarose powder was completely 
dissolved. After cooling, 12.5µl of SYBR®Safe DNA gel stain was added to the solution 
and gel was poured into casting trays and allowed to set before use. 
 
 
2.2.5.3 TaqMan® PCR reaction 
 
10µl reaction 
Universal gene expression master mix 5µl 
cDNA       1µl 
TaqMan® assay    0.5µl 
Nuclease free H20    3.5µl  
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2.2.5.4 cDNA synthesis reaction 
20µl reaction 
10X reverse transcriptase buffer  2µl 
25X dNTP mix    0.8µl 
10X RT random primers   2µl 
Reverse transcriptase    1µl 
RNAse inhibitor    1µl 
RNA (1µg) and nuclease free H20  13.2µl 
2.2.5.5 PCR mix 
 
50µl reaction 
MangoMix™     25µl 
Template     2µl 
Primers (10µM)    2µl 
Nuclease free H20    up to 50µl 
 
2.2.5.6 RT and preamplification mix 
 
5µl reaction 
0.2X TaqMan® probes mix   1.4µl 
Cells direct 2X reaction   2.8µl 
SUPERase-In     0.056µl 
SuperscriptIII RT    0.112µl 
TE buffer     0.672µl 
 
 
2.2.6 Cloning 
 
2.2.6.1 30% glycerol+ 
 
Glycerol     30mL 
dsH20      70mL 
 
+The solution was autoclaved prior to use for sterilisation. 
 
2.2.6.2 Bacterial glycerol stocks+ 
  
Bacteria in LB broth    500µl 
30% glycerol     500µl 
 
+The solution was prepared with a Bunsen burner and immediately stored on ice and 
transferred to -80ºC for storage. 
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2.2.6.3 RE digestion 
 
DNA      1-3µg 
RE      1µl 
10X Buffer      1µl 
10X BSA     1µl 
Nuclease free H20    up to 10µl 
 
 
2.2.6.4 Ligation 
 
DNA insert and backbone   appropriate volume+ 
T4 DNA ligase    1µl 
DNA ligase buffer    1µl 
Nuclease free H20    up to 10µl 
 
+A molar ratio of insert to vector as shown in Equation 1 was used to determine volume of 
DNA to use per reaction. Insert to vector ratios 3:1, 6:1 and 9:1 were used and a reaction 
minus DNA insert was used as a negative control with every reaction. 
 
 
((ng vector) x (kb size of insert))/(kb size of vector)) x (molar ratio of (insert/vector)) = (ng 
insert) 
Equation 1 Molar ratio of insert to backbone.  
The equation was used to calculate the quantity of insert to use in a ligation to achieve a particular molar ratio 
of insert to vector. 
 
 
2.2.7 Transfection 
 
2.2.7.1 2X HEPES-buffered saline (HBS) 
 
NaCl      8g 
KCl      0.37g 
Na2HP042H20     106.5mg 
Dextrose     1g 
HEPES     5g 
dsH20      to 500mL 
pH 7.05 to 7.1 
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2.2.7.2 2M CaCl2 
 
CaCl2      147g 
dsH20      to 500mL 
 
 
 
2.2.7.3 Transfection solution/T125cm2 flask 
 
dsH20      440µl 
2 X HBS     500µl 
2M CaCl2      60µl 
pCML HIV-1 plasmid   6µg 
pCML VSV-g plasmid   3.3µg 
Plasmid for transfection   10µg 
 
 
 
 
2.2.8 Microbiology 
 
2.2.8.1 Ampicillin (100mg/mL)+ 
 
Ampicillin sodium salt   5g 
dsH20      50mL 
 
+The solution was filter sterilised through a 0.2µM filter, aliquoted and stored at -20ºC. 
 
 
2.2.8.2 LB broth 
 
Miller’s LB base®    20g 
dsH20      up to 1L 
Ampicillin (100mg/mL)+   1mL 
 
+The solution was autoclaved immediately after prepared, allowed to cool and 
supplemented with ampicillin prior to use. 
 
2.2.8.3 LB agar plates 
 
Miller’s LB base®    20g 
Microagar     7g 
Ampicillin (100mg/mL)+   1mL 
 
 
+The solution was autoclaved and allowed to cool in a waterbath at 50ºC. Ampicillin was 
supplemented and 10mL of solution was added to individual sterile petri dishes. Dishes 
were allowed to solidify and stored at 4ºC for future use. 
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2.3 Methods 
2.3.1 General tissue culture 
A list of the materials used for tissue culture can be seen in Table 2-2. 
2.3.1.1 Technique 
Tissue culture was conducted using a laminar air flow hood. An aseptic technique was 
maintained with all materials sprayed in 70% alcohol prior to use. 
2.3.1.2 Cryopreservation of cells 
Primary cells and cell lines were stored in liquid nitrogen long term. For cryopreservation, 
a cell suspension was made in medium which was added to an equal volume of ALBA + 
20% DMSO to give a final concentration of 10% DMSO (2.2.1.9). Cell lines were 
resuspended in a solution containing neat FCS supplemented with 10% DMSO (2.2.1.10). 
Cells were resuspended in the appropriate freezing solution at a concentration of 106 
cells/mL and dispensed into cryotubes at a final volume of 2mL. The cryotubes were 
placed in a freezing container (‘Mr Frosty’) that contained neat isopropyl alcohol and were 
incubated in a -80ºC freezer overnight. This technique allowed a controlled reduction in 
temperature over time. Subsequently, cells were stored in -80ºC for short term or liquid 
nitrogen for long term storage. 
2.3.1.3 Recovery of frozen samples 
To recover the maximum number of cells from cryopreservation, it was necessary to exert 
extreme care with primary samples. On removal from liquid nitrogen, cells were 
immediately thawed in a waterbath at 37ºC. The cell solution was transferred to a 50mL 
falcon tube and thawing solution DAMP (2.2.1.6) was added dropwise to cells over 
approximately 20 minutes (min). Cells were centrifuged for 10 min at 200 x g and the step 
was repeated. After centrifugation, cells were washed in PBS/2% FCS (2.2.1.5) and 
resuspended in SFM supplemented with GF (2.2.1.8) overnight for recovery. Cell lines 
were thawed as described for primary cells and resuspended in appropriate culture medium 
for each cell line (2.2.1), washed in PBS and resuspended in medium overnight with a 
medium change the next day to remove dead cells/debris after thaw. 
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2.3.1.4 Assessment of viability 
Cell viability and cell counting was carried out using the trypan blue exclusion method and 
performed using a counting chamber. Trypan blue is a coloured chemical that cannot pass 
the cell membrane barrier in live, viable cells with an intact membrane. Dead cells allow 
the absorption of the compound, therefore the cells display a blue colour under the 
microscope and can be discriminated from viable cells. Trypan blue stock solution (Cat 
No. T8154-100ML) was diluted in 1 in 10 in PBS to make a working solution. The cell 
suspension was diluted 1 in 2 in the trypan blue solution. 10µl of the solution was 
transferred to two sides of a haemocytometer counting chamber. Four squares within each 
counting chamber side were counted, averaged and repeated with the second side of the 
haemocytometer. To ensure accuracy, a minimum of 100 cells was counted across four 
squares. The cell count was multiplied by the dilution factor and 104 to get the cell 
count/mL.  
2.3.1.5 CFC assay 
The CFC/methycellulose is widely used to detect and quantify haemopoietic progenitor 
cells based on their ability to proliferate and differentiate to produce colonies in response 
to culture in a particular growth medium. Resulting colonies are scored based on number 
and type of colony which gives an indication of cell growth and differentiation. This assay 
can be of particular use for monitoring the activity of cells in response to treatment in 
culture or genetic manipulation. In addition, cells harvested from a primary CFC assay can 
be reseeded into replating assays which can be used to get an indication of the self renewal 
activity of cells. The particular cytokines used in this study were optimised to support 
growth of erythroid progenitors (blast forming units-erythroid and colony forming units-
erythroid (CFU-E)), granulocyte-macrophage progenitors (colony forming units-
granulocyte macrophage (CFU-GM)) and multi-potential granulocyte, erythroid, 
macrophage and megakaryocyte progenitors (colony forming units-granulocyte erythroid 
macrophage megakaryocyte (CFU-GEMM)).  
Primary human (Cat No. 04444) or mouse (Cat No. 03434) cells were plated in 
Methocult™, vortexed to ensure homogenous mixing of cells/cytokines and plated in 
duplicate in 6 well plates using a sterile needle and syringe. DsH20 was added to the 
surrounding wells in each plate to ensure humidity during the incubation period. Cells were 
incubated for a period between 10-14 days (based on growth) at 37ºC, 5% C02 and 
resulting colonies were counted and scored based on colony type (Figure 2-2) and images 
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taken using a standard light microscope. After counting, colonies were harvested 
resuspended in IMDM (2.2.1.3), counted and an equal number of cells was added to fresh 
aliquots of Methocult™ and plated as described above. It was noted that the resulting 
colonies formed in a secondary assay were all CFU-GM so colony numbers were counted 
and not scored based on type. Primary human CD34 enriched samples were seeded at 
1,000 cells/mL/dish and replated at 104 cells/mL/dish. Primary mouse BM, spleen and PB 
were seeded at 104, 105 and 105 cells/mL/dish respectively and replated at the same 
density. Mouse c-Kit enriched cells after lentiviral transduction were seeded at 104 
cells/mL/dish. A red blood cell (RBC) lysis step was carried out on mouse PB samples 
before plating as described in section 2.3.7.4 to remove RBC which would interfere with 
the analysis. 
 
Figure 2-2 Representative images of colonies obtained in a CFC assay.  
Images display representative examples of different types of colonies observed in this 
study. CFU-GM progenitor colonies consisted of colonies of varying sizes with a compact 
centre consisting of small white cells (A), CFU-E progenitor colonies were small, 
condensed and solely red in colour (B) and CFU-GEMM progenitor colonies were large in 
size and contained a mixture of white and red cells within the colony (C). This scoring 
system was used consistently to identify colony types throughout this study using both 
human and mouse samples.  
 
 
 
A B C 
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2.3.1.6 Culture of cell lines and primary cells 
HEK293, HT 1080 and PC-3 cell lines were maintained in DMEM (2.2.1.1) and HEK293 
cell lines were maintained in a higher concentration of serum for viral production (2.2.1.2). 
Cell lines were maintained at a density of 105-106 cells/mL in tissue culture flasks 
(T25cm2, T75cm2 or T175cm2). Cells were counted every two days and passaged with 
warm, fresh medium. 
Primary human CD34+ or mononuclear cells (MNC) were cultured in SFM supplemented 
with a high GF cocktail containing IL-3, IL-6, SCF, G-CSF and FLT3-L for cell survival 
(2.2.1.8). Cells were maintained at a density of 105-106 cells/mL in non-adherent tissue 
culture flasks (T25cm2, T75cm2 or T175cm2). Primary mouse MNC or c-Kit enriched cells 
were cultured in IMDM supplemented with a GF cocktail containing IL-3, IL-6 and SCF 
for cell survival and to aid the integration of lentiviral particles (2.2.1.4).  
2.3.1.7 Drug treatment 
CXCR2 inhibitor SB-225002 was purchased commercially (Cat No. 559405-1mg). SB-
225005 was solubilised in DMSO at a stock solution of 1mg/mL, aliquoted and stored at -
20ºC. SB-225002 was made fresh and diluted to the appropriate concentration in medium 
prior to use with a DMSO treated control. 
Recombinant human CXCL1 (Cat No. 300-11) was reconstituted in dsH20 and further 
diluted in PBS/0.1% BSA (2.2.1.11). Recombinant protein was added to CD34+ cells in 
culture in various concentrations with an appropriate vehicle treated control. 
2.3.1.8 Granulocyte isolation 
Histopaque® is a Ficoll gradient solution designed for cell separation techniques. Whole 
blood can be layered over the solution and after a centrifugation step allows cells of 
different densities to be isolated. Histopaque®-1077 is of a particular density that allows 
the isolation of MNC while removing erythrocytes, plasma and granulocytes. To allow 
isolation of granulocytes, Histopaque®-1077 can be combined with Histopaque®-1119. 
Human PB was collected from normal, healthy donors with informed consent. Blood was 
diluted in PBS and layered onto a double layer of Histopaque®-1077 and Histopaque®-
1119. Solution was spun at 400 x g for 30 min and the layer containing the granulocytes 
was isolated, washed in PBS/2% FCS and used immediately for downstream applications. 
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2.3.2 Transfection 
2.3.2.1 Lentiviral infection 
Lentiviral transduction is a technique which was developed as an effective method for the 
introduction of stable expression of protein in any cell type, including primary 
haemopoietic cells which are largely non-dividing therefore do not integrate plasmid DNA. 
The method involves transiently transfecting HEK293 cell lines with vectors encoding the 
desired lentiviral vector and packaging plasmids. These cells then package the lentiviral 
expression construct into pseudoviral particles which are released into the cell supernatant 
which can be added to cells of interest to allow highly efficient transduction. HEK293 cells 
were plated at 80% confluence 24 hours prior to transfection in T125cm2 tissue culture 
flasks. Immediately prior to transfection (CaCl2 method), fresh medium was added. A 
solution containing plasmids was prepared as described in 2.2.7.3, mixed and incubated at 
37ºC for 30 min. The mix was then added drop wise to the medium and cells were 
incubated overnight. The following day, the medium was removed and fresh medium 
supplemented with 20% FCS (2.2.1.2) was added to cells to remove the CaCl2 mix 
precipitate and to allow viral production for subsequent collection. 48 hours after the 
addition of fresh medium, the medium containing viral particles was removed and filtered 
through a 0.44µm sterile filter. The cells of interest to be transduced were resuspended in 
the viral medium and the appropriate transduction reagent was added to the medium and 
the following protocols were carried out depending on the cell type. Viral particles were 
prepared fresh for every transduction and not used from frozen due to a decrease in viral 
transduction efficiency with frozen viral supernatant. 
2.3.2.1.1 Cell lines 
HT 1080 cells were resuspended in the viral medium with the addition of Polybrene® (Cat 
No. H9268) at a final concentration of 4µg/mL. Cells were cultured for 24 hours in the 
viral supernatant. 
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2.3.2.1.2 Primary human samples 
Primary human samples are not actively dividing, difficult to transduce and required a 
different transduction reagent and a protocol of spin inoculation. Primary human cells were 
thawed and cultured over night as mentioned in sections 2.3.1.3 and 2.3.1.6. After 
overnight recovery, an appropriate number of cells were resuspended in viral medium with 
the addition of Transdux™ (Cat No. LV850A-1) at a 1 in 200 dilution,  spun at 400 x g for 
1.5 hours at 32ºC and subsequently cultured for several hours in the viral supernatant at 
37ºC. Cells were infected with 2 rounds of infection with fresh supernatant containing viral 
particles at each round of infection.  
2.3.2.1.3 Primary mouse samples 
Primary mouse samples were enriched for stem/progenitor marker c-Kit as mentioned in 
section 2.3.3.4 to assess a more primitive cell population. For transduction of primary 
mouse samples, Retronectin™ (Cat No. T100A) (50µg/mL) was coated onto tissue culture  
6 well plates and incubated overnight at 4ºC prior to transduction. Retronectin™ was 
removed, viral medium was added and centrifuged at 400 x g for 1.5 hours at 32ºC. Viral 
supernatant was removed, cells were seeded at 1x106 cells cells/well, centrifuged at 400 x g 
for 1.5 hours at 32ºC and subsequently cultured for several hours in the viral supernatant at 
37ºC. Cells were infected with 3 rounds of infection with fresh supernatant containing viral 
particles. 
After 24 hours in final viral medium, cells were washed several times in PBS and 
resuspended in appropriate medium for 24 hours before downstream applications. 
Depending on the lentiviral vector of interest containing a puro resistance cassette or a 
sequence encoding GFP protein, cells were either cultured in puro (Cat No. P8833-10mg) 
(2µg/ml) for 7 days or sorted for GFP positive cells (GFP+) using FACS as mentioned in 
section 2.3.3.13. 
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2.3.3 Stem cell selection 
2.3.3.1 Collection of human primary cell samples 
All samples were collected with the approval from the local research and ethics committee 
and with written informed patient consent from patients. Samples were obtained from 
patients undergoing autologous stem cell collection. Patients had been treated with G-CSF 
following chemotherapy and had excess CD34+ cells remaining after those required for 
clinical use had been processed. The CD34+ content is deemed ‘normal’ and used for these 
studies. A table listing the samples used in this study can be seen in (Table 2-8). A 
combination of male and female donors were used. BM samples used in this study were 
from normal healthy volunteers or purchased from commercial companies (AllCells and 
Lonza). Further information including age and gender was not available for the BM 
samples.  
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Sample ID Age Gender Disease 
121106 N/A Male Lymphoma 
121121 N/A Male Lymphoma 
130201 N/A N/A Lymphoma 
121113 N/A N/A Germ Cell Tumour 
Non CML 014 42 Male N/A 
Non CML 017 33 Male Lymphoma 
Non CML 019 64 Male Mantle Cell 
Lymphoma 
Non CML 021 31 Male Myeloma 
Non CML 022 50 Female Relapsed Follicular 
Lymphoma 
Non CML 023 61 Female Hodgkin’s 
Lymphoma 
Non CML 024 59 Female Relapsed Hodgkin’s 
Lymphoma 
 
Table 2-8 Patient sample information. 
Table shows sample identification number, age, gender and disease status of the samples 
used in this study. N/A: Non applicable states that the information was not available for the 
particular sample. 
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2.3.3.2 Removal of RBC 
To remove RBC from primary human material, a separation based on density gradients 
was used. Whole blood was diluted in PBS and layered onto Histopaque®-1077. The 
suspension was centrifuged at 400 x g for 30 min and the layer containing the MNC 
fraction was isolated and washed in PBS. This technique allows the isolation of MNC, 
leaving the plasma, granulocytes and RBC separated. 
2.3.3.3 Stem cell enrichment 
For enrichment of the human stem/progenitor population, the mononuclear fraction of PB 
and BM was enriched for cell surface marker CD34 using magnetic beads and a magnet 
separation method. The mononuclear layer of cells was counted and the appropriate 
number of cells was mixed with magnetic beads against human CD34 IgG (Cat No. 130-
046-702). The cells were then loaded onto a column and washed to remove negative cells. 
The cell suspension was removed from the magnetic column and the positively selected 
cells were collected and washed. To ensure the enrichment worked correctly and to assess 
the efficiency, resulting cells were stained with an antibody against CD34 (Cat No. 
555824) and FACS was performed. The samples used in this study were kindly processed 
by Dr Alan Hair.  
2.3.3.4 c-Kit enrichment of mouse BM cells 
For enrichment of the mouse stem/progenitor population, unmanipulated BM was enriched 
for cell surface marker c-Kit using magnetic beads (Cat No. 130-091-224) and a magnet 
separation method. BM was prepared as mentioned in section 2.3.7.4. The BM cell 
suspension was counted and the appropriate number of cells was mixed with magnetic 
beads against mouse c-Kit IgG. The cells were then loaded onto a column and washed to 
remove negative cells. The cell suspension was removed from the magnetic column and 
the positively selected cells were collected and washed. To ensure the enrichment worked 
correctly and to assess the efficiency, resulting cells were stained with an antibody against 
c-Kit (Cat No. 105825) and FACS was performed. Figure 2-3 demonstrates the enrichment 
of c-Kit positive cells after magnetic bead selection. 
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Figure 2-3 Representative plot of c-Kit staining in unmanipulated mouse BM and BM after c-
Kit bead selection.  
C-Kit staining can be visualised on the X axis. Viable cells were selected using forward 
angle light scatter (FSC) and side angle light scatter (SSC) and an unstained control was 
used to set the positive cell gate. A small percentage of positive cells for c-Kit staining can 
be seen in an unmanipulated BM sample (A) in contrast to cells stained after enrichment 
using c-Kit magnetic beads (B). 
A B 
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Flow cytometry and cell sorting 
2.3.3.5 Flow cytometry 
All reagents used for flow cytometry can be seen in Table 2-4. Flow cytometry permits the 
visualisation and sorting of cells according to the presence of antigens which are detected 
through fluorescently labelled antibodies, which when bound and excited with a laser can 
be detected. This allows a quantitative technique to compare protein expression between 
samples. A FACSCanto II flow cytometer (BD Biosciences) was used for flow cytometry 
analysis and a FACSAria (BD Biosciences) was used for sorting.  With the exception of 
apoptosis assays, viable cells were gated on using FSC and SSC. Unstained cells, single 
colour controls and fluorescence minus one (FMO) controls were used for compensation 
analysis and to set appropriate gates for analysis. Data was acquired using BD FACSDiva 
(BD Biosciences) and analysis was performed using FlowJo (Tree Star Inc., Ashland, 
USA) software.  
2.3.3.6 Antibody staining 
All antibodies were titrated for optimal concentration before use. Antibodies used in this 
study are described in Table 2-4. Controls consisted of an appropriate isotype matched 
antibody at the same concentration. Isotype controls were used for all human antibodies 
used. Mouse primary cells were incubated in Fc block (CD16/CD32) (Cat No. 553141) and 
incubated on ice prior to antibody staining with the exception of mouse progenitor staining 
which uses a CD16/CD32 antibody.  
2.3.3.7 Cell surface antibody staining 
An appropriate number of cells were centrifuged at 300 x g for 5 min and washed several 
times. Cells were resuspended in PBS/2% FCS with antibodies at an appropriate 
concentration and incubated for the period and temperature as per the manufacturer’s 
protocol. After staining, cells were washed, resuspended in 200µl PBS/2% FCS and 
analysed. Cells required for sorting were filtered using a 0.2µM filter prior to use. 
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2.3.3.8 Apoptosis assays 
To examine apoptosis of cells in response to drug treatment or gene manipulation, 
Annexin-V (Cat No. 550475) and dapi (Cat No. D9542) were used. Briefly, protein 
phosphatidylserine is bound to the inner cell membrane, however during apoptosis this 
protein translocates to the outer cell membrane which can be detected using flow 
cytometry using stain Annexin-V. Annexin-V positive cells contain both early and late 
apoptotic cells which can be further discriminated with the addition of dapi. Dapi is used as 
a dead cell discriminator and is present only in late apoptotic cells due to the ability of the 
dye to penetrate the cell membrane when it becomes disrupted in late apoptosis. 
Approximately 105 cells were incubated with Annexin-V and a solution containing HBSS 
and dapi as mentioned in section 2.2.3.2 for 15 min at room temperature (RT) in the dark. 
Subsequently, cells were diluted in HBSS and analysed. Cells Annexin-V-/dapi- were 
deemed as viable, with Annexin-V+/dapi- early apoptotic and Annexin-V+/dapi+ late 
apoptotic (Figure 2-4).  
 
Figure 2-4 Representative plot of Annexin-V/dapi staining in viable and apoptotic cells.  
Annexin-V and dapi are visualised on the X and Y axes respectively. Viable cells can be 
seen in quadrant I, early apoptotic II and late apoptotic III. The low percentage of cells 
positive for Annexin-V and dapi can be seen in unmanipulated cells (A) which increases in 
response to stimuli (B). 
 
 
A B 
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2.3.3.9 Cell cycle analysis 
Ki-67 and dapi were used to examine the proportion of cells in different stages of the cell 
cycle. Ki-67 is a nuclear protein which is expressed during cellular proliferation (Gerdes et 
al., 1984). The protein is therefore only present in cells in active states of the cell cycle and 
is excluded from cells in G0. Using this staining pattern, cells can be discriminated between 
G0 and other phases using Ki-67 staining. Analysis of Ki-67 protein staining in 
combination with DNA dye dapi can be used to identify cells in all stages of the cell cycle 
(Jordan et al., 1996). Dapi stains intercalating DNA and distinguishes between cells in 
G0/G1 and S/G2/M.  
Cells were washed in PBS/2%FCS and resuspended in 1mL of PBS/3.65% formaldehyde 
(2.2.4.1) and incubated for 30 min on ice for fixation. 1mL of PBS/0.25% Triton-X-100 
(2.2.4.2) was added without washing to permeabilise the cells which were incubated at 4ºC 
overnight. Cells were washed in PBS/2%FCS and resuspended in 1mL of PBS/2%FCS and 
the cell suspension was divided equally between two flow cytometry tubes for incubation 
with Ki-67-FITC (Cat no. 556026) or the appropriate isotype control. After incubation at 
RT for 40 min, the remaining unbound antibody was washed in PBS/2%FCS and the cells 
were resuspended in 100µl PBS/2% FCS with dapi. The cell solution was incubated for 
several hours at 4ºC, washed and analysed. In cases where all available channels of the 
flow cytometer were in use with other fluorochromes, Ki-67 staining was used in the 
absence of dapi. Figure 2-5 demonstrates a representative staining profile of cells stained 
with Ki-67 and dapi. 
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Figure 2-5 Representative plot of cell cycle staining using Ki-67 and dapi.  
Dapi (linear) and Ki-67 (log) are visualised on the X and Y axes respectively. Viable cells 
were identified using FSC and SSC and gates were set up according to cells unstained with 
dapi and an isotype control for the Ki-67 antibody. Cells in G0, G1 and G2/S/M phases can 
be identified in gates I, II and III respectively.  
2.3.3.10  Selection of human stem cell fractions 
The CD34 antigen represents a marker of stem/progenitor cells which can be further sub 
fractionated using additional cell surface markers. Primary CD34 enriched samples were 
centrifuged and washed in PBS/2% FCS. Cells were incubated with CD34, CD38 and 
CD90 (2.1.6) at optimal concentrations for 15 min at RT in the dark. Cells were washed in 
PBS/2% FCS to remove unbound antibody and resuspended in approximately 1x106 
cells/100µl PBS/2% FCS, filtered through a 0.7 µm mesh and analysed on the FACSAria. 
Appropriate gates were set up using single colour controls with appropriate isotypes and 
single cell sorting was carried out. Figure 2-6 demonstrates the gating strategy used for the 
identification of CD34+CD38+, CD34+CD38-, CD34+CD38-CD90+ and CD34+CD38-
CD90- populations.  
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Figure 2-6 Representative plots of CD34, CD38 & CD90 staining.  
Viable cells were gated using FSC and SSC and isotype controls were used to select 
positive populations. Within the viable cell gate, cells were analysed for CD34+CD38+ and 
CD34+CD38- gates (A). For further purification within the CD34+CD38- gate, cells were 
selected for CD90- or CD90+ gates (B). 
2.3.3.11  Selection of mouse stem and progenitor fractions 
Mouse BM, spleen or PB cells were prepared as described in section 2.3.7.4. Cells were 
spun at 400 x g for 5 min and resuspended in PBS/2%FCS. Cells were stained with 
appropriate antibodies (2.1.6) at optimal concentrations for 30 min at 4ºC in the dark. Cells 
were washed in PBS/2% FCS to remove unbound antibody and resuspended in streptavidin 
and stained for a further 30 min at 4ºC. Cells were washed, filtered through a 0.7µm mesh 
and analysed or sorted. Appropriate gates were set up using single colour controls and 
FMO. Figure 2-7 demonstrates the gating strategy used to identify and isolate stem and 
progenitor populations from mouse cells.  
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105 
 
Figure 2-7 Representative plots for identification of mouse stem and progenitor cells.  
Viable cells were identified using FSC and SSC. Gates were set up using single colour and 
FMO controls. Within the viable cells, lineage negative cells were selected (A) and lineage 
negative, c-Kit+ (LK) or lineage negative, c-Kit+, Sca-1+ (LSK) gates were selected (B). 
Within LK population, progenitors were assayed using CD34 and CD62 staining (D). 
Within LSK cells, stem cell populations were examined using CD150 and CD48 staining. 
The stem/progenitor populations are marked according to literature available at the time of 
doing the experiments for this thesis. 
2.3.3.12 Selection of mouse mature cell types 
Mouse BM, spleen or PB cells were prepared as described in section 2.3.7.4. Cells were 
spun at 400 x g for 5 min and resuspended in PBS/2%FCS. Cells were stained with 
appropriate antibodies (2.1.6) at optimal concentrations for 30 min at 4ºC in the dark. Cells 
were washed in PBS/2% FCS to remove unbound antibody. Cells were washed, filtered 
through a 0.7µm mesh and analysed. Appropriate gates were set up using single colour 
controls and FMO. Figure 2-8 demonstrates the gating strategy used to identify and isolate 
various mature cell populations from mouse organs. Myeloid, B, erythroid and T cells were 
selected as GR1+CD11b+ (A), CD19+B220+ (B), TER119+ (C) and CD4+CD8+, CD4-CD8-, 
CD4+CD8- and CD4-CD8+ (D) respectively (Figure 2-8). 
A B C 
D 
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Figure 2-8 Representative plots for identification of mouse mature cell types. 
  
Viable cells were identified using FSC and SSC. Gates were set up using single colour 
controls. Within the viable cells, particular cell types were selected using different 
antibodies. Panels A-C display representative images of myeloid (GR1+CD11B+), B 
(B220+CD19+) and erythroid (TER119+) staining in a WT BM. Panel D displays different 
T cell populations identified in stained WT thymocytes.  
 
2.3.3.13  Flow cytometry cell sorting 
Cells were prepared in PBS/2% FCS at an appropriate concentration, approximately 1x106 
cells/300µl. Cells were filtered through a nylon sterile filter before use. Sorted cells were 
analysed for purity post-sort (Figure 2-9). A purity of ≥90% was achieved for all samples 
in this study. 
A B 
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Figure 2-9 Representative plots demonstrating sorting efficiency.  
Viable cells were gated using FSC and SSC and a GFP positive gate was identified using 
negative cells. Image shows small percentage of GFP positive cells prior to sort (A) and 
post sort (B). 
2.3.4 Immunofluorescence and immunohistochemistry 
2.3.4.1 Immunofluorescence 
All reagents used for immunofluorescence can be found in Table 2-3. Cells at 
approximately 2x104 cells/spot were added to a pre-coated microscope slide with Poly-L-
lysine. Cells were allowed to attach to the slide for several hours during incubation at 37ºC. 
Cells were fixed with 3.75% formaldehyde solution (2.2.4.1) for 15 min at RT and washed 
several times in PBS. Cells were permeabilised to allow intracellular staining with 0.25% 
Triton-X-100 (2.2.4.2) for 15 min at RT and washed several times in PBS. Antigen sites 
were blocked using 5% BSA solution (2.2.4.3) for 30 min at RT before subsequent 
addition of appropriate primary antibody. After overnight incubation at 4ºC, the primary 
antibody was washed in PBS and the appropriate conjugated secondary antibody was 
added to the cells for 1 hour at RT. After washing, the cells were mounted with a coverslip 
using Vectashield with dapi (Cat No. H-1200). Fluorescence was analysed using a Zeiss 
Imager M1 microscope with equal exposure times between samples to ensure reliability 
and appropriate isotype controls. Data was acquired using AxioVision software and 3-
dimensional (3-D) images were generated using Image J software. 
A B 
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2.3.5 Western blotting 
Briefly, proteins were isolated, fractionated on a gel and transferred to a membrane for 
subsequent blotting against specific antibodies to analyse expression of protein of interest. 
2.3.5.1 Preparation of protein lysates 
RIPA lysis buffer (Cat No. PI-89901) was prepared immediately prior to use with the 
addition of protease and phosphatase inhibitors. Equal cell numbers were washed twice in 
ice cold PBS and transferred to an eppendorf. An appropriate volume of RIPA lysis buffer 
was added to cells and incubated for 15 min on ice. Cells were centrifuged for 10 min at 
4ºC to remove the nucleic acid and debris leaving the supernatant containing protein which 
was used immediately or stored at -20ºC. In cases of small cell numbers, equal cell 
numbers were immediately resuspended in 2X SDS sample buffer (2.2.2.1) and stored at -
20ºC for future use. 
2.3.5.2 Protein quantification 
In cases of small cell numbers, equal cell numbers were immediately resuspended in 2X 
SDS sample buffer and loaded neat onto a gel. Samples lysed using RIPA buffer were 
quantified using the BCA™ protein assay kit (Cat No. 23227) as per the manufacturer’s 
instructions.  The BCA assay is a biochemical assay used for determining the concentration 
of protein in a solution. Reagents are added to samples of proteins which results in colour 
change which is correlated to protein concentration which can be measured using 
colorimetric techniques such as absorbance (Smith et al., 1985). Briefly, BSA standards 
were prepared with varying concentrations of a standard protein in PBS. Standards were 
used to create an equation using a known concentration of protein standard against 
absorbance. Unknown lysates were then examined for protein concentration using the 
equation. The absorbance was read at 562nm using a plate reader. Based on the protein 
concentration of samples, equal amounts of protein were then added in each assay. 
2.3.5.3 Gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a denaturing separation method 
commonly used to analyse protein samples. Proteins migrate through a matrix at varying 
speeds according to their molecular weight in a gel solution containing SDS which is a 
negatively charged detergent. These can be applied with an electric current in which 
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negatively charged proteins migrate towards a positive electrode therefore allowing 
separation. Protein samples were diluted in 2X SDS buffer according to concentrations 
desired and boiled at 95ºC for 5 min. Samples were loaded onto a gel alongside a 
prestained protein ladder (Cat No. BIO-33065) to assess the molecular weight of proteins 
migrating through the gel. Samples were run in running buffer (2.2.2.4) for 80 volts (V) for 
30 min and at 120V for the remaining 1 hour.  
2.3.5.4 Membrane transfer 
After protein separation, proteins were required to be transferred to a membrane which 
could be subsequently blotted with antibodies against the protein of interest. Briefly, an 
electrical current can be used to transfer proteins from a gel to a membrane. Proteins were 
transferred from the acrylamide gel to an Immun-Blot PVDF membrane. The PVDF 
membrane was activated in a solution of neat methanol. A solution of transfer buffer 
(2.2.2.5) was used to soak sponges, papers and PVDF membrane. The sponges and papers 
were layered onto a transfer system with the isolated gel layered below the PVDF 
membrane with the addition of sponges and gel blotting paper (1.0mm) paper on top. The 
transfer was run for 30V at 1 hour and successful transfer was noted due to the addition of 
the protein ladder from the gel to the membrane. The membrane was kept moist at all times 
to prevent drying out and damage to the proteins. 
2.3.5.5 Immunolabelling 
Immediately, post transfer, the PVDF membrane was carefully transferred to a solution to 
block antigen sites and prevent non specific binding (2.2.2.6). After 1 hour blocking at RT, 
the membrane was transferred to a fresh blocking solution with the addition of the 
appropriate primary antibody (2.1.5) with a gentle rotation at 4ºC overnight. After 
overnight incubation, the blot was washed several times with gentle shaking in a wash 
solution (2.2.2.2). The blot was then incubated in the appropriate secondary antibody 
conjugated to enzyme HRP for 1 hour at RT with gentle rotation. After incubation, the blot 
was washed several times and an ECL detection method was used to visualise the protein 
bands (ImmunoStar™Western C kit (Cat No. 170-5070) as per manufacturer’s 
instructions. Protein bands were visualised using the Molecular Imager® ChemiDoc™ 
XRS machine (Bio-Rad Laboratories Ltd). After visualisation of bands showing protein of 
interest, the blot was blocked and probed with the appropriate primary antibody for 
housekeeping protein to ensure equal protein loading between samples. The blot was then 
probed with the appropriate secondary antibody, washed and visualised as detailed above. 
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Densitometry was used to quantify protein expression between samples using Quantity 
One® software. 
2.3.6 Molecular biology 
All reagents used can be found in Table 2-3. 
2.3.6.1 Primer design 
Primers were designed using NCBI software and the sequences can be seen in Table 2-5. 
Primers were synthesised commercially (Eurofins MWG Operon). Primers were 
reconstituted with the appropriate volume of nuclease free H20 to achieve a stock 
concentration of 100µM. Dilutions were made to achieve the appropriate working 
concentration of 10µM and aliquots were prepared to ensure sterility and stored at -20ºC. 
PCR reagent concentrations and thermal cycling conditions were optimised for each primer 
set. 
2.3.6.2 Generation of DNA 
Approximately 5x106 cells were centrifuged and washed in PBS. DNA was extracted using 
the Bioline DNA extraction kit (Cat No. BIO-52067) or QIAamp DNA blood mini kit (Cat 
No. 51104) as per the manufacturer’s instructions. Animal ear/tail samples or MNC were 
incubated for several hours up to overnight in DNA lysis buffer plus Proteinase-k with 
intermittent vortexing to ensure complete digestion.  
2.3.6.3 Generation of RNA 
To ensure work was free from ribonucleases (RNAses), RNA extraction and downstream 
applications was carried out with the addition of RNAZap™ (Cat No. AM9780) on all 
surfaces and pipettes before use. Reagents were also treated with UV light before use. An 
appropriate number of cells were spun and washed in PBS before use. Depending on cells 
numbers, the RNA mini (5x106≥) (Cat No. 74106) or micro kit (5x106≤) (Cat No. 74004) 
was used as per manufacturer’s instructions. The resulting RNA was quantified and 
examined for purity using a NanoDrop spectrophotometer ND-1000. RNA was kept on ice 
at all times and stored at -80ºC. 
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2.3.6.4 First strand synthesis 
RNA was synthesised to cDNA using the High Capacity cDNA Archive kit according to 
the manufacturer’s instructions. 1µg of RNA was converted to cDNA in a 20µl reaction 
(2.2.5.4). When low RNA yields were obtained, the maximum volume of RNA was added 
to a 20µl reaction. A non-template control with reagents minus RNA was included with 
every synthesis to ensure no contamination of reagents was present and cDNA was stored 
at 4ºC.  
2.3.6.5 Standard PCR 
PCR is a technique widely used in molecular biology. The technique is based on the 
principle of amplifying DNA using thermal cycling so DNA can be detected. The use of 
DNA primers which are sequences complementary to the DNA region of interest are used 
to selectively amplify particular regions of DNA. The process of DNA synthesis requires 
enzyme Taq polymerase. Positive control samples and a PCR reaction minus DNA was 
used to assess reagent contamination with every reaction (2.2.5.5). PCR reactions were run 
with appropriate PCR conditions according to primers used (2.1.7.1). PCR products were 
analysed using agarose gels with the addition of SybrSafe™ to visualise DNA with UV 
illumination. Molecular ladders at an appropriate size for analysis were run with samples to 
know exact size of PCR products. Agarose gels were made solubilising agarose powder in 
a solution of 1X TBE (2.2.5.2). The solution was heated in a microwave to dissolve the 
powder, the solution was cooled, SybrSafe™ was added and poured into a gel setting with 
combs. Once solidified, the gel was put in an electrophoresis tank in 1X TBE solution, 
samples were loaded into the wells and an electric current was used to allow the migration 
of DNA samples through the gel according to size. DNA was visualised using UV 
illumination using a molecular imager® ChemiDoc Chemidoc™ XRS visualisation 
system. 
2.3.6.6 Quantitative-PCR 
Real-time quantitative PCR (or Q-PCR) is based on the principles of standard PCR, 
however this technique allows gene expression differences to be analysed between 
different samples. In this thesis, Q-PCR was carried using the TaqMan® system and 
reagents. This technique is widely used and has a high sensitivity and specificity. Briefly, 
amplification is quantified using fluorescently labelled probes which are cleaved during 
amplification resulting in a fluorescent signal which allows detection and quantification 
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during the PCR reaction. To achieve this, each TaqMan® probe has been designed to 
contain a fluorophore and quencher. The quencher stops fluorescence emitted by the 
fluorophore when excited by the cyclers light source using fluorescence resonance energy 
transfer. The juxtaposition of the fluorophore and quencher inhibits fluorescence and 
therefore its detection. Amplification of the target sequence using Taq polymerase results 
in probe displacement which results in fluorescence emission. The fluorescence emitted 
correlates with the DNA template and is therefore quantified. RNA was converted into 
cDNA as mentioned in section 2.3.6.4 and was combined with TaqMan™ inventoried 
probes (Table 2-6), H20 and 2X universal PCR mastermix in a 10µl reaction (2.2.5.3). 
Samples were prepared in triplicate with an appropriate housekeeping control for every 
sample. A non-template control was included in every reaction to exclude the possibility of 
contamination of reagents. Samples were loaded into a 384 well plate, centrifuged and 
loaded onto a 7900HT real-time PCR system (Applied Biosystems). The standard thermal 
cycling conditions were used as per the manufacturer’s instructions: 50ºC for 2 min, 95ºC 
for 10 min and finally 40 cycles of 95ºC for 15 seconds (sec) and 60ºC for 1 min. Data was 
acquired using SDS software and analysed using RQ manager (Applied Biosystems). CT 
values were examined and compared between samples using fold change relative to 
calibrator using the ∆∆CT standard method for analysis (Schmittgen and Livak, 2008). To 
show the variation between biological replicates of calibrant samples, relative expression is 
shown using the 2-DeltaCT as detailed in the text. 
2.3.6.7 Single cell RT and preamplification 
Due to small cell numbers of primary material, Q-PCR was carried out using small 
numbers of cells and the Fluidigm™ platform and TaqMan reagents®. A small number of 
cells (200) were sorted using a FACS into a 5µl mix containing a lysis buffer, Taqman® 
probe mix and 2X reaction mix (Cat No. 11753-100) (2.2.5.6). The cell suspension was 
vortexed and spun before added to a PCR machine for RT and preamplification of 
particular genes using Taqman® probes. The standard thermal cycling conditions were 
used as per the manufacturer’s instructions: 50ºC for 15 min, 95ºC for 2 min and finally 
18-22 cycles of 95ºC for 15 sec and 60ºC for 4 min. Subsequently, the cDNA sample was 
diluted with the addition of 20µl TE buffer (Cat No. 12090-015) and stored at -20ºC. The 
cDNA was used as described in sections 2.3.6.6 and 2.3.6.8.  
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2.3.6.8 Fluidigm 
A high-throughput Q-PCR was carried out using the Fluidigm™ platform. Fluidigm™ has 
developed an approach to analyse large sets of gene expression analysis using very small 
cell numbers based on microfluidic technology. Q-PCR is carried out as described in 
section 2.3.6.6 with the addition of a system in which multiple samples and genes can be 
analysed simulateously. A 48 x 48 or 96 x 96 (sample x gene) chip format is available 
which dramatically increases the number of PCR reactions that can be achieved in one 
assay. After the preamplification of samples, the resulting cDNA was used with the 
Taqman™ probes of interest to examine gene expression of 48 genes across 48 samples. 
Briefly, cDNA and probes were mixed with appropriate sample or assay buffer and added 
to inlets of gene chips. The chip is primed before use and the loaded chip is run on the 
Fluidigm™ BioMark HD system. Data was acquired using the BioMark acquisition 
software and analysed using Fluidigm real-time PCR analysis software. Fold changes in 
gene expression were calculated according to methods described in the Q-PCR section 
(2.3.6.6). 
2.3.6.9 Cloning of DNA fragments 
2.3.6.9.1 CXCL1 and CXCL4 shRNA 
Human CXCL1 and mouse CXCL4 shRNA hairpins were purchased in a pLKO.1 plasmid 
with an ampicillin resistance cassette and a puro resistance cassette as described in section 
2.1.2. The plasmids purchased came with multiple plasmids each with a unique shRNA 
sequence, designed to ensure adequate coverage of the target gene. The sets purchased 
contained six and five plasmids for CXCL1 and CXCL4 respectively. It is predicted that 
some of the shRNA sequences will give at least 70% knock down of the gene of interest, 
however it is necessary to test which sequence from the set is best at gene reduction for 
future experiments. Each plasmid was transduced into positive control cells as mentioned 
in section 2.3.2.1 and selected in puro for seven days when an untransfected control had 
undergone apoptosis therefore all cells growing had stable integration of the expression 
vector. Resulting cells were tested for reduction in gene and protein levels using Q-PCR as 
mentioned in section 2.3.6.6 and western blotting as mentioned in section 2.3.5. The 
shRNA sequences found to result in the highest levels of gene reduction were subcloned 
into a plasmid with a reporter tag (GFP) for use in primary cell transduction. Two plasmids 
from human CXCL1 and one plasmid (due to time constraints) from mouse CXCL4 were 
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subcloned into a pLKO.1 plasmid containing a GFP insert. Briefly, 10µg of DNA from 
pLKO.1-CXCL1 or pLKO.1-CXCL4 and pLKO.1-Scr (GFP) were digested with NdeI and 
SpeI RE (New England Biolabs) (2.2.6.3). After 3 hours at 37ºC, digestion products were 
incubated with SAP at 37ºC for 45 min to dephosphorylate the ends of the cut fragments, 
reducing the probability of the cut fragments joining together. The products were then run 
on a 2% agarose gel and analysed using UV illumination. The inserts containing the 
shRNA sequences from pLKO.1-CXCL1 and pLKO.1-CXCL4 and the plasmid backbone 
from pLKO.1-Scr were cut using a sterile scalpel and the DNA was extracted from the gel 
(2.3.6.10). DNA was quantified and insert was ligated to the backbone using T4 DNA 
ligase and incubated overnight at 14ºC (2.2.6.4). Bacteria was transformed and grown as 
mentioned in 2.3.6.11 and individual clones were examined for the correct plasmid using 
RE digestion and sequencing analysis using primers spanning the shRNA sequence 
(2.1.7.1) (GATC Biotech, Konstanz, Germany). Bacterial stocks with the correct plasmid 
were made in glycerol as mentioned in 2.3.6.11, stored at -80ºC and cultured when 
required. 
2.3.6.9.2 CXCL1 over expression 
DNA was extracted from cell line PC-3 and PCR set-up with primers spanning the human 
CXCL1 coding sequence (2.1.7.1). The correct band was visualised using UV and 
extracted as mentioned in section 2.3.6.10. The insert was ligated into vector PCR® 2.1 
TOPO® using the TOPO® TA cloning® kit according to the manufacturer’s instructions. 
The ligation mix was incubated overnight at 14ºC and transformed into competent bacteria 
as mentioned in 2.3.6.11. Colonies were screened for the presence of a single insert in the 
correct orientation using RE digests with HindIII and the plasmid was sent for sequencing 
analysis. The CXCL1 insert was extracted from PCR® 2.1 TOPO®  using BamHI and 
Ecor V RE digests and ligated into lentiviral plasmid PRRL backbone cut with BamHI and 
SnabI overnight at 14ºC and transformed into bacteria. Correct clones were sent for 
sequencing analysis and PRRL without the CXCL1 insert was used as an empty vector 
control. 
2.3.6.10 Extraction of gel bands 
DNA was extracted from agarose gel fragments using the Qiaquick gel extraction kit 
(Qiagen) as per manufacturer’s instructions. The resulting DNA was quantified and 
examined for purity using a nanodrop spectrophotometer Nd-1000. 
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2.3.6.11 Growth of plasmids 
All microbiology work was completed on a sterile bench with a bunsen burner. Competent 
bacteria were transformed with DNA plasmid according to the manufacturer’s instructions. 
Briefly, bacteria were allowed to thaw on ice for 30 min and 1µl of plasmid DNA or 5µl of 
ligation product was incubated for 30 min. Bacteria were then incubated at 42ºC for 90 
seconds (sec) resulting in the disruption of the cell membrane allowing the introduction of 
the DNA into the bacterial cells. Subsequently bacteria were incubated on ice for 2 min, 
SOC medium was added and incubated on a shaking platform for 1 hour at 37ºC to allow 
the production of the appropriate antibiotic resistance gene. Subsequently, approximately 
50µl of bacterial suspension was added to agar plates grown in ampicillin and streaked or 
spread according to transformation reaction. Single colonies were selected and cultured for 
approximately 8-12 hours in LB medium plus ampicillin. The bacterial culture was then 
incubated approximately 8-12 hours in a large culture of LB medium plus ampicillin. 
Bacterial stocks containing correct the plasmid were made with the addition of 30% 
glycerol stocks and stored at -80°C for future use (2.2.6.1; 2.2.6.2). 
2.3.6.12 Isolation of plasmid DNA 
Plasmid DNA was isolated from bacteria using mini, midi or maxi kits according to 
volume of bacteria and manufacturer’s instructions were followed. DNA was eluted in 
nuclease free H20 and stored at -20ºC. 
2.3.6.13 Verification of DNA sequence 
The correct plasmid sequence was verified using RE digest and sequencing analysis. 
pLKO.1 plasmids were digested using NdeI and SpeI double digestion. PRRL-CXCL1 was 
digested using EcoRI single digestion. 1µg of DNA was incubated with enzymes with 
appropriate buffer and BSA solution for 3 hours at 37ºC as mentioned in section 2.2.6.3. 
Resulting DNA was visualised using UV for correct cuts. To ensure correct plasmid, DNA 
was sent for sequencing analysis using primers spanning the shRNA sequence with primers 
mentioned 2.1.7.1. 
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2.3.7 Animal work 
2.3.7.1 Ethical issues 
All animal work was carried out in accordance with regulations set by the Animals 
Scientific Procedures Act 1986 and UK Home Office regulations. Animals were housed at 
the Beatson Institute for Cancer Research or at the Veterinary Research Facility at the 
University of Glasgow. All experiments were carried out under my personal licence 
(60/12683) and Dr Kamil Kranc’s project licence (60/4076). Stem cell analysis was carried 
out on animals between 6 and 12 weeks and animals were matched for sex where possible. 
Specifics of numbers of animals used and gender for each experiment is provided in detail 
in each figure legend. 
2.3.7.2 Mouse models 
2.3.7.2.1 Rosa26-RFP;Cxcl4-Cre 
Rosa26-RFP;Cxcl4-Cre mice were a kind gift from Professor Laura Machesky and 
experiments were done in collaboration with Dr Simon Calaminus (Beatson Institute for 
Cancer Research, Glasgow, UK). Briefly, Cxcl4-Cre transgenic mice (C57/BL6 
background) were crossed with mice containing a conditional tandem dimer red 
fluorescent protein (RFP) construct under the control of the Rosa26 promoter (C57/BL6 
background). Cxcl4-Cre animals were constructed through a Cre recombinase cDNA 
insertion in bacteria into a bacterial artificial chromosome (BAC) clone containing Cxcl4 
(Tiedt et al., 2007).  It should be noted that the BAC used to create the Cxcl4-Cre 
transgene contained the entire Cxcl4 gene in addition to several others as described in 
Table 2-9. These genes have a variety of different functions including mouse neutrophil 
chemotaxis, megakaryocyte/platelet biology and HSC maintenance (Tiedt et al., 2007). 
The Rosa26-RFP animals were generated by targeting RFP into the ubiquitously expressed 
ROSA26 locus of C57/BL6 ES cells (Luche et al., 2007). A schematic of the Rosa26-
RFP;Cxcl4-Cre mouse model is displayed in Figure 2-10. Rosa26-RFP+;Cxcl4-Cre+ mice 
were used with Rosa26-RFP+;Cxcl4-Cre- mice as a control. Ear or tail samples were used 
to genotype the mice using Transnetyx at the Beatson Institute for Cancer Research.   
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Gene Name Gene ID 
Cxcl5 20311 
Cxcl7 57349 
Cxcl15 20309 
Gm1960 330122 
 
Table 2-9 List of genes contained on the BAC clone used in the construction of Cxcl4-Cre 
animals.  
The BAC that was used for the transgenic animals contained Cxcl4, Cxcl5, Cxcl7, Cxcl15 
and Gm1960 (Tiedt et al., 2007).  
  
118 
 
 
Figure 2-10 Rosa26-RFP;Cxcl4-Cre mouse model 
Panel A shows the transgene construct. Each box denotes the Cxcl4 exons and the Cre 
denotes a codon-improved cDNA for Cre recombinase and polyA is the polyadenylation 
signal. Panel B displays the Rosa26-tdRFP construct. The tdRFP cassette is inserted in an 
anti-sense orientation. Two oppositely oriented WT loxP sites (loxP 1) flank the whole 
element. Two additional mutant loxP sites (loxP 2) surround the reversed tdRFP cassette 
with one of the loxP 1 sites. Cre mediates the inversion at the loxP sites and results in the 
removal of the NEO STOP cassette (1 and 2). The tdRFP is under full transcriptional 
control of the ROSA26 locus. Panel C demonstrates the activity of the RFP reporter. In 
cells in which Cxcl4 is active, cells are all resulting progeny are RFP+ irrespective of the 
subsequent activity of Cxcl4. Images A and B are from the published literature on the 
constructs used (Luche et al., 2007, Tiedt et al., 2007). Image C is an original diagram. 
 
 
 
 
 
A 
B 
C 
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2.3.7.2.2 Cxcl4 null animals 
Cxcl4-/- mice were kindly donated by Professor Mortimer Poncz (Philadelphia children’s 
hospital, Philadelphia, USA). Briefly, Cxcl4-/- mice were generated by replacing the entire 
coding region for Cxcl4 with a neomycin resistance gene (C57/BL6 background). Cxcl4-/- 
mice were imported from Philadelphia children’s hospital into the Veterinary research 
facility (University of Glasgow). Cxcl4-/- animals were crossed with WT C57/BL6 mice 
purchased in house (Harlan Laboratories, UK) to generate heterozygous animals. Unrelated 
heterozygous animals were then crossed to generate Cxcl4+/+ (WT) and Cxcl4-/- (KO) 
animals which were used for the analysis detailed in chapter 5. Ear or tail samples were 
used to genotype animals as described in section 2.3.6.5 by using primers against 
endogenous Cxcl4 or the neomycin cassette to ensure the sole use of WT or Cxcl4-/- 
animals in the analysis. The sequences of the primers were provided by Professor 
Mortimer Poncz. 
 
2.3.7.2.3 CXCR2 null animals 
Cxcr2-/- mice were kindly donated by Professor Owen Sansom (Beatson Institute for 
Cancer Research, Glasgow, UK). Briefly, Cxcr2-/- mice were generated by replacing the 
entire coding region for Cxcr2 with a neomycin resistance gene (C57/BL6 background). 
Heterozygous with homozygous animals were crossed and Cxcr2+/+ (WT) and Cxcr2-/- 
animals (KO) were used for analysis. Ear or tail samples were used to genotype animals 
using Transnetyx at the Beatson Institute for Cancer Research by using primers against 
endogenous Cxcr2 or the neomycin cassette to ensure the sole use of WT or Cxcr2-/- 
animals in the analysis. 
2.3.7.2.4 CD45.1+ animals 
Animals containing the congenic marker CD45.1+ (Ly5.1) were kindly donated by Dr 
Kamil Kranc. This strain carriers the allele of the SJL mouse Ptprc gene locus. C57/BL6 
animals are CD45.2+ (Ly5.2) therefore this strain can be used to discriminate between the 
animals used in this study as described in more detail in section 2.3.7.6.  
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2.3.7.3 Dissection 
Animals were sacrificed using appropriate schedule 1 methods. Femur, tibia, hip bones, 
spleen and thymi were dissected and stored in PBS/2%FCS on ice. PB was taken by tail 
vein bleed prior to sacrifice or through collection from femoral vein post sacrifice and 
collected into tubes containing EDTA to ensure anti coagulation, stored at RT and analysed 
within several hours. 
2.3.7.4 Cells  
Bones from femur, tibia and hips were crushed in PBS/2% FCS using a mortar and pestle 
and made into a single cells suspension through filtering through a sterile 0.2µm filter. 
Spleen and thymi were mashed in PBS/2% FCS using a sterile plunger and filtered. 
Peripheral blood (PB) was analysed neat for cellularity analyses and RBC were lysed 
before downstream applications in NaCl solution according to manufacturer’s instructions 
(Cat no. 07850).  
2.3.7.5 Analysis 
Single cell suspensions of organs were analysed using a haematology automated analyser 
(Hemovet). This was used to perform full blood counts. Bones, spleen and thymi were 
resuspended in a volume of 30mL, 12mL and 12mL respectively in PBS/2% FCS. Cells 
were spun and resuspended in appropriate antibodies and analysed by flow cytometry. 
White blood cell (WBC) counts were multiplied to percentage of cells to get cell 
count/mouse. 
2.3.7.6 Transplantation assays 
A BM reconstitution assay allows the detection of a primitive class of HSC that allow the 
survival of lethally irradiated mice transplanted with few numbers of cells due to their 
ability to repopulate haemopoeisis. This assay can be used to compare stem potential of 
different cell types or to compare stem cell activity in transgenic mice. 
Lineage negative, Sca-1+, c-Kit+, CD150+, CD48- (LT-HSC) cells from Cxcr2-/- or Pf4-/- 
with wildtype (WT) animals were sorted using flow cytometry into a cell suspension of 
CD45.1+ BM MNC at a concentration of 102 LT-HSC donor cells plus 2x105 BM CD45.1+ 
cells per mouse. 200µl of the cell suspension was injected by intravenous transfer into 
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lethally irradiated mice at a maximum of 24 hours post irradiation. CD45.1+ animals were 
irradiated using a dosage of 7 gray (Gy) radiation using an x-ray irradiator at the Beatson 
Institute for Cancer Research and subsequently housed in individually ventilated cages 
(IVC) and treatment with Baytril. Every 4 weeks post transplant up to 16 weeks, PB was 
taken and prepared as described in section 2.3.7.4. Cells were stained for antibodies against 
CD45.1, CD45.2 and antibodies against mature cell types including mature B (CD19+), T 
(CD4+, CD8+) and myeloid (GR-1+, CD11B+) cells (2.1.6). After 16 weeks, the BM, spleen 
and PB were taken from sacrificed mice and examined for CD45.1+ and CD45.2+ positive 
cells in mature cell types and within stem/progenitor cell populations (Figure 2-11). 
 
 
Figure 2-11 Schematic digram demonstrating BM transplantation assay.  
CD45.2+ donor derived HSC were transplanted with CD45.1+ derived support BM in 
irradiated CD45.1+ recipients. PB was analysed every 4 weeks post transplant to examine 
CD45.2+ cells in the whole blood and mature cell types. At 16 weeks post transplant, BM 
and spleen was analysed for the CD45.2+ cells in the organs, stem, progenitor and mature 
cell types.  
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2.3.8 Statistics 
The results are shown as the mean with standard deviation values unless otherwise stated. 
All statistical analyses were performed using the Graph Pad prism software package. To 
test if values came from a Gaussian distribution, normality was analysed using the 
Kolmogorov-Smirnov test. Depending on the results of the test, the appropriate parametric 
or non parametric tests were used. In cases of low sample numbers (i.e. n ≤ 3), the 
normality test could not be used and therefore values were assumed to come from a 
Gaussian distribution. Specific details of the statistical test carried out for each data set are 
provided in the figure legends. A level of P <0.05 was deemed significant and levels of P 
<0.01 and P <0.001 were deemed very significant. Values of P  >0.05 were deemed not 
significant. 
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3 Results I: The role of CXCL1/CXCR2 signalling 
in human HSC survival  
3.1 Introduction  
A key property of HSC is their ability to maintain quiescence, which is thought to 
important for their ability to sustain haemopoiesis over a long period of time (Pietras et al., 
2011). A variety of methods have been used to identify novel genes in quiescence, 
including gene-targeted deletion/knock-in mouse models. In addition, high-throughput 
approaches including global gene expression studies have been used (Passegue et al., 2005, 
Venezia et al., 2004, Forsberg et al., 2010). Such screens have identified genes involved in 
quiescence including in metabolism and cell cycle regulation. Despite the identification of 
a variety of genes involved in quiescence, it is still not well understood. In addition, 
limitations in previous studies have been due to a lack of data on human HSC populations. 
A previously published microarray study by our group reported that the most up regulated 
group of genes in quiescent compared to proliferating human HSC were chemokine 
ligands, specifically within the CXC group (Graham et al., 2007). This was a novel 
finding, however their biological function in this context was unclear.  
The previous microarray study reported that chemokine ligands CXCL1, CXCL2, CXCL6 
and CXCL13 were the most up regulated genes in normal G0 versus dividing HSC. As 
described in the introduction section, chemokines CXCL1, CXCL2 and CXCL6 share a 
common receptor, CXCR2 and for simplicity we decided to focus on this signalling 
pathway. The literature available on these chemokines in terms of stem cell properties is 
scarce. Regarding CXCL1, a previous study reported that CXCL1 supported growth and 
regulated self renewal or adoption of a particular cellular fate in ESC (Krtolica et al., 
2011). CXCL2 shares sequence similarity with CXCL1 and they share some functional 
activity, however CXCL2 has not been identified to play a role in ESC properties. CXCL2 
has been shown to cause mobilisation of HSC from the BM into the periphery in animal 
studies (Pelus et al., 2002). The molecular mechanism is poorly understood with no data on 
expression of the chemokine on HSC, and it is not well defined which cell types are 
involved. CXCL6 was reported to be expressed in primitive (CD34+CD38-) BM derived 
HSC in another study, however there was no data to suggest its biological function in these 
cells (Lu et al., 2004). There is literature which showed CXCL6 was expressed on MSC, 
however in this context it was shown to play a role in angiogenesis (Kim et al., 2012).  
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Data obtained from a microarray study provides a global analysis of mRNA expression and 
alterations in different cell populations/treatments. However, it is important that the targets 
identified are validated before further study. The experiments in this chapter were designed 
to validate the microarray data and to extend the research through examining protein 
expression, in particular focusing on key chemokine ligand CXCL1. To examine the 
biological function in vitro, several approaches including an over expression and knock 
down approach of the protein were used. These techniques were first tested and optimised 
on cell lines before use on primary samples. 
Chemokine ligands signal to their receptor and this can occur in an autocrine or paracrine 
fashion. To date, CXCR2 expression has not been detected on HSC. In terms of other stem 
cell systems, the receptor has been shown to be expressed on MSC and plays a role in cell 
migration (Ringe et al., 2007). A variety of cell types express CXCR2 including 
granulocytes and other inflammatory cell types which exist within the BM. Indeed an 
interaction between HSC and other cell types in the BM niche is already well known. 
Based on this, an aim of this chapter was to examine CXCR2 expression at the mRNA and 
protein level in HSC populations. Based on this research we would be able to identify 
whether chemokine ligands are potentially signalling through an autocrine loop or in a 
paracrine manner.  
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3.2 Aims and objectives 
The specific aims of this chapter were: 
I  To validate gene expression data from a previous microarray study and 
investigate whether CXC ligands are up regulated in quiescent, primitive human 
HSC  
It is fundamental that candidates identified from a microarray study are validated. In this 
objective we wanted to ensure we could validate microarray data which would merit 
further study of these genes. 
II To examine protein expression of CXC ligands on HSC  
It is well known that gene expression is not always indicative of protein expression or 
indeed function. In this objective we wanted to examine protein expression of CXC ligands 
to ensure protein was translated.  
III To investigate whether HSC express receptor CXCR2 
To date, the expression of receptor CXCR2 is not clear in the literature. We wanted to 
confirm whether human HSC express CXCR2 at the gene and protein level. This would 
give an indication of the mechanism of how chemokine ligands are eliciting their effects. 
IV To determine the biological function of CXC signalling on HSC behaviour 
We designed experiments to determine whether CXC signalling plays a biological role in 
terms of stem cell properties. To complete the objective the plan was to construct an over 
expression and knock down vector against chemokine ligands and use an inhibitor against 
receptor CXCR2. The resulting effect would be examined in terms of HSC properties 
including viability, self renewal/differentiation and cell cycle status. 
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3.3 Results 
3.3.1 CXCL1, CXCL2 and CXCL6 are up regulated in primitive, BM 
derived HSC  
Data from a published microarray reported differential expression of genes in human HSC 
populations that were sorted and isolated according to their cell cycle status (Graham et al., 
2007). More specifically, CD34+ cells were isolated using flow cytometry and a 
combination of DNA and RNA stains (Hoechst 33342 and Pyronin Y). Due to 
technicalities, including the lack of a UV laser to detect Hoechst staining, this approach 
could not be replicated. An alternative approach to sorting cells according to cell cycle 
status was required. Initially, alternative DNA stains were tested which can be used in 
viable cells and do not require a UV laser, however these were shown to be unreliable 
(data not shown). As an alternative approach, cell populations were sorted using cell 
surface markers CD34 and CD38. CD34 is a cell surface marker known to be expressed on 
a heterogeneous population of cells including primitive stem cells and progenitor cells and 
including CD38 allows a generally accepted discrimination between more primitive, and 
therefore more quiescent cells (Civin et al., 1996, Bhatia et al., 1997, Paz et al., 2007).  
Cells used in the original microarray study were derived from normal controls in which the 
stem cells had been mobilised (Graham et al., 2007). It is possible that this treatment could 
alter the gene expression signature, in particular for chemokine expression. Indeed, 
CXCR2 binding ligands are modulated in response to G-CSF treatment (Richards et al., 
2003, Eash et al., 2010). Therefore CD34+CD38- and CD34+CD38+ cells were isolated 
from normal BM samples derived from the BM to examine whether high levels of 
chemokine expression is inherent to a primitive stem cell population regardless of cellular 
location and cytokine treatment. 
Normal BM samples were enriched for cell surface marker CD34, stained with antibodies 
against CD34 and CD38 and sorted using flow cytometry into different cell populations 
according to their cell surface expression of CD34 and CD38. RNA was extracted, RT and 
examined for mRNA levels of CXC chemokines identified in the microarray; CXCL1, 
CXCL2 and CXCL6 using Q-PCR analysis. It can be seen in Figure 3-1 that all CXC 
ligands were down regulated in the CD34+CD38+ fraction in comparison to the 
CD34+CD38- fraction at the mRNA level however CXCL6 was not statistically significant. 
It is likely this has arisen from a smaller sample size and variation between individuals. 
From this result it can be inferred that CXC chemokines CXCL1 and CXCL2 are up 
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regulated in quiescent HSC derived from BM and mobilised PB samples as carried out in 
the original microarray study. It can also be inferred that sorting of CD34+ cells into 
CD34+CD38- and CD34+CD38+ fractions separates cells which are in different stages of 
the cell cycle as the results corroborate the findings from the original microarray. 
However, it should be noted that a huge variation between samples was noted in both 
populations as seen by relative expression. It is possible chemokine levels vary greatly 
between individuals and information regarding gender and age would have been useful, 
however this information was not available. 
As a control to validate that the CD34+CD38- fraction represents a more quiescent fraction 
than the CD34+CD38+ population, normal BM samples were examined for gene expression 
of genes associated with cell cycle status. CDC6 is only transcribed during the G1 phase of 
the cell cycle therefore it is predicated this will be at higher levels in CD34+CD38+ cells 
(Pelizon, 2003). In addition, gene expression analysis of cell surface marker CD38 was 
carried out to demonstrate the sorting efficiency. In one representative BM sample, CDC6 
and CD38 mRNA levels were examined in CD34+CD38- and CD34+CD38+ sorted 
populations. It can be seen from Figure 3-2 that both CDC6 and CD38 showed an increase 
in expression in the CD34+CD38+ fraction in comparison to the CD34+CD38- fraction. The 
higher expression of CD38 in the CD34+CD38+ fraction confirms that the sorting was 
efficient. Differential expression of CDC6 confirms that CD34+CD38+ are more 
proliferative than CD34+CD38- cells, which justifies the use of these populations in this 
study. However due to one sample used, no significant differences are noted. 
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Figure 3-1 CXCL1 and CXCL2 are up regulated in CD34+CD38- compared to CD34+CD38+ 
cells derived from normal BM samples. 
Normal BM samples were freshly isolated or recovered from cryogenic storage. Cells were 
enriched for CD34 and recovered overnight in medium supplemented with GF for cell 
survival. Cells were stained for antibodies against CD34 and CD38 and sorted for 
CD34+CD38- and CD34+CD38+ populations. RNA was extracted, RT and Q-PCR was 
carried out for CXCL1, CXCL2 and CXCL6  mRNA expression (A). Fold change was 
calculated relative to housekeeping control GAPDH according to the DeltaDeltaCT 
method. Data are presented as the mean fold change of expression in the CD34+CD38+ 
fraction using the CD34+CD38- fraction as a calibrator which is set to the value of 1. The 
chemokines CXCL1¸CXCL2 and CXCL6 showed a mean 50 (P <0.05), 81 (P <0.05) and 84 
(n.s) percent reduction in expression levels in the CD34+CD38+ fraction in comparison to 
the CD34+CD38- fraction. The panels in B demonstrate relative expression (2-DeltaCT) in 
both populations for each gene tested (B). Each dot displays an average of technical 
triplicates from independent samples. Statistical differences were analysed using the 
Wilcoxon matched paired test (n = 4-7) (* P <0.05). Details of age and gender from 
samples were not available. 
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Figure 3-2 CDC6 and CD38 show up regulation in CD34+CD38+ compared to CD34+CD38- 
cells derived from one normal, representative BM sample. 
  
Normal BM samples were freshly isolated or recovered from cryogenic storage. Cells were 
enriched for CD34 and recovered overnight in medium supplemented with GF for cell 
survival. Cells were stained for antibodies against CD34 and CD38 and sorted for 
CD34+CD38- and CD34+CD38+ populations. RNA was extracted, RT and Q-PCR was 
carried out for CDC6 (A) and CD38 (B) mRNA expression. Fold change was calculated 
relative to housekeeping control GAPDH according to the DeltaDeltaCT method. Data are 
presented as the mean fold change of expression in the CD34+CD38+ fraction using the 
CD34+CD38- fraction as a calibrator which is set to the value of 1. Both CDC6 and CD38 
showed an increase in expression in the CD34+CD38+ fraction with a 25.1 and 31.0 fold 
increase in expression levels in comparison to the CD34+CD38- fraction. No statistical 
analysis was used due to the sample size of 1. Details of sample age and gender were not 
available. 
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3.3.2 CXCL1 is expressed in both CD34+CD38- and CD34+CD38+ 
cells at the protein level 
CXCL1 is up regulated in CD34+CD38- cells in comparison to CD34+CD38+ cells at the 
mRNA level, however it is important to ensure gene expression is translated into protein 
expression. Examining protein expression for several ligands was thought to be potentially 
wasteful of primary material, time consuming and technically challenging due to the 
known quality issues associated with chemokine ligand antibodies. The experiments in the 
remaining study focus on chemokine ligand CXCL1 for several reasons. 1. CXCL1 was 
consistently found to be highly expressed in quiescent HSC in several microarrays from 
our group ((Graham et al., 2007); (Irvine et al., data unpublished)). 2. Previous research 
has shown that CXCL1 controls fundamental cellular processes including survival and 
proliferation (reviewed in the introduction section). Therefore this ligand seemed like an 
ideal candidate for further study. 
CXCL1 was examined for protein expression on CD34+CD38- and CD34+CD38+ cells. As 
previous results in this study found that CXCL1 was up regulated in CD34+CD38- cells 
regardless of cellular location, samples were derived from BM or mobilised PB samples 
depending on availability. As CXCL1 is a protein which is expressed intracellularly and 
secreted, intracellular flow cytometry analysis and enzyme-linked immunosorbent assays 
(ELISA) were thought to be ideal for examining CXCL1 protein expression. However, 
both techniques resulted in technical problems as antibody staining was found to be non 
specific and no signal was generated from the ELISA (data not shown). It was thought that 
this was due to a poor quality antibody against CXCL1 and due to the small cell numbers 
of primary cells available and used in the ELISA. As alternative approaches, 
immunofluorescence and western blotting were used to detect CXCL1 expression. 
Immunofluorescence allows the detection of intracellular protein expression and although 
not particularly quantitative, would show the presence or absence of signal. Western 
blotting allows validation of the immunofluorescence staining and provides a quantitative 
technique for examining different expression levels between populations. Antibodies 
against CXCL1 were optimised for both immunofluorescence and western blotting using 
positive control HT 1080 cell lines before use with precious primary samples. 
It can be observed in Figure 3-3 and Figure 3-4 that CXCL1 was detected in HT 1080 cells 
by immunofluorescence staining and western blotting analysis. After optimisation of these 
techniques, human CD34 enriched samples were sorted for CD34+CD38- and 
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CD34+CD38+ populations using CD34 and CD38 expression and examined for protein 
expression of CXCL1. Experiments showed that positive staining for CXCL1 was found in 
all populations tested. A representative figure of staining is seen for CD34+ cells (Figure 
3-3). As immunofluorescence is not quantitative, western blotting analysis showed that 
CXCL1 was detected in both CD34+CD38- and CD34+CD38+ fractions in HSC derived 
from sources of mobilised PB and BM (Figure 3-4). Densitometry was used as a tool for 
quantification as the housekeeping protein expression showed unequal loading between 
samples. Densitometry analysis showed a 0.66 and 1.17 fold change for the CD34+CD38+ 
population in comparison to the CD34+CD38- fraction for BM and PB respectively (n = 1). 
The small differences in expression likely represent no change and no conclusions can be 
drawn due to the sample size of n = 1. 
Recombinant protein of human CXCL1 was tested against the antibody used for 
immunofluorescence and western blotting. Analysis showed multiple bands at ~8Kd, 
~12Kd and ~16Kd (Figure 7-1). Primary samples showed multiple bands with strongest at 
16Kd (Figure 7-2). Without sequencing methods it is difficult to confirm that the band 
found in cell extracts is CXCL1. It seems as though CXCL1 is expressed by human 
primary cells but perhaps a better antibody would clarify this. Using the recombinant 
antibody, the 8kD band is most likely the correct band for CXCL1 as it is the correct 
molecular weight for the CXCL1 protein. The higher band at 12kD is likely to be the 
unprocessed precursor protein which is larger and runs at a higher molecular weight. The 
band at 16kD could represent a dimer as chemokines frequently dimerise in SDS or the 
band could represent a non specific antibody band. Therefore the band visualised in cell 
extracts in this study could be CXCL1 protein which has dimerised or it could be a non 
specific band. Further experimental work is required to address this. 
If the CXCL1 staining is correct, these results raise the question, why is an up regulation of 
CXCL1 observed in mRNA levels and not protein levels? The culture of HSC and 
progenitor cells with particular GF in vitro may play a role in modulating cell cycle status 
and therefore chemokine expression. If the addition of GF results in the activation of the 
quiescent fraction after a certain time period this would alter CXCL1 expression in the 
cells. A difference in expression would therefore not be observed in CD34+CD38- cells in 
comparison to CD34+CD38+ cells. Alternatively, it is possible that CXCL1 is expressed on 
stem and progenitor cells and may play a biological role in both cell types. At this stage, 
this could not be concluded. However, collectively the combination of techniques provides 
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support that CXCL1 is expressed in HSC and progenitor populations and merited 
justification for further investigation into the role of CXCL1 in stem cell function.  
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Figure 3-4 CXCL1 is expressed on HT 1080 and CD34+CD38- and CD34+CD38+ cells using 
western blotting analysis.  
HT 1080 cell lines were cultured in standard medium and protein lysates were prepared. 
Human CD34+ cells were thawed, recovered overnight in medium and GF, sorted for 
CD34+CD38- and CD34+CD38+ populations, cultured for 48 hours and protein lysates 
were prepared. Protein lysates were examined for CXCL1 protein expression by western 
blotting. A band was observed in HT 1080 cells (image taken from from Figure 3-7A), (n 
= 3) CD34+CD38- and CD34+CD38+ cells (A, B). Lanes 1-4 represent the following: 1. 
BM CD34+CD38+; 2. BM CD34+CD38-; 3. PB CD34+CD38+, 4. PB CD34+CD38- (n = 1) 
(B). Housekeeping protein β-tubulin (~50kDa) was used as a loading control which was 
observed at the predicted molecular weight. Densitometry analysis was used to examine 
differential expression of CXCL1 between populations with each CD34+CD38- population 
set to the value of 1 for comparison (C). A full image of the blot with molecular ladder can 
be seen in the supplementary Figure 7-2.  
  
A B 
C 
135 
3.3.3 CXCR2 is expressed by human CD34+CD38- and CD34+CD38+ 
cells 
CXCL1 functions through binding to its receptor CXCR2 (reviewed in the introduction 
section). A lack of CXCR2 expression on HSC would suggest that CXCL1 is signalling in 
a paracrine fashion to other cell types, possibly in the BM niche where diverse cell types 
exist and can regulate HSC behaviour (reviewed in the introduction section). However, if 
the receptor is expressed by HSC, this would suggest that CXCL1 and potentially other 
ligands are signalling to the receptor in an autocrine loop. The expression of the CXCR2 
receptor at the gene and protein level was therefore examined on human HSC and 
progenitor populations using analysis on CD34+CD38- and CD34+CD38+ sorted 
populations.  
Gene expression analysis showed that CXCR2 is detected on human HSC and progenitor 
populations, however a marked variation in expression level was noted between samples. 
This was likely due to sample variability and an increased sample size was not possible in 
this study. Collectively the results showed a trend towards an up regulation in the 
CD34+CD38+ fraction in comparison to the CD34+CD38- fraction with a 2.01 fold increase 
(n.s.) (n = 3) (Figure 3-6). This was not statistically significant and showed a high standard 
deviation therefore likely reflects no change in expression between populations. To 
examine protein expression of CXCR2, several techniques were used. Flow cytometry was 
initially tested with cell surface staining of the receptor which showed negative staining 
(data not shown). However, a previous study examining CXCR2 expression documented 
that flow cytometry with cell surface staining is not ideal for chemokine receptor 
expression. The receptor can become internalised and expressed in intracellular vesicles, 
therefore negative staining using flow cytometry cell surface analysis does not reflect a 
lack of expression (Acosta et al., 2008). Based on this research, immunofluorescence was 
used to examine CXCR2 staining on human HSC. Immunofluorescence staining using a 
CXCR2 antibody was optimised using human neutrophils as a positive control. It can be 
seen in Figure 3-6 that positive staining of CXCR2 can be clearly seen in human 
neutrophils with membranous and cytoplasmic staining as predicted. 
Analysis using human HSC showed that CD34+CD38- and CD34+CD38+ cells expressed 
the CXCR2 receptor at the protein level (Figure 3-6). The technique was not considered to 
be quantitative, but a more cell membranous staining pattern was observed in the 
CD34+CD38- fraction and more intracellular staining was observed in the CD34+CD38+ 
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fraction. 3-D images were generated to demonstrate CXCR2 staining patterns in the 
different cell populations. Studies using CXCR2 immunofluorescence expression have 
indicated that intracellular staining represents a more active protein (Acosta et al., 2008). 
However, this could reflect the difference in cell cycle status between the quiescent and the 
progenitor fraction. To validate this result, western blotting technique was used to examine 
CXCR2 expression in protein lysates, however preliminary experiments showed the 
antibody produced multiple strong bands and time constraints did not permit further study 
(data not shown). 
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Figure 3-5  CXCR2 is expressed in human HSC CD34+CD38- and progenitor CD34+CD38+ 
cells in BM samples at the mRNA level.  
Normal BM samples were isolated fresh or thawed from cryogenically frozen. Cells were 
recovered overnight in medium supplemented with GF. Cells were sorted for CD34+CD38- 
and CD34+CD38+ populations, RNA was extracted, RT and Q-PCR was carried out. Fold 
change in gene expression was calculated relative to housekeeping control GAPDH using 
the DeltaDeltaCT method. Data are presented as the mean fold change of expression in the 
CD34+CD38+ fraction using the CD34+CD38- fraction as a calibrator which is set to the 
value of 1 (A). Panel B demonstrates the relative expression with each dot displaying the 
average from technical triplicates from three independent samples (B). Statistical analysis 
was performed using an unpaired student’s t test with Welch’s correction for unequal 
variance (n.s., n = 3). Details of sample age and gender were not available. 
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Figure 3-6 CXCR2 is expressed in human HSC CD34+CD38- and CD34+CD38+ cells at the 
protein level using immunofluorescence staining.  
Human PB neutrophils were isolated from a normal donor and used immediately after 
isolation. Human CD34+ cells were thawed, recovered overnight in medium supplemented 
with GF, sorted for CD34+CD38- and CD34+CD38+ populations and cultured for 48 hours. 
Cells were then adhered to slides and examined for CXCR2 expression. CXCR2 
expression was visualised in green using an Alexa-Fluor-488 labelled antibody and the 
nuclei were visualised in blue using DNA stain dapi. Images display CXCR2 expression in 
CD34+CD38- (A), CD34+CD38+ (B) and neutrophils (C). Images shown are representative 
images from three independent experiments with appropriate isotype controls used at the 
same concentration and exposure time as the primary antibody of interest. Patient samples 
used were of mixed age, gender and health status. 
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3.3.4 Modulation of CXCL1 in HT 1080 cell lines alters cell viability 
and proliferation 
Experiments in sections 3.3.2 and 3.3.3 show both ligand CXCL1 and receptor CXCR2 are 
expressed on human CD34+CD38- and CD34+CD38+ cells. The next objective was to 
elucidate the biological significance of this signalling pathway. First, we aimed to 
modulate CXCL1 expression in cell lines to optimise the techniques and to examine the 
resulting phenotype. We designed experiments to knock down and over express CXCL1. 
Appropriate vectors were constructed and relevant techniques were optimised in HT 1080 
cells.  
To knock down expression of CXCL1, a lentiviral transduction approach with a shRNA 
vector was taken. A set of several vectors with different unique sequences against the 
CXCL1 protein was purchased and each vector was tested in HT 1080 cells. Several 
shRNA vectors against CXCL1 were shown to result in different levels of protein 
reduction using western blotting analysis which can be visualised in Figure 3-7. 
Densitometry showed the following fold changes of 1.0, 0.99, 0.75. 1.1, 0.84 and 0.86 for 
untransduced, sh1, sh2, sh3, sh4 and sh5 respectively in comparison to the Scr controlled 
which was set to the value of 1 (Figure 3-7). The two vectors corresponding to the greatest 
knock down of the CXCL1 protein were cloned into the same vector (pLKO.1), but with 
the presence of a GFP coding sequence. Both vectors were confirmed to significantly 
reduce gene expression levels of CXCL1 in comparison to the control at the mRNA level 
(40% and 50% reduction in sh2 and sh5 in comparison to Scr control set to the value of 1, 
P <0.01, n = 3) (Figure 3-7).  
The effect of CXCL1 reduction in HT 1080 cells was examined by assessing proliferation 
and viability using cell counts. CXCL1 reduction (sh2 and sh5) in HT 1080 cells resulted 
in a decrease in cell counts in comparison to the control (Scr) after 48 hours in culture (P 
<0.05, n = 3) (Figure 3-8). The cell counts obtained using sh1 and sh2 were below the 
density of the input cells (10x103) indicating a loss of cells in culture after CXCL1 
reduction. This would infer cells were undergoing apoptosis in response to CXCL1 
reduction. Apoptosis analysis using Annexin-V and dapi staining showed no differences in 
apoptosis (n  = 3) (Figure 3-9). However a decrease in the percentage of GFP positive cells 
was observed with both hairpins in comparison to the control (P <0.01 and P <0.001 sh2 
and sh5 respectively) (n = 3) (Figure 3-9).  
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Collectively, the data shows that CXCL1 reduction reduces cell proliferation in HT 1080 
cells. As the reduction in cell counts was below that of the input, it was implicated that 
CXCL1 reduction also reduced cell survival. However, the apoptosis data suggested there 
was no/very little change in apoptosis in response to CXCL1 reduction. The apoptosis 
assay was carried out at a later time point than the cell counts and it is therefore possible 
that CXCL1 reduction did reduce cell viability and at the time of the apoptosis assay, these 
cells had disappeared from the culture. Indeed, analysis of the cell populations showed that 
there was a reduction in the percentage of GFP cells in response to CXCL1 reduction. 
Assuming that 100% of cells at the beginning of the assay are positive for GFP and a loss 
is found in response to CXCL1 reduction, this suggests positively transduced cells are 
being lost from the culture. It is predicted that this is due to apoptosis. To conclude this, 
apoptosis should be analysed at an earlier time point after transduction. 
The data highlight that CXCL1 plays an important role in proliferation and survival in cell 
lines. To complement these experiments, an over expression vector (CXCL1-PRRL) was 
constructed to increase levels of CXCL1 and examine the resulting effect on HT 1080 cell 
properties. CXCL1-PRRL showed an increase in CXCL1 protein levels through mRNA 
(68.4 fold change, P <0.05) (n = 3) and protein levels (1.4 fold change increase) (n = 1) 
(Figure 3-10). CXCL1-PRRL was found to increase cell counts after culture for 48 hours 
in comparison to the control (P <0.05, n = 3) (Figure 3-11). Finally, apoptosis staining 
using Annexin-V and dapi staining showed an increase in the percentage of viable cells in 
the CXCL1-PRRL cells in comparison to the control (P <0.05, n = 3) (Figure 3-12).  
Taken together, the results show that over expression of CXCL1 in cell lines increases cell 
proliferation and cell viability. The results in combination with the knock down studies 
suggest that CXCL1 is a key factor involved in proliferation and survival in HT 1080 cells. 
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Figure 3-7 CXCL1 reduction using shRNA mediated lentiviral reduction reduces CXCL1 
protein and mRNA levels in HT 1080 cell lines.  
HT 1080 cells were lentivirally transduced with 5 plasmids (pLKO.1-CXCL1 or a 
pLKO.1-Scr). After selection in puro, protein lysates were examined for expression of 
CXCL1 or housekeeping β-tubulin (A). Blot represents representative image. Densitometry 
analysis shows the fold reduction of density intensity/mm2 in response to CXCL1 
reduction (B). A larger image of the blot with ladder can be seen in the supplementary 
Figure 7-3. The 2 vectors which corresponded to the best reduction in CXCL1 protein were 
cloned into a GFP plasmid and lentivirally transduced into HT 1080. GFP positive cells 
were sorted using flow cytometry, RNA was extracted, RT and analysed for CXCL1 
mRNA levels. Fold change in gene expression was calculated relative to housekeeping 
control GAPDH according to the DeltaDeltaCT method. Data are presented as the mean 
fold change of expression in the knock down cells using the control (Scr) as a calibrator 
which is set to the value of 1 (C). Data is also presented as relative expression (2-DeltaCT) 
(D). A repeated measures one-way ANOVA was used with the Dunnetts’s multiple 
comparison test to compare the control (Scr) with each hairpin (** P <0.01) 
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Figure 3-8 CXCL1 reduction decreases proliferation in HT 1080 cell lines. 
HT 1080 cells were lentivirally transduced with 2 separate plasmids pLKO.1-CXCL1 (sh2 
or sh5) or a pLKO.1-Scr (Scr). After lentiviral transduction, GFP positive cells were 
isolated and cultured for 48 hours and cells were counted using trypan blue exclusion 
method and total cell count per sample was calculated. Data are presented as the mean cell 
count obtained. The input represents the starting number of cells seeded for all conditions. 
Statistical analysis was performed using a repeated measures one-way ANOVA with 
Dunnett’s multiple comparison test to measure differences between the control (Scr) and 
each hairpin (n = 3) (* P <0.05).  
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Figure 3-9 CXCL1 reduction reduces the percentage of GFP+ cells in HT 1080 cell lines. 
HT 1080 were lentivirally transduced with sh1, sh2 or a Scr control. After lentiviral 
transduction, GFP+ cells were isolated and cultured for 96 hours and cells were examined 
for apoptosis using Annexin-V and dapi staining. Data are presented as the mean 
percentage of cells that were viable or dead (A). Cells were examined for percentage of 
GFP+ cells using flow cytometry. Data are presented as the mean percentage of cells that 
were GFP+ (B) after 96 hours in culture. Statistical analysis was performed using a 
repeated measures one-way ANOVA with Dunnett’s multiple comparison test to assess 
differences between the control column with sh2 and sh5 (B). A statistically significant 
difference was found between the Scr group and both sh2 and sh5 (n = 3) (**P <0.01; *** 
P <0.001). A representative histogram of GFP+ cells between conditions is shown (C). 
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Figure 3-10 CXCL1 over expression vector CXCL1-PRRL increases CXCL1 expression by 
protein and mRNA analysis. 
HT 1080 cells were lentivirally transduced with CXCL1-PRRL or a PRRL empty vector 
control. After transduction, cells were sorted for GFP+ cells and protein lysates were made 
and RNA was extracted, RT and both were examined for expression of CXCL1 using 
western blotting or Q-PCR. Blot shows CXCL1 expression in empty vector (-) and 
CXCL1-PRRL transduced (+) cells using housekeeping protein β-tubulin as a loading 
control (A). Blot represents representative protein image and larger image of blot with 
molecular ladder is available in the supplementary Figure 7-4. Densitometry analysis 
demonstrates the fold change intensity/mm2 in CXCL1-PRRL relative to the empty vector 
control (B). CXCL1 gene expression was calculated relative to housekeeping control 
GAPDH using the DeltaDeltaCT method. Data are presented as mean fold change of 
expression in the CXCL1-PRRL cells using the empty vector cells as a calibrator which is 
set to the value of 1 (C). Relative expression (2-DeltaCT) is shown with each dot displaying 
an average of technical triplicates in three independent experiments (D). Statistical analysis 
was performed using a two-tailed paired t test assuming equal variance (n = 3) (*P <0.05).  
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Figure 3-11 CXCL1 over expression increases proliferation in HT 1080 cell lines. 
HT 1080 cells were lentivirally transduced with CXCL1-PRRL or a PRRL empty vector 
control. After transduction, cells were sorted for GFP+ cells and cells were cultured for 48 
hours in medium. Cells were counted using trypan blue exclusion method and total cell 
count per sample was calculated. Data are presented as the mean cell count. The input 
represents the starting number of cells seeded for both conditions. Statistical analysis was 
performed using a paired t test assuming equal variance comparing the empty vector 
control with the CXCL1-PRRL group (n = 3) (*P <0.05).  
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Figure 3-12 CXCL1 over expression increases cell viability in HT 1080 cell lines. 
HT 1080 cells were lentivirally transduced with CXCL1-PRRL or a PRRL empty vector 
control. After transduction, cells were sorted for GFP positive cells and cells were cultured 
for 96 hours in medium. Cells were analysed for levels of apoptosis using Annexin-V and 
dapi staining. Data are presented as the mean percentage of viable cells. Statistical analysis 
was performed using a paired t test assuming equal variance comparing the empty vector 
control with the CXCL1-PRRL group (n = 3) (*P <0.05). 
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3.3.5 Reduction of CXCL1 in CD34+ cells leads to a reduction in 
cell viability and colony formation capability 
To determine if CXCL1 also affects survival and proliferation in human HSC and 
progenitor populations, a lentiviral transduction approach using shRNA was used. 
CD34+CD38- and CD34+CD38+ cells were transduced with a vector encoding a CXCL1 
shRNA (sh1) or a control (Scr). 
To get an indication of differentiation and proliferation activity transduced cells were 
plated in a CFC assay. In this assay, CXCL1 reduction reduced colony numbers in both 
CD34+CD38- and CD34+CD38+ cells (Figure 3-13). The colonies grown in the CXCL1 
knock down arm (~5% of the number obtained in the control arm) were smaller and less 
dense than those in the control arm (Figure 3-13). Due to limiting cell numbers after the 
lentiviral transduction, cells were available for flow cytometry analysis from the 
CD34+CD38+ fraction only. 72 hours post infection, CD34+CD38+ cells showed a 
reduction in viability in response to CXCL1 reduction as measured by Annexin-V and dapi 
staining (n = 1) (Figure 3-14). Due to the observed effects on CD34+CD38- and 
CD34+CD38+ cells, the assay was repeated using unsorted CD34+ cells. This was to 
increase the material available for assays as the sorting process loses a large amount of 
cells. The assays were repeated with the addition of a second shRNA vector with an 
alternative sequence against CXCL1 (sh5) to exclude the possibility of non-targeting 
effects of one single shRNA sequence. CXCL1 reduction using 2 vectors reduced the 
percentage of viable cells in comparison to the control in CD34+ cells (Figure 3-15). In 
addition, CXCL1 reduction resulted in a reduction in the number of colonies obtained in 
comparison to the control (Figure 3-15).  
Collectively, the data shows that CXCL1 reduction reduces colony formation and induces 
apoptosis in human stem/progenitor cells. Although this experiment has not been 
reproduced several times, it provides a good indication that CXCL1 plays a role in survival 
in human HSC. It is interesting that only a small percentage of cells underwent apoptosis in 
response to CXCL1 reduction, however a large reduction in colony numbers was observed 
in comparison to the control. The viability staining was carried out after 72 hours after 
transduction, whereas colony growth was examined approximately 10-14 days post 
transduction. A possible explanation is that apoptosis is induced over time and 72 hours is 
too early to detect dramatic changes in viability. Another possible explanation is that 
CXCL1 reduces cell viability and inhibits proliferation therefore a dramatic reduction in 
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colony formation is found. This is supported by the results in Figure 3-8 and Figure 3-11 in 
which proliferation is reduced and increased in HT 1080 cells in response to CXCL1 
reduction and over expression respectively. It will be necessary to confirm that CXCL1 
expression is reduced in CD34+ cells in response to both shRNA vectors, however due to a 
lack of cells this was not possible in this study. It can be inferred from the experiments on 
HT 1080 cells that the vectors work to reduce CXCL1 expression. However, it will be 
important to confirm this in primary material. 
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Figure 3-13 Reduction of CXCL1 reduces colony formation in human HSC CD34+CD38+ and 
CD34+CD38- cells. 
Human CD34+ cells were recovered from frozen and cultured overnight in medium 
supplemented with GF. Cells were stained, sorted for CD34+CD38- and CD34+CD38+ 
fractions and lentivirally transduced with viral supernatant for CXCL1 knock down (sh6) 
or with a control (Scr). 24 hours after the addition of fresh medium, cells were sorted for 
GFP+ cells and 103 cells per mL of Methocult™ was plated in duplicate and cultured for 
10-14 days and colonies were counted. Data are presented as the mean total number of 
colonies for Scr and sh6 arms in CD34+CD38+ (A) and CD34+CD38- (B) fractions (n = 2). 
No statistical test was carried out due to the sample size of 2. Images are representative of 
colonies obtained in control or with CXCL1 knock down (C). 
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Figure 3-14 Cell viability of CD34+CD38+ cells in response to CXCL1 reduction. 
Human CD34+ cells were recovered from frozen and cultured overnight in medium 
supplemented with GF. Cells were stained and sorted for CD34+CD38- and CD34+CD38+ 
fractions and lentivirally transduced with viral supernatant for CXCL1 knock down (sh5) 
or with a control (Scr). 24 hours after the addition of fresh medium, cells were sorted for 
GFP+ cells and cultured for 72 hours and analysed for Annexin-V and dapi staining. Data 
are presented as the percentage of cells that were viable or dead (with early and late 
apoptosis combined) for Scr and sh5 arms (A) (n = 1). Image shows Annexin-V and dapi 
staining in Scr and sh5 arms (B). No statistical test was carried out due to the sample size 
of 1.  
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Figure 3-15 Cell viability and colony formation in response to reduction of CXCL1 in CD34+ 
cells. 
 
Human CD34+ cells were recovered from frozen and cultured overnight in medium 
supplemented with GF. Cells were lentivirally transduced with viral supernatant for 
CXCL1 knock down using 2 separate vectors (sh2 and sh5) or with a control (Scr). 24 
hours after the addition of fresh medium, cells were sorted for GFP+ cells and 103 cells 
plated in duplicate in 1mL of Methocult™ and incubated for 10-14 days or cultured for 72 
hours and analysed using Annexin-V and dapi for apoptosis staining. Data are presented as 
the total number of colonies obtained in Scr, sh2 and sh5 treatment arms (A) and as the 
percentage of cells that were viable or dead (with the combination of early and late 
apoptosis) for Scr, sh2 and sh5 arms (B). No statistical test was carried out due to the 
sample size of 1. Images are representative of colonies obtained in control or with CXCL1 
knock down (C).  
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3.3.6 CXCL1 over expression in CD34+ cells does not alter colony 
formation 
To examine if over expression of CXCL1 enhances cell viability and colony formation in 
primary HSC and progenitor cells, cells were lentivirally transduced with a vector 
encoding the CXCL1 coding sequence (CXCL1-PRRL). Due to limitations in cell 
numbers, cells were lentivirally transduced and cultured in a colony formation assay only.  
The results showed that there was no difference between CD34+ cells transduced with an 
empty vector or with CXCL1-PRRL (n.s., n = 3) (Figure 3-16). There was no difference in 
the types of colonies between treatments therefore data are presented as the total number of 
colonies. To ensure that the vector was functioning correctly, gene expression analysis was 
examined and showed an increase in CXCL1 levels in CD34+ cells transduced with 
CXCL1-PRRL in comparison to the control (P <0.01, n = 3). 
It was hypothesised that an increase in colonies would be found in response to CXCL1 
over expression. However the result found in Figure 3-16 does not support his hypothesis. 
Possible explanations include a saturation of CXCL1 levels in human primary cells or that 
a more in depth analysis including cell counts and apoptosis would show differences 
between conditions. 
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Figure 3-16 Over expression of CXCL1 does not affect colony numbers in CD34+ cells. 
Human CD34+ cells were thawed and cultured overnight in medium and GF. Cells were 
lentivirally transduced with viral supernatant for CXCL1-PRRL or an empty vector 
control. 24 hours after the addition of fresh medium GFP positive cells were cultured and 
plated 1,000 cells per mL in Methocult™ and incubated for 10-14 days. Colonies were 
then counted. Data are presented as the total number of colonies with empty vector or 
CXCL1-PRRL arms (A). Images are representative of colonies obtained in control or with 
CXCL1 over expressionknock down (B). CXCL1 gene expression was calculated relative 
to housekeeping control GAPDH using the DeltaDeltaCT method. Data are presented as 
mean fold change of expression in the CXCL1-PRRL cells using the empty vector cells as 
a calibrator which is set to the value of 1 in three independent samples in triplicate (C). 
Relative expression is displayed (2-DeltaCT) with each dot displaying an average of technical 
triplicates from three independent experiments (D). Statistical analysis was performed 
using a paired t test (n = 3) (** P <0.01). Patient samples used were of mixed age, gender 
and health status. 
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3.3.7 Recombinant CXCL1 treatment of CD34+ cells does not alter 
cell viability or cell cycle status  
To examine if human stem/progenitor cells can respond to CXCL1 signalling, CD34+ cells 
were treated with recombinant CXCL1 (CXCL1) protein at a concentration typically used 
in the literature (100ng/mL).  After 24 hours treatment with CXCL1 or an appropriate 
vehicle control, cells were examined for viability and cell cycle status. No difference was 
found in the viability (n.s., n = 3) or cell cycle status (n.s., n = 3) (Figure 3-17).  
It is proposed that the exogenous treatment of CXCL1 would increase viability and 
proliferation of CD34+ cells. A possible explanation is that the time point and 
concentration used are not optimal for this experiment. A more in depth analysis with 
longer time points and higher concentrations would allow a more definitive conclusion on 
whether human HSC or progenitor cells respond to CXCL1. 
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Figure 3-17 Treatment of CD34+ cells with rCXCL1 does not alter cell viability or cell cycle 
status after 24 hours. 
Human CD34+ cells were thawed and cultured overnight in medium and GF. Cells were 
treated with 100ng/mL CXCL1 or with a vehicle control for 24 hours. Cells were then 
washed and analysed for viability using Annexin-V and dapi staining or fixed, 
permeabilised and stained for Ki-67 and dapi. Data are presented as percentage of viable 
cells (A) or percentage of cells in each phase of the cell cycle (B) for both conditions. A 
paired t test (A) and two-way repeated measures ANOVA with Sidak’s multiple 
comparisons was used to examine significance between treatments (n.s., n = 3). Patient 
samples used were of mixed age, gender and health status. 
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3.3.8 CXCR2 inhibition on human CD34+ cells using SB-225002 
alters cell viability, cell cycle status and colony formation  
Results in section 3.3.3 show CXCR2 is expressed on CD34+CD38- and CD34+CD38+ 
cells by mRNA and protein analysis. We wanted to use an antagonist of CXCR2 signalling 
to complement the experiments using CXCL1 reduction. Compound SB-225002 was 
selected as it is an antagonist of CXCR2 signalling and has been shown to inhibit the 
binding of CXCL1 to CXCR2 (White et al., 1998). Due to the limiting availability of 
material and the observation that CXCR2 was expressed on both CD34+CD38- and 
CD34+CD38+ fractions, the cells used in this study were unsorted CD34+. Cells were 
treated for 72 hours with the compound at various concentrations ranging from 0.1µM up 
to 10µM and apoptosis, cell cycle and CFC assays were carried out.  
With the use of inhibitors there is always concern that any effects observed may be due to 
off target non specific effects or general toxicity. SB-225002 is known to inhibit murine 
CXCR2 signalling (Bento et al., 2008). To examine the specificity of SB-225002 on 
CXCR2 inhibition, a stem/progenitor population (c-Kit+) was isolated from WT or Cxcr2-/- 
mice and treated with various concentrations of SB-225002 in vitro. A decrease in the 
percentage of viable cells was found at 10µM in comparison to the untreated control in 
both WT and Cxcr2-/- cells (P <0.01) (n = 3) (Figure 3-18). It can be inferred from this 
result that 10µM is non specific as cells lacking Cxcr2 respond to the compound. 
Alternatively, a possible explanation is that the compound does not function to inhibit 
Cxcr2 in mouse cells and effects on viability are non specific which is not mediated 
through inhibition of CXCR2 signalling. Unfortunately the compound at lower 
concentrations does not affect the WT cells. This experiment cannot conclude whether 
Cxcr2 inhibition using SB-225002 alters cell viability.  
A reduction in the percentage of viable cells in comparison to a vehicle treated control was 
observed with 1µM (P <0.05) but not with 0.1µM (n.s.) (n = 3) (Figure 3-19). Cell cycle 
analysis was examined in concentrations from 0.1 to 1µM. An increase in the percentage 
of cells in G0 phase of cell cycle (P <0.05) and a decrease in percentage of cells in G1 
phase of cell cycle was found (P <0.05) (n = 3) (Figure 3-20) in the 1µM treatment arm. 
There were no significant differences found with the 0.1µM treatment arm however a trend 
towards a decrease in G0 and an increase in G2, S and M phases was reported. However, 
the increase in G0 cells with 1µM could also be due to the effects on viability and this 
should be further investigated. 
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Colony formation assays showed a trend towards a decrease in colony numbers in a 
primary plating assay with treatment with 1µM (n = 2) (Figure 3-21). However a sample 
size of 2 does not allow statistical analysis. Cells were harvested from the assay, counted 
and replated at equal numbers in Methocult™. The differentiation and proliferation 
potential in a secondary replating assay is thought to be indicative of self renewal activity. 
In a secondary colony formation assay, a trend towards a reduction in the number of 
colonies was found with both 0.1 and 1µM treatments (Figure 3-21) (n = 2). Again, sample 
size did not permit statistical analysis. Unfortunately, conclusions cannot be drawn, 
however some evidence is provided to suggest that CXCR2 signalling regulates survival in 
human HSC. 
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Figure 3-18 CXCR2 inhibition using SB-225002 decreases cell viability in c-Kit enriched cells 
derived from WT and Cxcr2-/- animals. 
To examine the specificity of SB-225002 on CXCR2 inhibition, c-Kit+ cells were enriched 
from WT or Cxcr2-/- animals. Cells were cultured with GF for 72 hours in the presence of 
various concentrations of SB-225002 or a vehicle control. Cells were then analysed for 
apoptosis using Annexin-V and dapi staining. Data are presented as the mean percentage of 
viable cells in response to treatment. Animals were between 8 and 12 weeks and male. 
Statistical analysis was performed using a repeated measure’s two-way ANOVA with the 
Sidak’s multiple comparison test to compare the treatments within each group and for each 
treatment between groups (*** P <0.001, n = 3).   
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Figure 3-19 CXCR2 inhibition using SB-225002 reduces cell viability in CD34+ cells in vitro. 
CD34+ cells derived from mobilised PB were thawed and recovered overnight in medium 
supplemented with GF. Cells were cultured for 72 hours with medium and GF in the 
presence of the desired concentration of inhibitor or the appropriate vehicle control. Cells 
were washed and stained for Annexin-V and dapi and analysed. Data are presented as the 
mean percentage of viable cells relative to the vehicle treated control (set to 100%) (B) 
with representative dot plots for Annexin-V and dapi staining with vehicle treated and 
1µM treatment arms (A). Statistical analysis was performed using a one-way repeated 
measure ANOVA with Tukey’s multiple comparisons test to compare differences between 
untreated and each treatment (n = 3) (n.s., * P <0.05). Patient samples used were of mixed 
age, gender and health status. 
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Figure 3-20 CXCR2 inhibition using SB-225002 on CD34+ cells alters cell cycle status.  
CD34+ cells derived from mobilised PB were thawed and recovered overnight in medium 
supplemented with GF. Cells were cultured for 72 hours in medium and GF in the presence 
of the desired concentration of inhibitor or appropriate vehicle control. Cells were washed, 
fixed, permeabilised and stained for Ki-67 and dapi and analysed. Data are presented as the 
mean percentage of cells in each phase of the cell cycle; G0, G1 or G2, S and M (B) with 
representative dot plots for Ki-67 and dapi staining (A). Statistical analysis was performed 
using a repeated measures two-way ANOVA with Tukey’s multiple comparison test to 
assess differences between treatments (n = 3) (**P <0.01).  Patient samples used were of 
mixed age, gender and health status. 
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Figure 3-21 CXCR2 inhibition using SB-225002 decreases colony formation in primary and 
secondary colony assays in CD34+ cells in vitro. 
CD34+ cells derived from mobilised PB were thawed and recovered overnight in medium 
supplemented with GF. 1,000 CD34+ cells were plated per mL of methylcellulose™ with 
the addition of the desired concentration of inhibitor or appropriate vehicle control. The 
mix was vortexed and plated in duplicate and incubated for 10-14 days. After this time 
period, colonies were counted, cells were resuspended, counted and replated at 10,000 cells 
per mL of methycellulose™ with the addition of fresh inhibitor. All cells were replated and 
no differences were noted in colony type between conditions therefore data is presented as 
the mean total number of colonies after culture in primary (A) and secondary colony 
formation assay (B). No statistical significance tests were carried out due to the sample 
size of 2. Patient samples used were of mixed age, gender and health status. 
A B 
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3.4 Discussion 
 
Published microarray data from our laboratory reported than CXCL1, CXCL2 and CXCL6 
were up regulated in quiescent, human HSC populations although CXCL6 did not reach 
significance (Graham et al., 2007). Significantly differentially expressed candidates from 
microarray studies offer important discoveries. However, it is understood that these 
candidates should be experimentally validated as in particular, microarray expression data 
can contain a high level of noise. In addition, although gene expression differences can be 
validated, there are cases where the protein is not translated or indeed not functional. 
Considering these points, the first objectives in this study was to validate this gene 
expression data from the previous microarray study and extend the research to investigate 
the biological function. 
In this study, CD34 and CD38 cell surface markers were used to isolate populations taking 
the assumption that cells in these populations are in different states of the cell cycle with 
the CD34+CD38- population existing as more quiescent than the CD34+CD38+ population. 
The results obtained in this chapter showed that chemokines were up regulated in the 
quiescent fraction using CD34 and CD38 cell surface markers. In addition, the differential 
expression of CD38 and CDC6 in sorted samples provided conclusive evidence that the 
sorted populations showed differential expression of CD38 therefore the sort was efficient 
and CDC6 therefore the cells were in differential status of the cell cycle. It can be argued 
that the CD34+CD38+ fraction is more of a progenitor population, therefore experiments 
should compare chemokine gene expression of chemokines in different populations within 
the stem CD34+CD38- fraction to get a more in depth analysis of a stem cell population. 
Ideally, a more enriched HSC population should have been used in this study, however this 
would have reduced the material obtained and therefore the ability to perform techniques 
accurately.  
The microarray study did not implicate the receptor CXCR2 as being differentially 
expressed between quiescent and proliferating human HSC populations and it remains 
unclear from the available literature whether this particular receptor is expressed on any 
subsets of HSC. One study stated that CXCR2 was not expressed by human stem or 
progenitor populations (CD34+CD38- and CD34+CD38+), including cells isolated from 
adult BM or mobilised PB (Rosu-Myles et al., 2000). However, the technique used in this 
study to analyse protein expression was flow cytometry for cell surface staining only. In 
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the results in this chapter, it can be clearly seen that CXCR2 is expressed on human HSC 
and progenitor populations, both at the mRNA and protein level by immunofluorescence. 
One previous study showed positive staining of CXCR2 on CD34+ cells isolated from PB 
from normal controls, however this was variable between samples (Emadi et al., 2005). 
The results here are completely novel with the only chemokine receptor known to be 
expressed by HSC or progenitor cells is CXCR4 which is involved in cell survival and 
mobilisation (reviewed in the introduction section). However, to fortify the results in this 
chapter another method can be used to examine CXCR2 expression. 
Experiments in this chapter show that CXCR2 inhibition using SB-225002 on CD34+ cells 
resulted in a decrease in cell viability, cell cycle status and colony formation. This 
implicates that CXCR2 may be controlling these stem cell properties. In the literature, the 
compound has been tested in vitro and in vivo to show it can be used to prevent CXCR2 
ligand CXCL1 and CXCL8 induced neutrophil chemotaxis at similar concentrations 
(Catusse et al., 2003, Lane et al., 2001, White et al., 1998). However, due to the nature of 
compounds it could not be conclusively concluded that SB-225002 mediated CXCR2 
inhibition is responsible for the cellular effects. The literature also suggests that higher 
concentrations of the compound can inhibit CXCR1 signalling. It would therefore be 
useful to examine whether human HSC express CXCR1 as this is unclear in the literature. 
One study showed that human CD34+ cells derived from the cord blood (CB) of normal 
donors expressed high levels of CXCR1, however this should be validated (Rosu-Myles et 
al., 2000). However, as both CXCR2 inhibition and CXCL1 reduction showed a reduction 
in cell viability and colony formation, collectively this provided evidence that CXCL1-
CXCR2 signallin may play a role in HSC survival and maintenance but these experiments 
should be repeated to allow significance to be assessed. 
There is little literature available on the role of CXCR1 or CXCR2 on stem cell properties. 
A study on CB cells showed that inhibition against CXCR1 and CXCR2 decreased the 
percentage of stem cells, defined by CD133 positive staining, suggesting these receptors 
are fundamental to cell survival (Khalaf et al., 2010). A study on myeloid metaplasia with 
myelofibrosis showed that inhibition of CXCR1 and CXCR2 on CD34+ cells resulted in an 
increase in proliferation and skewed differentiation, however this was in a disease setting 
and not in normal haemopoiesis (Emadi et al., 2005). The predominant role of CXCR2 
signalling is in directed cell movement. CXCR2 expressing cells including granulocytes 
are directed towards different sites due to ligand expression. The studies in this chapter did 
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not examine cell migration, however it will be interesting to examine whether CXCR2 
expressing human HSC migrate in response to ligand stimulation.  
The results show that CXCL1 is expressed on CD34+CD38- cells at the mRNA level. 
Protein analysis through several techniques provided opposite results. Flow cytometry and 
ELISA showed negative expression, while immunofluorescence and western blotting 
showed positive expression. It is possible that technical reasons are responsible for a lack 
of signal with flow cytometry and ELISA. However, this can not be concluded. Further 
experiments are required to firmly conclude the expression of CXCL1 on human HSC. 
Results showed CXCL1 reduction in both cell lines (HT 1080) and primary CD34+ cells 
reduced cell survival and proliferation. Previous studies have shown that CXCL1 knock 
down decreases cell viability in melanoma cell lines (Botton et al., 2011). Furthermore, 
CXCL1 knock down and over expression have been shown to decrease and increase cell 
proliferation in epithelial ovarian cancer cell lines (Bolitho et al., 2010). CXCL1 reduction 
has also been shown to reduce cell proliferation in other cell types, including 
oligodendrocyte progenitors (Zhou et al., 2005). Collectively, the role of CXCL1-CXCR2 
signalling in survival and proliferation is not novel, however this has not been shown on 
primary HSC. To conclude this chapter, the results provide some evidence that CXCL1-
CXCR2 is a novel signalling pathway that may play a role in stem cell survival and 
proliferation however repetition of experiments are required to conclude this hypothesis.  
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4 Results II: Analysis of haemopoieisis and stem 
cell activity in Cxcr2-/- mice  
4.1 Introduction 
Results from chapter 3 provide evidence that the CXCR2 signalling pathway may support 
human HSC and progenitor survival in vitro. However, the haemopoietic structure is 
incredibly complex with HSC interacting with various other cell types in the BM niche. 
Consequently, HSC are influenced by external cues as well as internal cues (reviewed in 
the introduction section). With a particular focus on Cxcr2 signalling, there is evidence in 
the literature that Cxcr2 binding ligands play a role in HSC mobilisation (Pelus et al., 
2002). However the role of Cxcr2 signalling in HSC behaviour is largely unstudied and not 
well understood. Gene-targeting studies have been used to identify key roles of signalling 
pathways in biological processes and a mouse model in which mouse Cxcr2 is excised, is 
available for study. In addition, the mouse system provides the advantages of more 
material for in depth experiments including the use of in vivo assays. 
In this chapter, we wanted to extend the research in the first part of this study and examine 
how Cxcr2 signalling controls stem cell properties in vivo using a mouse model which 
lacks Cxcr2 (Cxcr2-/-). This model has been generated and animals are viable and live to 
adulthood. The mice have previously been characterised and animals lacking Cxcr2 display 
an increase in the numbers of mature myeloid cells and progenitors in the haemopoietic 
organs including the BM, spleen and PB. This phenotype has been shown to be 
environment dependent (Cacalano et al., 1994, Broxmeyer et al., 1996). It is proposed from 
previous literature that Cxcr2 negatively regulates myeloid cell production and this 
regulation is mediated through Cxcr2 binding ligands. However, whether mouse HSC 
express Cxcr2 and whether this signalling plays a role in the function of the stem cells has 
not been assessed to date.  
The results in this chapter were designed to investigate whether HSC and progenitor 
populations derived from Cxcr2-/- animals differ in terms of their frequency and function in 
comparison to WT controls. Data from the human experiments suggests that CXCR2 is 
controlling cell survival. Therefore the prediction is that in a Cxcr2-/- mouse model, the 
HSC will show loss of function in terms of stem cell activity. 
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4.2 Aims and Objectives 
The specific aims of this chapter were: 
I To examine Cxcr2 expression on mouse HSC 
The results in chapter 3 show that human HSC show positive expression of CXCR2. 
However whether mouse HSC express Cxcr2 is not known to date.  
II To investigate how a lack of Cxcr2 alters the frequency of mature cells in the 
haemopoietic organs  
This objective was to examine how Cxcr2 signalling affects the haemopoietic system. 
Previously published data shows differences in the frequency of mature haemopoietic cells 
in Cxcr2-/- animals. However this has been shown to be dependent on the environment the 
animals are housed in. We wanted to examine the phenotype of the mice used in this study. 
III To investigate whether a lack of Cxcr2 alters HSC and progenitor populations 
in terms of their frequency, properties and function  
This objective was to understand whether a lack of Cxcr2 signalling affects the number and 
function of HSC/progenitor populations. 
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4.3 Results 
4.3.1 CXCR2 is expressed on mouse HSC  
Data from chapter 3 showed human HSC populations express CXCR2 and an autocrine 
signalling loop with ligand CXCL1 is involved in stem cell viability and proliferation. It is 
unclear in the literature whether mouse HSC populations express the receptor. One study 
identified positive expression in lineage negative, CD45+ cells derived from mouse BM 
(Yoon et al., 2012). However, this population represents a mix of stem and progenitor 
cells. A similar study examined a more primitive population (LSK) for Cxcr2 expression. 
Variation was found between samples with both positive and negative expression reported 
(Wright et al., 2002). It is therefore unclear in the literature whether Cxcr2 is expressed on 
mouse HSC. Furthermore, recent research has identified cell surface markers expressed by 
mouse HSC and more primitive populations can be isolated and studied. The first objective 
in this chapter was to examine Cxcr2 expression on mouse HSC. Due to the small numbers 
of stem cells available from mouse HSC populations (including the most primitive subset), 
single cell Q-PCR was used to assess expression of Cxcr2 on sorted populations. Mouse 
BM was harvested, stained for a cocktail of antibodies against stem cell markers and sorted 
for LSK in addition to CD150+CD48- (LT-HSC), CD150-CD48- (ST-HSC), CD150+CD48+ 
and CD150-CD48+ (MPP) populations and examined for Cxcr2 expression. The 
terminology used in this thesis follows previous research (Khandanpour et al., 2010, Kiel 
et al., 2005). The experiments in section 4.3.1 were carried out in collaboration with Dr 
Amelie Guitart.  
Results showed Cxcr2 was expressed at the mRNA level on all HSC populations examined 
with no trend towards differences in expression between populations (Figure 4-1). Relative 
expression was used to compare expression with a stem cell gene p21 (Cheng et al., 2000). 
This is the first study to show that Cxcr2 is expressed on mouse HSC populations 
including the most primitive LT-HSC. The lack of difference in expression between stem 
and progenitor populations suggests that signalling is important for stem and progenitor 
function. Alternatively, it is possible that CXCR2 is differentially expressed at the protein 
level in these populations. However, protein expression of CXCR2 was not examined due 
to time constraints in this study and the low cell numbers that are available from mouse 
HSC and progenitor populations. Protein expression analyses will be useful to confirm the 
protein is translated. 
168 
To determine whether an autocrine loop of Cxcr2 signalling exists on mouse HSC, mouse 
homologs of human Cxcr2 binding ligands Cxcl1, Cxcl2 and Cxcl5/6 (as highlighted from 
the original microarray) were examined for gene expression using the methodology 
described above. Results showed that the ligands tested were not detected on any of the 
populations using single cell Q-PCR (data not shown). It can be interpreted from these 
results that either a Cxcr2 autocrine signalling loop is not present on mouse HSC, or 
alternatively, other CXC ligands are expressed which were not assessed in this particular 
experiment. Alternatively, it is possible that Cxcr2 expressing HSC signal to other cell 
types in the BM niche in a paracrine manner. To support this, previous studies have shown 
that CXCR2 expression is detected on BM derived lineage negative cells which respond to 
Cxcl5 expressed by EC (Yoon et al., 2012). Therefore, there is literature to support the 
result that CXCR2 is expressed on stem/progenitor populations and they can respond to 
ligand expression from other cell types present in the BM niche.  
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Figure 4-1 Mouse HSC populations express Cxcr2 at the mRNA level. 
Normal BM was freshly isolated and stained for antibodies against LSK, CD150 and 
CD48. 500 cells were sorted, RT and Q-PCR was carried out for Cxcr2 mRNA expression. 
Fold change was calculated relative to housekeeping control β2M (A). Data is also 
displayed as the relative expression (2-DeltaCT) (B). Results show the mean of technical 
triplicates from two independent experiments using two separate WT animals, both male at 
age 6-12 weeks (n = 2) (A). Panel B shows relative expression in comparison to a stem cell 
gene p21. No statistical analysis was carried out due to the sample size of 2.  
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4.3.2 Cxcr2-/- animals display differential numbers of mature 
haemopoietic cells 
Preliminary experiments were carried out on Cxcr2-/- animals on a Balb/c background. 
However, analysis of the stem cell populations in these animals showed little/no staining of 
stem cell marker Sca-1 which was confirmed in the literature (data not shown) (Spangrude 
and Brooks, 1993). A lack of Sca-1 staining made the stem cell analysis difficult to 
interpret without the ability to examine populations which were Sca-1+. In addition, 
animals on a Balb/c background are not commonly used in BM reconstitution assays with 
no clear way to discriminate between donor and host cells. Consequently, experiments 
were carried out on animals on a C57/BL6 background in which normal Sca-1 staining was 
observed (Figure 4-7). C57/BL6 animals are commonly used for BM reconstitution assays 
due to the existence of two strains with different cell surface markers (Weissman, 2000). 
This allows the discrimination of donor versus host cells in transplantation assays.  
Previous literature has documented that the observed phenotype in Cxcr2-/- animals is 
dependent upon the environment in which the animals are housed in (Broxmeyer et al., 
1996). In this section, immunophenotypic analysis and cell counts were used to assess the 
cellularity and frequency of mature haemopoietic cells (myeloid (GR1, CD11B), lymphoid 
(CD19 and B220) and erythroid cells (TER119)) in the haemopoietic organs (BM, spleen, 
PB and thymus). Cxcr2-/- animals were examined with age and sex matched WT littermates 
as controls. 
4.3.2.1 BM 
Analysis of the BM showed a trend towards an increase in the cellularity in the absence of 
Cxcr2, which was not statistically significant (n.s., n = 12) (Figure 4-2). 
Immunophenotypic analysis showed a significant decrease in erythroid cells in the absence 
of Cxcr2 (P <0.05, n = 12) (Figure 4-2). A significant increase was found in the 
granulocyte cells in the Cxcr2-/- mice (P <0.001, n = 12) (Figure 4-2). Finally a trend 
towards a decrease was found in the B cells in the Cxcr2-/- mice which was not significant 
(n.s., n = 12) (Figure 4-2).  
4.3.2.2 Spleen 
Analysis of the spleen showed a trend towards an increase in the cellularity in the Cxcr2-/- 
animals, which was not statistically significant (n.s., n = 6) (Figure 4-3). This was most 
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likely due sample variation as an increase in spleen size in the Cxcr2-/- animals was clearly 
noted after dissection. There was an increase in the numbers of erythroid cells in the Cxcr2-
/-
 mice (P <0.01. n = 6) and in the granulocyte cells (P <0.05, n = 6) (Figure 4-3) (Figure 
4-4). There was no statistically significant differences in the B and T cell numbers between 
strains (n.s., n = 6) (Figure 4-3).  
4.3.2.3 PB 
PB analysis showed an increase in cellularity in the Cxcr2-/- animals (P <0.05, n = 12) 
(Figure 4-5). There was no difference in the numbers of erythroid cells in the Cxcr2-/- 
animals (n.s., n = 6) (Figure 4-5). A trend towards an increase was found in the 
granulocytes (n.s., n = 6) (Figure 4-5) which was not significant due to small sample size 
and inter sample variability. Finally no difference in the numbers of B cells was found 
between strains (n.s., n = 6) (Figure 4-5). T cells information is not available due to 
technical problems during the staining. 
4.3.2.4 Thymi 
Analysis of the thymi showed no difference in cellularity (n.s., n = 6) with no difference in 
the number of T cells between strains (n.s., n = 6) (Figure 4-6).  
Collectively, the data in this section is in accordance with results from previous reports 
(Broxmeyer et al., 1996, Cacalano et al., 1994). Previously it has been shown that the 
number of myeloid cells are increased in Cxcr2-/- animals which is only displayed in 
animals housed in a normal environment and not under germ-free conditions (Broxmeyer 
et al., 1996). Although the use of animals in this chapter were housed in a ‘clean’ facility, 
it is likely this was not germ-free and therefore the reason why a difference in myeloid 
cells was observed. As reported previously, an increase in myeloid cells was observed in 
the BM, spleen and PB with an overall increase in WBC cellularity. It has been proposed 
that Cxcr2 is a negative regulator of myeloid cells therefore a lack of Cxcr2 in the 
organism results in an expansion of the myeloid compartment. In addition to differences in 
the number of myeloid cells between strains, differences were found in numbers of 
erythroid cells in the BM and spleen between strains. It is possible that a reduction in the 
BM is due to the increase of myeloid cells which reduces the overall number of erythroid 
cells. However, an increase of erythroid cells was found in the spleen of Cxcr2-/- animals. It 
is possible that Cxcr2 plays a role in both myeloid and erythroid regulation. The lack of 
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difference in the cellularity of thymus and numbers of T cells suggests that this is not 
altered by Cxcr2 signalling. 
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Figure 4-2 Cellularity and absolute numbers of mature cells in the BM between WT and 
Cxcr2-/- animals. 
Whole BM was assessed for cellularity and the absolute number of mature cells was 
assessed using flow cytometry and WT and Cxcr2-/- (KO). Data are presented as the mean 
total number of cells (WBC) between strains (A) or absolute numbers of mature cells; 
erythroid (TER119+), granulocyte (GR1+CD11B+) or B cells (CD19+B220+) (B). Statistical 
analysis was carried out using a two-tailed unpaired student’s t test with Welch’s 
correction for unequal variance (* P <0.05; *** P <0.001, n = 12). Plots display a 
representative image of staining observed with GR1+CD11B+ dotplots (C) or TER119+ 
histogram (D). Animals were between 6 to 12 weeks and mixed gender (WT 7 male, 5 
female; Cxcr2-/- 6 male, 6 female).  
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Figure 4-3 Cellularity and absolute numbers of mature cells in the spleen between WT and 
Cxcr2-/- animals.  
Spleen was assessed for cellularity and the absolute number of mature cells was assessed 
using flow cytometry. Data are presented as the mean total number of cells (WBC) 
between strains (A) or absolute numbers of mature cells; erythroid (TER119+), granulocyte 
(GR1+CD11B+), B cells (CD19+B220+) (B) or T cell subsets (CD4+CD8+ , CD4-CD8-, 
CD4+CD8- and CD4-CD8+) (C). Statistical analysis was carried out using a two-tailed 
unpaired student’s t test with Welch’s correction for unequal variance (* P <0.05; ** P 
<0.01, n = 6). Animals were between 6 to 12 weeks and mixed gender (WT 3 male, 3 
female; Cxcr2-/- 4 male, 2 female).  
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Figure 4-4 Flow cytometry plots of mature cells in the spleen between WT and Cxcr2-/- 
animals. 
Plots display a representative image of staining observed in GR1+CD11B+ dotplots (A) or 
TER119+ histogram (B) in Cxcr2-/- or WT spleens.  
 
 
 
  
A 
B 
176 
 
Figure 4-5 Cellularity and absolute numbers of mature cells in the PB between WT and 
Cxcr2-/- animals.  
PB was assessed for cellularity and the percentage of mature cells was assessed using flow 
cytometry. Data are presented as the mean total number of cells (WBC) between strains 
(A) or absolute numbers of mature cells; erythroid (TER119+), granulocyte 
(GR1+CD11B+) or B cells (CD19+B220+) (B). Statistical analysis was carried out using a 
two-tailed unpaired student’s t test with Welch’s correction for unequal variance (* P 
<0.05, n = 6). Plots display a representative image of staining observed in GR1+CD11B+ 
dotplots (C). Animals were between 6 to 12 weeks and mixed gender (WT 3 male, 3 
female; Cxcr2-/- 4 male, 2 female). 
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Figure 4-6 Cellularity and absolute numbers of mature cells in the thymi between WT and 
Cxcr2-/- animals.  
Thymi were assessed for cellularity and the percentage of mature cells was assessed using 
flow cytometry. Data are presented as the mean total number of cells (WBC) between 
strains (A) or absolute numbers of T cell subsets (CD4+CD8+, CD4-CD8-, CD4+CD8- and 
CD4-CD8+) (B). Statistical analysis was carried out using a two-tailed unpaired student’s t 
test with Welch’s correction for unequal variance (n.s., n = 6). Animals were between 6 to 
12 weeks and mixed gender (WT 3 male, 3 female; Cxcr2-/- 4 male, 2 female).  
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4.3.3 Cxcr2-/- animals show differences in the frequencies of 
stem and progenitor cells in the BM and spleen 
Analysis of the stem and progenitor compartment in terms of frequency and functionality 
has not been assessed in Cxcr2-/- animals to date.  
A method for assessing whether a gene plays a key role in stem or progenitor function is to 
examine the frequencies of stem and progenitor cells in animals lacking the gene. As an 
example, a reduction or expansion of the stem cell compartment can give an indication of 
genes involved in stem cell maintenance or cell cycle. Analysis of stem and progenitor 
populations can be examined using flow cytometry with a variety of cell surface markers to 
distinguish different cell types (as described in methods section). Stem cell populations can 
be identified as described in section (4.3.1). Progenitor populations can be analysed using 
the lineage negative fraction, with Sca-1 negative and c-Kit positive cells (LK) which can 
be further sorted into lineage restricted progenitor populations using CD16/CD32 and 
CD34 staining for the identification of GMP, CMP and MEP populations.  
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4.3.3.1 BM 
4.3.3.1.1 Stem cell frequency 
 
There was a decrease in the number of lineage negative cells in the Cxcr2-/- animals (P 
<0.05, n = 12) (Figure 4-7). Within the lineage negative fraction, the LSK and further 
enriched stem cell populations were examined. There was a trend towards an increase in 
the number of LSK cells which was not significant most likely due to high variability 
between Cxcr2-/- samples (n.s., n = 12) (Figure 4-7). The CD150+CD48- fraction (LT-HSC) 
showed an increase in the Cxcr2-/- animals (P <0.05, n = 12) (Figure 4-7). Finally, there 
were no differences between CD150-CD48- (ST-HSC), CD150+CD48+ (MPP) or CD150-
CD48+ (MPP) fractions but a trend towards an increase in all populations was noted (n.s., n 
= 12) (Figure 4-7). Representative flow cytometry plots are shown (Figure 4-8). 
As these animals show an expansion of myeloid cells within the BM, the reduction in the 
percentage of lineage negative cells and subsequently cell number is possibly due to this 
disruption of mature cells within the organ. The data collectively suggests that Cxcr2-/- 
animals have an expansion of the stem cell populations, including the most primitive (LT-
HSC) fraction in the BM. This suggests that Cxcr2 is important for steady state 
haemopoiesis. This could suggest that CXCR2 signalling is negatively regulating stem cell 
production. Stem cell frequency gives no conclusive indication of stem cell function. 
However, often ‘loss of function’ in HSC is initially associated with transient expansion in 
stem cells numbers due to increased proliferation but eventual exhaustion and depletion of 
repopulating stem cells. As an example, HSC with no cell cycle inhibitors show a transient 
expansion which results in exhaustion and reduced HSC activity in BM reconstitution 
assays (Cheng et al., 2000). To conclude this, in vivo cell cycle analysis and BM 
reconstitution assays are required. 
4.3.3.1.2 Progenitor frequency 
 
In terms of the progenitor populations, the LK fraction contains progenitor cells and shows 
a trend towards a decrease in the Cxcr2-/- condition (n.s., n = 6) (Figure 4-9). There were no 
statistically significant differences between GMP, CMP and MEP populations in terms of 
absolute numbers however there was a trend towards an increase in the GMP population 
and decrease in the CMP and MEP populations (n.s., n = 6) (Figure 4-9). It is likely that 
differences might be found with an increase in sample size as a high volume of variation 
was noted between animals and a sample size of n = 6 was used in this assay. Observation 
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of representative flow cytometry plots of GMP, CMP and MEP staining demonstrates that 
the distribution of cell types between strains is different with an increase in GMP and CMP 
populations and a decrease in MEP populations in Cxcr2-/- animals (Figure 4-9). 
It is not surprising that the flow cytometry plots show a differential distribution of GMP, 
CMP and MEP populations due to the differences in mature cell types (granulocytes and 
erythroid) that we see in the mature cells in the BM in section 4.3.2. This does however 
suggest that the deregulation of myeloid cells that occurs in the Cxcr2-/- mice occurs at the 
primitive, progenitor level. However, this cannot be concluded due to a lack of significance 
in absolute progenitor numbers between strains.  
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4.3.3.2 Spleen 
4.3.3.2.1 Stem cell frequency 
 
There was a trend towards an increase in the number of lineage negative cells in the Cxcr2-
/-
 animals in the spleen (n.s., n = 6) (Figure 4-10). There was a significant increase in the 
number of LSK cells in the Cxcr2-/- animals (P <0.05, n = 6) (Figure 4-10). Finally, All 
HSC fractions showed a trend towards an increase in the Cxcr2-/- animals which was not 
statistically significant, most likely due to the low sample size for this result (n.s., n = 3) 
(Figure 4-10).   
The data suggests that Cxcr2-/- animals have an expansion of the stem cell populations both 
in the BM and spleen and show extramedullary (spleen) haemopoiesis. This suggests that 
the HSC are both expanded and there is enhanced mobilisation in the Cxcr2-/- animals. This 
is in accordance with previous literature which shows an increase in the numbers of CFU 
in BM and spleen derived cells in Cxcr2-/- conditions in comparison to WT controls 
(Broxmeyer et al., 1996, Cacalano et al., 1994). However, this study extends this previous 
research and shows detailed analysis of the stem cell populations. 
4.3.3.2.2 Progenitor frequency 
 
In terms of progenitor cells in the spleen, the LK fraction showed an increase in the   
Cxcr2-/- animals (P <0.05, n = 6) (Figure 4-11). There were trends towards increases in all 
progenitor populations including the GMP, CMP and MEP populations (n.s. for GMP and 
CMP respectively with P <0.001 for MEP, n = 3) (Figure 4-11). It can be seen from 
representative flow cytometry plots that the distribution of progenitor populations differ 
between strains with a greater population of GMP and CMP populations in the Cxcr2-/- 
animals (Figure 4-11). The increase in progenitor populations is in accordance with results 
in the previous sections which showed an increase in mature myeloid and erythroid cells in 
the spleen derived from Cxcr2-/- animals.  
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Figure 4-7 Absolute numbers of stem cell populations between WT and Cxcr2-/- animals in 
the BM. 
Whole BM was made into a single cell suspension and stained for antibodies to examine 
the stem cell populations and analysed using flow cytometry. Data are presented as the 
mean absolute cell numbers for lineage negative (A), LSK (B) or HSC (C) populations 
between WT and Cxcr2-/- animals. Statistical analysis was carried out using a two-tailed 
unpaired student’s t test with Welch’s correction for unequal variance (* P <0.05, n = 12). 
Animals were between 6 to 12 weeks and mixed gender (WT 7 male, 5 female; Cxcr2-/- 6 
male, 6 female). 
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Figure 4-8 Representative flow cytometry plots of lineage negative, LSK and HSC 
populations between WT and Cxcr2-/- animals. 
 
Plots display a representative image of lineage negative (A), LSK (B) and HSC 
populations (C) between WT and Cxcr2-/- animals.  
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Figure 4-9 Absolute numbers of progenitor populations between WT and Cxcr2-/- animals in 
the BM. 
The BM was made into a single cell suspension and stained with antibodies to examine the 
progenitor populations and analysed using flow cytometry. Data are presented as the mean 
absolute cell numbers for LK (A) or progenitor populations (B) between WT and Cxcr2-/- 
animals. Statistical analysis was carried out using Statistical analysis was carried out using 
a two-tailed unpaired student’s t test with Welch’s correction for unequal variance (n.s., n 
= 6). Images demonstrate representative flow cytometry plots for LSK (C) and progenitor 
(D) staining between WT and Cxcr2-/- animals. Animals were between 6 to 12 weeks and 
mixed gender (WT 3 male, 3 female; Cxcr2-/- 1 male, 5 female). 
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Figure 4-10 Absolute numbers of stem cell populations between WT and Cxcr2-/- animals in 
the spleen. 
Spleen was made into a single cell suspension and stained for antibodies to examine the 
stem cell populations and analysed using flow cytometry. Data is presented as the mean 
absolute cell numbers for lineage negative (A), LSK (B) or HSC (C) populations between 
WT and Cxcr2-/- animals. Statistical analysis was carried out using a two-tailed unpaired 
student’s t test with Welch’s correction for unequal variance (* P <0.05, n = 6). Dotplot 
shows representative flow cytometry staining profile for LSK staining between WT and 
Cxcr2-/- animals (D). Animals were between 6 to 12 weeks and mixed gender (WT 3 male, 
3 female; Cxcr2-/- 1 male, 5 female). 
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Figure 4-11 Absolute numbers of progenitor populations between WT and Cxcr2-/- animals in 
the spleen. 
The spleen was made into a single cell suspension and stained with antibodies to examine 
the progenitor populations and analysed using flow cytometry. Data are presented as the 
mean absolute cell numbers for LK (A) and progenitor (B) populations between WT and 
Cxcr2-/- animals. Statistical analysis was carried out using a two-tailed unpaired student’s t 
test with Welch’s correction for unequal variance (* P <0.05; *** P <0.001, n = 3). 
Dotplots display representative flow cytometry staining  observed for LK (C) and 
progenitor populations (D) between WT and Cxcr2-/- animals. Animals were between 6 to 
12 weeks and same gender (WT 3 female; Cxcr2-/- 3 female). 
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4.3.4 Cxcr2-/- animals show an increase in colony numbers 
derived from the spleen and PB 
HSC and progenitor cells are contained within the BM, spleen and PB and have the 
capacity to differentiate into cells of myeloid and lymphoid lineages. The CFC assay 
measures the differentiation and proliferation capacity using their ability to form colonies 
in culture as described in the previous chapter. This assay was used to examine the 
differences in proliferation and differentiation capacity of cells derived from the BM, 
spleen and PB from WT and Cxcr2-/- animals. To examine the self renewal capacity of BM 
derived cells, colonies grown in a primary plating assay were harvested and replated into a 
secondary assay. Using this assay, the self renewal capacity of BM stem/progenitor cells 
was compared between strains. 
4.3.4.1 BM 
BM derived from Cxcr2-/- and WT animals showed both strains generated colonies in 
methylcellulose and had comparable lineage differentiation potential. No difference in 
CFU was found in primary plating assays derived from BM cells between strains (n.s., n = 
8) (Figure 4-12). No difference in colony types were observed between strains therefore 
colonies were counted as total number of colonies (data not shown). After colony counts, 
colonies were harvested from plates, pooled and reseeded into a secondary colony 
formation assay to get an indication of the self renewal activity of the stem/progenitor 
cells. No difference in colonies in a secondary colony formation assay was found in cells 
derived from the BM however huge variation was noted between samples in the Cxcr2-/- 
condition (n.s., n = 3) (Figure 4-12).  
4.3.4.2 Spleen 
An increase in CFU-GM colonies was found in cells derived from the Cxcr2-/- spleen (P 
<0.001, n  = 3) (Figure 4-13). This was not statistically significant which likely reflects a 
small sample size and sample variability. Similarly, a trend towards an increase in CFU-E 
colonies was found (n.s., n = 3). Finally, no CFU-GEMM colonies were found in either 
condition. The increase in CFU-GM and CFU-E colonies resulted in an overall trend 
towards increase in the total number of colonies in the Cxcr2-/- animals in comparison to 
the WT controls (n.s., n = 3).   
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4.3.4.3 PB 
An increase in CFU-GM colonies was found in the PB of Cxcr2-/- animals (P <0.01., n = 6) 
(Figure 4-14). No difference in CFU-E or CFU-GEMM colonies was found between 
strains (n.s., n = 6). However the increase in CFU-GM colonies collectively resulted in a 
trend towards an increase in the total number of colonies in the Cxcr2-/- animals which 
failed to reach significance (n.s., n = 6) 
Data from previous literature which showed an increase in CFU in the spleen and PB in 
cells derived from Cxcr2-/- animals in comparison to controls  (Broxmeyer et al., 1996). 
This indicates that stem/progenitor activity exists in the circulation and extramedullary 
sites of haemopoiesis including the spleen and PB. The results in section 4.3.3.2 with 
immunophenotypic analyses support this. The lack of significance with colony assays in 
the spleen and PB likely represents inter sample variation. However, in the study by 
Broxmeyer et al., an increase in CFU in BM derived cells was reported in BM cells which 
lack Cxcr2. The lack of difference in CFU found in the BM between Cxcr2-/- and WT cells 
in this chapter could, and most likely reflects technical issues. Observation of the CFU 
numbers obtained from BM samples in the Broxmeyer et al., study showed a much higher 
number of CFU obtained in the WT condition than in the results in this thesis (>80 CFU 
per sample in comparison to ~20 per sample). Therefore it is likely that technical issues 
resulted in small CFU numbers and may not be as accurate. To support this idea, an 
increase in myeloid, stem and progenitor populations is noted in Cxcr2-/- animals using 
flow cytometry analysis as described in sections 4.3.2.1 and 4.3.3.1. Therefore it was 
predicted that BM derived Cxcr2-/- cells would produce an increase in CFU in comparison 
to WT controls.  
The results from the replating assay suggests that there is no difference in self renewal 
activity between strains however low numbers of CFU were noted, small sample sizes 
were used and high variation was noted between samples. Therefore this result is not 
conclusive to whether cells lacking Cxcr2 in the BM show altered 
proliferation/differentiation or self renewal activity. 
 
189 
 
Figure 4-12 WT and Cxcr2-/- CFC analysis in BM derived cells showed no difference between 
strains in primary or secondary plates. 
 
Whole BM from either Cxcr2-/- or WT animals was made into a cell suspension, WBC 
counted and 104 cells plated per mL in Methocult™ and incubated for 10-14 days. 
Colonies were subsequently scored, counted and replated into a secondary assay. Data are 
presented as the mean total number of colonies in a primary (A) (n  = 8) and secondary 
replating assay (B) (n = 3). Statistical analysis was carried out using a two-tailed unpaired 
student’s t test with Welch’s correction for unequal variance (n.s.). Animals were between 
6 to 12 weeks and mixed gender (CFC1 WT 5 male, 3 female; Cxcr2-/- 5 male, 3 female; 
CFC2 WT 1 male, 2 female; Cxcr2-/- 2 male, 1 female).   
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Figure 4-13 WT and Cxcr2-/- CFC analysis in spleen derived cells. 
Spleen was isolated from Cxcr2-/- or WT animals, WBC counted and 105cells plated per 
mL in Methocult™ and incubated for 10-14 days. Colonies were subsequently scored and 
counted. Data are presented as the mean total number and type of colonies (A) and total 
number of colonies (B) (n = 3). Statistical analysis was carried out using a two-way 
ANOVA with Sidak’s multiple comparisons to assess differences between groups (A) (*** 
P <0.001) and a two-tailed unpaired student’s t test with Welch’s correction for unequal 
variance (B) (n.s., P = 0.058). Animals were between 6 to 12 weeks and same gender (WT 
3 female; Cxcr2-/- 3 female). 
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Figure 4-14 WT and Cxcr2-/- CFC analysis in PB derived cells. 
PB was isolated from WT and Cxcr2-/- animals, WBC counted, RBC lysed and 100,000 
cells plated per mL in Methocult™ and incubated for 10-14 days. Colonies were 
subsequently scored and counted. Data are presented as the mean total number and type of 
colonies (A) and total number of colonies (B) (n = 3). Statistical analysis was carried out 
using a two-way ANOVA with Sidak’s multiple comparison test to assess differences 
between groups (A) (** P <0.01) and a two-tailed unpaired student’s t test with Welch’s 
correction for unequal variance (B). Animals were between 6 to 12 weeks and same gender 
(WT 3 female; Cxcr2-/- 3 female). 
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4.3.5 Analysis of viability in Cxcr2-/- HSC populations  
The results from section 4.3.3.1.1 showed an expansion of LT-HSC in the BM of Cxcr2-/- 
animals indicating expansion of stem cells with a lack of Cxcr2. To test whether HSC 
derived from Cxcr2-/- or WT animals differed in terms of their stem cell properties, it was 
aimed to examine viability and cell cycle status of HSC derived from both strains. BM was 
harvested and stained for antibodies to identify HSC populations with the addition of 
Annexin-V and Ki-67 to measure cell death and proliferation respectively. The results are 
representative of one sample therefore no statistical analysis has been carried out and only 
trends are discussed. 
Results showed a trend towards a decrease in the percentage of Annexin-V+ cells in cell 
populations in the Cxcr2-/- animals in the whole BM, lineage negative, LSK, 
CD150+CD48-, CD150-CD48-, CD150+CD48+ and CD150-CD48+ HSC populations 
(Figure 4-15). A sample size of n = 1 was used therefore no standard deviation or statistical 
significance is recorded. 
Although it cannot be concluded, the results suggest that the stem/progenitor populations 
are more viable (less Annexin-V+) in the Cxcr2-/- animals in comparison to the WT 
littermates (n = 1). Analysis of viability of the WT cells, showed a percentage of Annexin-
V+ cells in whole BM which is likely basal levels of apoptosis (16.4%). This is not 
surprising as the BM contains a mixture of diverse cell types including terminally 
differentiated mature cell types which have a short life span and are regulated by apoptosis. 
In addition, the cells were examined ex vivo which means they are taken from their niche 
environment where their survival and maintenance are regulated by extrinsic signals. The 
percentage of apoptotic cells was decreased as a more primitive cell population was 
analysed from lineage negative (9.77%) to LSK and LT-HSC population (5.0% and 5.5% 
respectively). This indicates that the Annexin-V staining is correct as the expression 
pattern of staining correlates to the pattern expected. Interestingly, an increase in the 
percentage of Annexin-V+ cells was found in the CD150+CD48+ population which 
suggests this particular MPP population exhibits a higher level of basal apoptosis than the 
other HSC populations. It is unclear why cells lacking Cxcr2 show increased viability in 
comparison to controls. It is possible that Cxcr2 inhibition results in a compensation of 
other chemokines including Cxcr1 which results in enhanced cell viability. However, this 
cannot be concluded without analysis of Cxcr1 and other chemokines in the absence of 
Cxcr2. 
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Ki-67 staining was used to examine proliferation in HSC populations. Although this stain 
used alone cannot discriminate between cells in G0 versus G1, the percentage of Ki-67+ 
cells shows cells in G2, S and M phases and therefore can indicate cells that are actively 
proliferating. Data showed a decrease in the percentage of Ki-67+ cell populations 
suggesting a decrease in cell proliferation in the Cxcr2-/- animals in the whole BM, lineage 
negative and LK populations (Figure 4-15). No difference was found between WT and 
Cxcr2-/- animals in the LSK or other HSC populations including the CD150+CD48- and 
CD150+CD48+ populations. A trend towards an increase was found in the CD150+CD48+ 
and CD150-CD48+ populations (n = 1) (Figure 4-15). No statistical tests were carried out 
due to the sample size of 1. 
In the WT cells, it can be seen that the BM and LK fractions show the highest levels of 
proliferation which is decreased in the HSC populations, with the lowest levels noted in the 
most primitive CD150+CD48- fraction. This staining pattern is as would be predicted as the 
most primitive HSC are known to be less proliferative. No difference in Ki-67+ cells is 
found between HSC populations between strains with the exception of the MPP population 
(CD150-CD48+) and this trend is found in the less primitive LK and lineage negative 
fraction also. Although with a sample size of 1, conclusions cannot be drawn, it can be 
inferred that the MPP population becomes more proliferative in the absence of Cxcr2. In 
contrast, the whole BM, lineage negative and LK fraction seem to be less proliferative in 
the absence of Cxcr2. Higher proliferation in the MPP population could result in cell 
exhaustion and Cxcr2 controls cell cycle differently in MPP in comparison to more mature 
cell types. A more in depth analysis of cell cycle analysis with the addition of DNA stains 
to distinguish between cells in G0 and G1 can be used. Alternatively, the cycling status of 
cells can be examined in vivo with the use of label retaining dyes including 
bromodeoxyuridine (Brd-U).  
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Figure 4-15 Cxcr2-/- HSC viability and proliferation. 
 
WT or Cxcr2-/- stem and progenitor populations were stained for Annexin-V and analysed 
for viability or fixed, permeabilised and stained for Ki-67. Data is presented as the mean 
percentage of Annexin-V+ cells (A) or Ki-67+ cells (B) in various cell populations in BM 
derived cells in the WT and Cxcr2-/- conditions. The sample size is one, therefore no 
standard deviation or statistical analysis is shown (n = 1). Dotplots of representative 
samples show flow cytometry staining of Annexin-V+ cells in the CD150+CD48+ fraction 
(C) or Ki-67 staining in LK fraction (D). Animals were between 6 to 12 weeks and same 
gender (WT 1 female; Cxcr2-/- 1 female).  
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4.3.6 Analysis of engraftment in a BM reconstitution assay with 
WT or Cxcr2-/- HSC  
The gold standard technique for assaying HSC functional activity is the BM reconstitution 
assay. More specifically, this technique involves the isolation of HSC and transplantation 
into a host in which the BM has been ablated with lethal irradiation. After transplantation, 
the HSC will home and engraft into the BM niche, where they will balance self renewal 
and multilineage differentiation to produce progeny including the mature cell types of 
haemopoiesis. A decrease in engraftment and multilineage differentiation infers that the 
HSC population is not functional. The use of donor cells (CD45.2+) from a different 
genetic background than the host (CD45.1+) allows the contribution of donor cells to be 
tracked using flow cytometry.  
WT or Cxcr2-/- HSC were isolated from animals on a CD45.2+ background and were 
transplanted into several host CD45.1+ animals which had been previously irradiated. The 
HSC were transplanted with unmanipulated BM from a CD45.1+ animal to act as a 
‘support’ for the survival of the hosts with ablated haemopoietic systems. Monoclonal 
antibodies against CD45.1 and CD45.2 were used with flow cytometry analysis to examine 
donor engraftment in different cell populations over time. It was hypothesised that Cxcr2 
null HSC would show a decrease in engraftment potential in comparison to the control WT 
HSC.  
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4.3.6.1 Primary BM reconstitution assays 
To examine whether HSC derived from WT or Cxcr2-/- animals contained differences in 
engraftment potential, PB from recipient animals was examined for the percentages of 
CD45.1+ versus CD45.2+ cells every 4 weeks up to 16 weeks post transplant. This time 
frame allows the donor HSC to engraft into the BM niche and result in multilineage BM 
reconstitution. The engraftment of donor cells was tracked in the PB over 16 weeks using 
CD45.1 and CD45.2 staining. Furthermore, within the CD45.2+ fraction, the percentage of 
myeloid (GR1+ and CD11B+), B (CD19+) and T (CD4+ and CD8+) cells were examined. 
This was to examine whether HSC from Cxcr2-/- animals had the potential for multilineage 
differentiation. Mice were sacrificed at 16 weeks post transplant and haemopoietic organs 
were examined for the presence of donor derived cells. 
From 4 weeks up to 16 weeks post transplant, a trend towards a decrease in the percentage 
of CD45.2+ cells was found in the PB of animals transplanted with Cxcr2-/- donor HSC in 
comparison to the control (n.s., n =7, 6) (Figure 4-16). In the WT control, a trend towards 
increase in CD45.2+ cells was found over the 16 week period indicative that the transplant 
was successful. No significant differences were noted between conditions, and it was 
observed that a great deal of variation was found within both conditions. It can be seen 
from Figure 4-16 that several samples showed no/little engraftment up until the 16 week 
timepoint in the recipients transplanted with WT HSC. This is likely due to a technical 
problem during the injection as WT HSC should home and engraft in irradiated recipients. 
Similarly, some samples in the Cxcr2-/- condition showed no/little engraftment and the 
majority of samples showed a small percentage of engraftment. However these were not 
excluded from the analysis as this would introduce bias. It can be seen from the WT donor 
cells that percentage of engraftment increases over time which is as expected in a BM 
reconstitution assay. Similarly, in the Cxcr2-/- condition, some HSC do engraft and the 
percentage engraftment increases over time. This indicates that the HSC that do engraft are 
capable of self renewal, however the overall percentage engraftment is lower than in 
comparison to the control. A possible explanation is a defect in cell homing in HSC 
lacking Cxcr2. 
In addition to examining engraftment of donor cells, the cells that did engraft (CD45.2+) 
were examined for their potential to produce cell types of different lineages. Within the 
CD45.2+ cells, the percentage of cells positive for mature cells of all the myeloid, 
lymphoid and T cell lineages was examined. Data showed no difference in the ability of 
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any of the recipient animals to produce all the mature cell types over a period of 16 weeks 
post transplant (n.s., n = 7, 6) for WT and Cxcr2-/- conditions respectively at 16 weeks post 
transplant (Figure 4-16).  These results indicate that although the HSC derived from Cxcr2-
/- show a trend towards decreased engraftment, the HSC that engraft are capable of 
multilineage differentiation. This would support the hypothesis that HSC lacking Cxcr2 
show a defect in homing, as it is clear from the result in Figure 4-16 that some HSC can 
engraft and produce multilineage differentiation.  Interestingly, there was no difference in 
the percentage of myeloid cells in the PB in animals transplanted with WT or Cxcr2-/- HSC. 
As the Cxcr2-/- animals show increased number of myeloid cells in the haemopoietic 
organs at steady state, this suggests that it is not a Cxcr2-/- cell autonomous HSC that is 
responsible for this expansion. As the host animals are WT with Cxcr2 not deleted, it is 
possible that a lack of this receptor is required in all tissues to result in the observed 
phenotype. However, this is speculation. 
At 16 weeks post transplant, the animals were sacrificed and haemopoietic organs were 
analysed for donor derived cells in mature cell types and stem/progenitor cells. To achieve 
this, CD45.1 and CD45.2 staining was examined in myeloid (GR1 and CD11B), lymphoid 
(CD19), progenitors (LK, GMP, CMP and MEP) and stem cells (LT-HSC, ST-HSC, MPP) 
in the BM and spleen.  
The results showed a similar pattern obtained in the PB analysis (Figure 4-16). A trend 
towards a decrease in engraftment was found in the BM and spleen (n.s., n = 7, 6). A trend 
towards a reduction in engraftment was noted in the mature cells in both in the BM (n.s.) 
and spleen (P<0.05 for myeloid and n.s. for T cells respectively, n = 7, 6) (Figure 4-17). In 
terms of progenitors, there was a trend towards a reduction in the LK, GMP, CMP and 
MEP populations in the WT and Cxcr2-/- conditions respectively (n.s., n = 7, 6) (Figure 
4-18). Similarly, the LK population in spleen derived cells showed trend towards a 
decrease in engraftment which was not statistically significant (n.s., n = 7, 6) (Figure 4-18).  
Analysis of the stem cell populations within the BM showed a decrease in the engraftment 
of lineage negative (P <0.05), LSK (n.s.), CD150+CD48- (n.s.), CD150-CD48- (n.s.), 
CD150+CD48+ (n.s.) and CD150-CD48+ (n.s.) populations in the WT and Cxcr2-/- 
conditions respectively (Figure 4-18). Similarly, the lineage negative and LSK populations 
in the spleen showed a trend towards decrease in donor cell engraftment in recipients 
transplanted with Cxcr2-/-  HSC (n.s.) (Figure 4-18). 
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Collectively, the data shows that Cxcr2 cell autonomous signalling is important for stem 
cell functional activity. The lack of significance across the analysis represents 
heterogeneity in engraftment observed in both WT and Cxcr2-/- donor derived cells and is 
likely technical. The evidence that Cxcr2-/- HSC can still contribute to mature cell types, 
stem and progenitor cells in the BM and spleen infers that Cxcr2-/- HSC can still function, 
however this is to a lesser extent than the WT. If the Cxcr2-/- HSC can produce 
multilineage reconstitution over time then they are still functional and it is possible that 
their defect is not in stem cell function but in cell homing after transplantation. It is unclear 
from these experiments whether the reduction in engraftment found with Cxcr2-/- donor 
cells is due to a decrease in stem cell function or a decrease in cell homing. If Cxcr2-/- 
could not engraft in the BM but engrafted in alternative sites of haemopoeisis, an increase 
of engraftment would be found in the spleen or PB from Cxcr2-/- transplanted animals. 
However, this was not the case. It may be possible that the cells cannot home and undergo 
apoptosis and therefore show a reduction in engraftment, however this cannot be 
concluded at this stage. 
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Figure 4-16 WT and Cxcr2-/- HSC show no significant differential engraftment in a primary 
BM transplantation assay.  
Data are presented as the mean percentage of CD45.2+ cells in recipient mice transplanted 
with either WT or Cxcr2-/- HSC (LT-HSC, 102 cells per mouse) along with CD45.1 support 
marrow (2x105 cells per mouse) over a 16 week period (A) (n.s. n = 7, 6). Each recipient 
animal is displayed as a single symbol on the graph at 16 weeks post transplant (B) (n.s., n 
= 7, 6). Representative flow cytometry plots of CD45.1 and CD45.2 staining in recipients 
with WT or Cxcr2-/- HSC are shown (C). The percentage of myeloid (GR1+, CD11B+), B 
(CD19+) and T (CD4+, CD8+ ) cells found in the PB within CD45.2+ donor cells are shown 
(D). Antibodies against CD4 and CD8 were used in the same fluorophore therefore T cells 
are labelled as double positive cells (CD4+, CD8+ ) only. Statistical analysis was carried out 
using two-way repeated measures ANOVA with Sidak’s multiple comparison test to 
compare conditions at each timepoint (A) and a student’s unpaired t test with Welch’s 
correction for unequal variance (D) (n.s.) (n = 7, 6). Animals were between 6 to 12 weeks 
and mixed gender (donor WT 2 female; Cxcr2-/- 2 female; recipients WT 4 male, 3 female; 
Cxcr2-/- 4 male, 2 female). 
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Figure 4-17 WT and Cxcr2-/- HSC show no differential engraftment in BM but show a 
decrease in myeloid cells in the spleen.  
Data are presented as the mean percentage of CD45.2+ cells within whole BM (A) or 
spleen (B) myeloid and B cells in recipient mice transplanted with either WT or Cxcr2-/- 
HSC after 16 weeks post transplant. Statistical analysis was carried out using a student’s 
unpaired t test with Welch’s correction for unequal variance (* P <0.05, n = 7, 6). Spleen B 
cell data was not available (B). Animals were between 6 to 12 weeks and mixed gender 
(donor WT 2 female; Cxcr2-/- 2 female; recipients WT 4 male, 3 female; Cxcr2-/- 4 male, 2 
female). 
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Figure 4-18 WT and Cxcr2-/- HSC show no differential engraftment in BM and spleen derived 
stem and progenitor cells. 
Data are presented as the mean percentage of CD45.2+ cells within BM and spleen HSC 
and progenitor cell types. The percentage of CD45.2+ cells within BM HSC (A), BM 
progenitor (B), spleen HSC (C) and spleen progenitor (D) was assessed in recipient mice 
transplanted with either WT or Cxcr2-/- HSC after a 16 week period (A). Statistical analysis 
was carried out using a student’s unpaired t test with Welch’s correction for unequal 
variance (n.s. n = 7, 6).  Animals were between 6 to 12 weeks and mixed gender (donor 
WT 2 female; Cxcr2-/- 2 female; recipients WT 4 male, 3 female; Cxcr2-/- 4 male, 2 
female). 
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4.3.7 Survival curve of WT and Cxcr2-/- animals over a year 
period 
A BM reconstitution assays stresses the haemopoietic system so HSC will be forced to 
reconstitute the BM and functional activity can be assessed. As an alternative approach to 
stress the haemopoietic system, Cxcr2-/- and WT animals were aged for 52 weeks and the 
haemopoietic system was examined. 
4.3.7.1 Survival curve 
Firstly, it was observed that the Cxcr2-/- animals showed a decrease in survival in aged 
animals with 2 animals sacrificed out of 5 (67% survival) in comparison to WT animals 
with no deaths up to 52 weeks old (100% survival) (Figure 4-19).  Limited assays were 
carried out on Cxcr2-/- animals post-mortem and it therefore cannot be concluded the 
reason for death of the animals. However, BM was analysed in one of the sacrificed mice 
and compared with a WT control at a similar age. The results showed that phenotype of the 
young mice is exaggerated with such an increase in the granulocyte population that the 
erythroid cells within the BM are at a very low level (Figure 4-19). Flow cytometry 
analysis of these populations on a WT aged mice was used as a comparison and it can be 
observed that an increase in myeloid cells and decrease in erythrocytes is strikingly 
observed in aged Cxcr2-/- animals. Based on this analysis, it is hypothesised that the BM 
became depleted of erythrocytes and this is likely to be the cause of premature death. 
However, this is purely speculative as more in depth assays were not carried out at this 
stage. Based on the survival animals, the experiments described in the following section 
used 5 WT and 3 Cxcr2-/- animals for analysis. 
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Figure 4-19 Survival curve for aged WT and Cxcr2-/- animals. 
The data are presented as a survival curve for the percentage survival of WT or Cxcr2-/- 
animals up to a 52 week period where the surviving animals for sacrificed for analysis (n = 
5) (A). Flow cytometry plots show granulocyte (B) and erythroid staining in the BM of a 
Cxcr2-/- animal that was sacrificed before the year period. Analysis of a WT control at a 
similar age was used as comparison (B, C). Animals were all F due to availability and 
between 48 and 52 weeks of age. A log-rank (Mantel-Cox) test was used to compare 
survival curves using percentage of survival over time and showed no statistically 
significant difference between the two survival curves (n = 5). 
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4.3.7.2 Cellularity and frequency of mature cell types 
BM, spleen, PB and thymus were analysed for cellularity and absolute numbers of mature 
cell types including granulocytes, erythroid, B, and T cells in aged WT and Cxcr2-/- 
animals as described in section 4.3.2. 
4.3.7.2.1 BM 
 
The BM showed no difference in cellularity between WT and Cxcr2-/- conditions (n.s., n = 
5, 3) (Figure 4-20). There was a significant decrease in erythroid cells in the Cxcr2-/- 
condition (P <0.01, n = 5, 3) (Figure 4-20). A trend towards an increase was found in the 
granulocytes in the Cxcr2-/- conditions (n.s., n = 5, 3) (Figure 4-20). Finally a trend towards 
a decrease was found in the B cells in the Cxcr2-/- condition which was not significant (n.s., 
n = 5, 3) (Figure 4-20).  
4.3.7.2.2 Spleen 
 
The spleen showed no difference in cellularity between WT and Cxcr2-/- conditions (n.s.) 
which likely reflects sample variation as an increase was noted in spleen size in Cxcr2-/- 
animals upon dissection (Figure 4-21). There was no difference in erythroid cells between 
strains (n.s.) (Figure 4-21). There was a trend towards an increase in the granulocytic 
population in the Cxcr2-/- condition (n.s.) (Figure 4-21). There was a trend towards a 
decrease in the B and T cell populations in the Cxcr2-/- condition (n.s., n = 5, 3) (Figure 
4-21).  
4.3.7.2.3 PB 
 
The PB showed a trend towards increase in cellularity in the Cxcr2-/- conditions (n.s., n = 5, 
3) (Figure 4-22). There was a trend towards an increase in erythroid cells in the Cxcr2-/- 
condition (n.s.) (Figure 4-22). A trend towards an increase was found in the granulocytes 
in the Cxcr2-/- condition (n.s.) (Figure 4-22). Finally a trend towards a decrease was found 
in the B cells in the Cxcr2-/- condition (n.s., n = 2, 3) (Figure 4-22). The lack of samples in 
these assays was due to technical problems with staining. T cells subsets were not analysed 
in the PB due to technical problems. 
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4.3.7.2.4 Thymi 
 
The thymi showed no difference in cellularity between WT and Cxcr2-/- conditions (n.s., n 
= 5, 3) (Figure 4-23). There was no difference in T cells in the thyme however only double 
positive cells (CD4+CD8+) were analysed (n.s., n = 5, 3) (Figure 4-23).  
Collectively, the data shows the same trend in the frequency of mature cell types between 
the conditions as in the young mice. The lack of significance for particular cell types 
including granulocytes in the BM, spleen and PB reflects a small sample size and variation 
between samples.  
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Figure 4-20 Cellularity and absolute numbers of mature cell types in BM of WT and Cxcr2-/- 
aged animals. 
Whole BM was assessed for cellularity and the absolute number of mature cells was 
assessed using flow cytometry. Data are presented as the mean total number of cells 
(WBC) between strains (A) or absolute numbers of mature cells; erythroid (TER119+), 
granulocyte (GR1+CD11B+) or B cells (CD19+B220+) (B). Statistical analysis was carried 
out using a student’s unpaired t test with Welch’s correction for unequal variance (* P 
<0.05; n = 5, 3). Plots display a representative image of staining observed with 
GR1+CD11B+ dotplots (C) or TER119+ histogram (D). Animals were between 6 to 12 
weeks and the same gender (WT 5 female; Cxcr2-/- 3 female). 
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Figure 4-21 Cellularity and absolute numbers of mature cell types in spleen of WT and 
Cxcr2-/- aged animals.  
Spleen was assessed for cellularity and the absolute number of mature cells was assessed 
using flow cytometry. Data are presented as the mean total number of cells (WBC) 
between strains (A) or absolute numbers of mature cells; erythroid (TER119+), granulocyte 
(GR1+CD11B+), B cells (CD19+B220+) or T cells (CD4+CD8+) (B). Statistical analysis 
was carried out using a student’s unpaired t test with Welch’s correction for unequal 
variance (n = 5, 3). Plots display a representative image of staining observed with 
GR1+CD11B+ dotplots (C). Animals were between 6 to 12 weeks and the same gender 
(WT 5 female; Cxcr2-/- 3 female). 
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Figure 4-22 Cellularity and absolute numbers of mature cell types in PB of WT and Cxcr2-/- 
aged animals.  
PB was assessed for cellularity and the absolute number of mature cells was assessed using 
flow cytometry. Data are presented as the mean total number of cells (WBC) between 
strains (A) (n = 5, 3) or absolute numbers of mature cells; erythroid (TER119+), 
granulocyte (GR1+CD11B+) or B cells (CD19+B220+) (B) (n = 2, 1). Statistical analysis 
was carried out using a student’s unpaired t test with Welch’s correction for unequal 
variance (A) and no statistical test was carried out in panel B. Plots display a representative 
image of staining observed with GR1+CD11B+ dotplots (C). Animals were between 6 to 12 
weeks and the same gender (WT 5 female; Cxcr2-/- 3 female). 
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Figure 4-23 Cellularity and absolute numbers of mature cell types in thymi of WT and Cxcr2-
/-
 aged animals.  
Thymi was assessed for cellularity and the absolute number of mature cells was assessed 
using flow cytometry. Data are presented as the mean total number of cells (WBC) 
between strains (A) or absolute numbers of T cells (CD4+CD8+) (B). For this particular 
experiment, CD4 and CD8 antibodies were used with the same fluorochrome therefore 
only double positive population data is available (CD4+CD8+). Statistical analysis was 
carried out using a student’s unpaired t test with Welch’s correction for unequal variance 
(n = 5, 3). Animals were between 6 to 12 weeks and the same gender (WT 5 female; 
Cxcr2-/- 3 female). 
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4.3.7.3 Frequency of stem and progenitor cells in aged WT 
and Cxcr2-/- mice 
The frequency of stem and progenitor populations was examined in aged WT and Cxcr2-/- 
animals as described in section 4.3.3. 
4.3.7.3.1 BM 
4.3.7.3.1.1 Stem cell frequency 
 
There was a trend towards a decrease in the number of lineage negative cells in the Cxcr2-/- 
animals which can be seen with representative flow cytometry plots (n.s., n = 5, 3) (Figure 
4-24; Figure 4-25). There was a trend towards an increase in the number of LSK cells in 
the Cxcr2-/- animals (n.s., n = 5, 3) (Figure 4-24; Figure 4-25). Finally there were no 
significant differences between the various HSC populations (n.s., n = 3, 5) (Figure 4-24; 
Figure 4-25).  
4.3.7.3.2 Progenitor populations 
 
In terms of progenitors, the LK fraction showed no difference between strains (n.s., n = 5, 
3) (Figure 4-26). There were no statistically significant differences between GMP, CMP 
and MEP populations between strains however representative flow cytometry plots show 
the differential distribution of populations between strains (n.s., n = 3, 5) (Figure 4-26). 
However the trends showed the same as found in the young animals. The lack of 
significance likely reflects the small sample size. 
The lineage negative and LSK frequency in the BM show a similar trend to those obtained 
in young animals (Figure 4-7). However, no difference was noted between strains for the 
HSC populations. This could be due to smaller sample sizes in the ageing analysis or it is 
possible that there are no differences in the frequency of HSC populations in aged animals. 
Interestingly, an increase (9.7 fold) is noted in the absolute number of LT-HSC in WT BM 
derived from young and aged animals. This is in accordance with previous literature to 
show that LT-HSC are increased in frequency in response to ageing, but display decreased 
functionality (Snoeck, 2013). Although an increase is still noted between young and aged 
LT-HSC in the Cxcr2-/- animals, the fold increase is lower than that observed with the WT 
(2.8 fold). It is possible that an expansion of LT-HSC occurs at an earlier stage in the 
Cxcr2-/- animals therefore no differences are seen in aged mice as an expansion is also 
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noted in the WT. This would infer that the HSC have reduced self renewal potential, 
however this cannot be concluded at this stage. 
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4.3.7.3.3 Spleen 
 
4.3.7.3.3.1 Stem cell populations 
 
There was a trend towards an increase in the number of lineage negative cells in the Cxcr2-
/-
 animals in the spleen (n.s., n = 5, 3) (Figure 4-27). There was no differences in the 
number of LSK cells between strains (n.s., n = 5, 3) (Figure 4-27). Finally there were no 
significant differences between the various HSC populations (n.s., n = 3, 5) (Figure 4-27). 
4.3.7.3.3.2 Progenitor populations 
 
In terms of progenitors, the LK fraction showed a trend towards an increase in the Cxcr2-/- 
condition (n.s., n = 5, 3) (Figure 4-28). There were no statistically significant differences 
between GMP, CMP and MEP populations between strains (n.s., n = 3, 5) (Figure 4-28). 
However the lack of significance likely reflects the small sample size, the differential 
distribution of cell types can be seen with representative flow cytometry plots between 
strains and the data showed the same trends as in the young mice. 
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Figure 4-24 Absolute numbers of stem cell populations in the BM between WT and Cxcr2-/- 
aged animals. 
Whole BM was made into a single cell suspension and stained for antibodies to examine 
the stem cell populations and analysed using flow cytometry. Data are presented as the 
mean±standard deviation absolute cell numbers for lineage negative, LSK or HSC 
populations between WT and Cxcr2-/- animals. Statistical analysis was carried out using a 
student’s unpaired t test with Welch’s correction for unequal variance (n.s., n = 5, 3). 
Animals were between 6 to 12 weeks and the same gender (WT 5 female; Cxcr2-/- 3 
female). 
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Figure 4-25 Representative flow cytometry plots of lineage negative, LSK and HSC 
populations between WT and Cxcr2-/- animals in aged animals. 
Images show representative flow cytometry plots of lineage negative (A), LSK (B) and 
HSC staining (C) in WT and Cxcr2-/- animals. Animals were all F due to availability and 
between 48 and 52 weeks of age. 
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Figure 4-26 Absolute numbers of progenitor populations between WT and Cxcr2-/- animals. 
Whole BM was made into a single cell suspension and stained for antibodies to examine 
the progenitor populations and analysed using flow cytometry. Percentages of cells within 
whole BM was multiplied by the WBC cellularity of the BM and absolute numbers 
compared. Data are presented as the mean absolute cell numbers for LK, CMP, GMP and 
MEP populations between WT and Cxcr2-/- animals. Statistical analysis was carried out 
using a student’s unpaired t test with Welch’s correction for unequal variance (n.s., n = 5, 
3). Animals were between 6 to 12 weeks and the same gender (WT 5 female; Cxcr2-/- 3 
female). 
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Figure 4-27 Absolute numbers of stem cell populations between WT and Cxcr2-/- aged 
animals in spleen. 
Spleen was made into a single cell suspension and stained with antibodies to examine the 
stem cell populations and analysed using flow cytometry. Percentages of cells within 
whole spleen was multiplied by the WBC cellularity of the spleen and absolute numbers 
compared. Data is presented as the mean absolute cell numbers for lineage negative, LSK 
or HSC populations between WT and Cxcr2-/- animals. Statistical analysis was carried out 
using a student’s unpaired t test with Welch’s correction for unequal variance (n.s., n = 5, 
3). Animals were between 6 to 12 weeks and the same gender (WT 5 female; Cxcr2-/- 3 
female). 
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Figure 4-28 Absolute numbers of progenitor populations between WT and Cxcr2-/- animals in 
the spleen. 
Spleen was made into a single cell suspension and stained with antibodies to examine the 
progenitor populations and analysed using flow cytometry. Percentages of cells within 
whole spleen was multiplied by the WBC cellularity of the spleen and absolute numbers 
compared. Data is presented as the mean absolute cell numbers for LK, CMP, GMP and 
MEP populations between WT and Cxcr2-/- animals. Statistical analysis was carried out 
using a student’s unpaired t test with Welch’s correction for unequal variance (n.s., n = 5, 
3). Animals were between 6 to 12 weeks and the same gender (WT 5 female; Cxcr2-/- 3 
female). 
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4.3.7.4 CFC assays 
As an in vitro measure of the stem/progenitor activity in a population, cells from aged 
animals were plated in Methocult™ and examined for colony growth as described in 
section 4.3.4.  
4.3.7.5 BM 
No difference in colonies was found in the BM between strains. Colonies were pooled and 
counted as total number of colonies as no difference in different types were found (n.s., n = 
3, 1) (Figure 4-29). No statistical analysis was carried out due to the sample size of 1 in the 
Cxcr2-/- population. This was due to contamination in several samples. Colonies were 
reseeded into a secondary colony formation assay to get an indication of the self renewal 
activity of the stem/progenitor cells. A trend towards an increase was noted in the Cxcr2-/- 
condition, however small sample size does not allow for statistical analysis (n.s., n = 3, 1) 
(Figure 4-29).  
4.3.7.6 Spleen 
There is a trend towards an increase in CFU-GM colonies was found in the spleen. No 
difference in CFU-E or CFU-GEMM colonies were found. The increase in CFU-GM 
colonies causes an overall trend towards increase in the total number of colonies in the 
Cxcr2-/- animals (n.s., n = 5, 3) (Figure 4-30). The lack of significance is likely due to 
variation between samples in this assay and a small sample size in one of the conditions. 
Not enough material from PB in aged animals was available for colony formation assays. It 
is predicted an increase would be found in the Cxcr2-/- condition as reported in the young 
animals. 
Taken collectively, the data shows the same trend as in young animals. The lack of 
difference in CFU in the BM of Cxcr2-/- animals is likely technical due to small numbers of 
CFU obtained. 
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Figure 4-29 WT and Cxcr2-/- CFC analysis in BM derived cells shows no difference between 
strains in primary or secondary plates in aged animals. 
 
Whole BM was made into a cell suspension, WBC counted and 105 cells plated per mL in 
Methocult™ and incubated for 10-14 days. Data are presented as the mean total number of 
colonies in a primary (A) and secondary replate (B) (n = 3, 1). No statistical test was 
carried out due to the sample size of 1 in one of the conditions. Animals were between 6 to 
12 weeks and the same gender (WT 3 female; Cxcr2-/- 1 female). 
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Figure 4-30 WT and Cxcr2-/- CFC analysis in spleen derived cells shows no difference 
between strains in aged animals. 
 
The spleen was made into a cell suspension, WBC counted and 105 cells plated per mL in 
Methocult™ and incubated for 10-14 days. Data are presented as the mean total number of 
colonies in a primary plating assay (n  = 5, 3). Statistical analysis was carried out using a 
student’s unpaired t test with Welch’s correction for unequal variance (n.s.). Animals were 
between 6 to 12 weeks and the same gender (WT 5 female; Cxcr2-/- 3 female). 
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4.3.7.7 Stem cell viability and cell cycle status 
The stem and progenitor populations were examined for viability and cell cycle status in 
aged mice as described in section 4.3.5.  
Data shows a trend towards a decrease in the percentage of Annexin-V+ cells in cell 
populations in the Cxcr2-/- animals in the LSK, CD150+CD48-, CD150-CD48- (P <0.05), 
CD150+CD48+ (P <0.01) and CD150-CD48+ populations (P <0.05). A total of 5 and 3 
animals for WT and Cxcr2-/- conditions were analysed respectivel (Figure 4-31). A trend 
towards an increase in Annexin-V+ cells was found in the Cxcr2-/- animals in the whole 
BM, lineage negative and LK fractions but this is not statistically significant and likely 
represents no differences between populations (n.s., n = 5, 3) (Figure 4-31).  
The data suggests that the stem/progenitor populations are more viable in the Cxcr2-/- 
animals in comparison to the WT littermates. This is in accordance with data obtained on 
HSC populations in young mice. Furthermore, the increase in sample sized in aged animals 
allowed statistical analysis. It can seen from data on the WT cells that there is a basal level 
of apoptosis in BM cells which decreases in the LSK and more primitive HSC populations 
which suggests the staining is correct. Interestingly, in the WT mice in both young and 
aged mice show a high percentage of Annexin-V+ cells in the CD150+CD48+ (MPP) 
population in comparison to the other HSC fractions suggesting this is a more apoptotic 
population. In addition, the CD150+CD48+ population in the Cxcr2-/- mice shows a lower 
percentage of Annexin-V+ cells in comparison to the WT. 
Ki-67 staining was used to examine proliferation, although this stain used alone cannot 
discriminate between cells in G0 versus G1, percentage of positive cells can indicate 
proliferation. Data shows a trend towards decrease in the percentage of Ki-67+ cell 
populations Cxcr2-/- animals in the whole BM, lineage negative and LK populations 
(Figure 4-31) (n.s., n = 4, 2).  
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Figure 4-31 Cxcr2-/- HSC show an increase in viability in aged HSC. 
 
WT or Cxcr2-/- stem and progenitor populations were stained for Annexin-V and analysed 
for viability or fixed, permeabilised and stained for Ki-67. Data are presented as the mean 
percentage of Annexin-V+ cells (n = 5, 3) (A) or Ki-67+ cells (B) (n = 4, 2). Statistical 
analysis was carried out using a student’s unpaired t test with Welch’s correction for 
unequal variance. Sample size is too low for the Cxcr2-/- conditions in the Ki-67 
experiment, therefore no statistical analysis is shown. Representative plots of Annexin-V 
staining in the CD150+CD48+ fraction (C) or Ki-67 staining in the LK fraction (D) are 
displayed. Animals were between 6 to 12 weeks and the same gender (A WT 5 female; 
Cxcr2-/- 3 female; B WT 4 female; Cxcr2-/- 2 female). 
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4.4 Discussion 
The results in this chapter focus on the analysis of a mouse model which lacks Cxcr2. The 
results are found to be in accordance with published literature which shows an increase in 
the myeloid cells in the haemopoietic organs, and an increase in CFU in the spleen and PB 
in the Cxcr2-/- animals (Broxmeyer et al., 1996, Cacalano et al., 1994). However, it has not 
been examined to date whether this signalling pathway may play a role in HSC function.   
Previous literature which first documented the phenotype of the Cxcr2-/- mice showed data 
to suggest that Cxcr2 signalling controlled myeloid regulation (Broxmeyer et al., 1996). 
Therefore it was proposed this signalling pathway is controlling negative regulation of 
myeloid cells. However, if Cxcr2 signalling was solely controlling myeloid regulation, 
there would be no additional phenotype in Cxcr2-/- animals particularly involving the HSC 
population. More specifically, this does not explain the expansion of the LT-HSC in the 
BM and enhanced mobilised with extramedullary haemopoiesis in the spleen and PB. In 
addition, this does not explain why Cxcr2-/- HSC show a defect in BM engraftment.  
The expansion of the myeloid cells is due to a lack of Cxcr2 signalling. However it was 
interesting to observe that the progenitor populations (GMP, CMP and MEP) show a trend 
towards differences in the Cxcr2-/- animals in comparison to the WT controls. If this was to 
be repeated and gain statistical significance, this could suggest that Cxcr2 regulates 
myeloid cell production at a more primitive level than at the mature cells. In addition to an 
increase in myeloid cells, the Cxcr2-/- animals show an increase in the HSC in comparison 
to the controls in the BM. It is possible that Cxcr2 signalling contributes to establishing 
numbers of HSC in addition to mature cells. A previous study has noted that Cxcr2 
signalling is involved in the regulation of oligodendrocyte numbers as Cxcr2-/- animals 
show differences in comparison to the controls (Padovani-Claudio et al., 2006).  
In addition to the expansion of LT-HSC in the BM of Cxcr2-/- animals, the HSC were 
shown to be more viable than the WT counterparts. Although a sample size of 1 in the 
young animals does not allow a valid conclusion to be drawn. However, from the human 
data in the previous chapter it is predicted that a lack of Cxcr2 would decrease cell 
viability. It is possible that mechanisms of signalling differ between species and this should 
be further examined. It could be inferred that Cxcr2 signalling negative controls stem cell 
viability, or alternatively the lack of the receptor is causing a compensatory effect resulting 
in an increase in viability.  As an example, it could be that Cxcr2 reduction results in an 
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increase in Cxcr1 expression. In support of this, Cxcr1 and Cxcr2 have been shown to 
show compensatory effects with each other. Furthermore, mRNA transcripts of CXCR1 
have been shown to be expressed in the BM and spleen. In a previous study, Cxcr2-/- 
animals showed an over expression of Cxcr1 in endothelium in comparison to levels in WT 
mice (Sanchez et al., 2007). Studies inhibiting Cxcr1 have shown a decrease in cell 
viability, it is therefore likely that an increase in expression could support viability 
however this has not been tested in this study (Ginestier et al., 2010).  
The true functional assay of a stem cell is the ability to reconstitute a host with a lethally 
ablated BM. In this experiment, it was found that there was a trend towards a reduction in 
the ability of the HSC derived from the Cxcr2-/- donor to engraft to the same level as the 
WT donor HSC. This suggests that Cxcr2 signalling may have an effect on stem cell 
function in a cell autonomous manner. However, inter experimental variation resulted in 
the difference between conditions to be not significant. Therefore, it cannot be concluded 
that Cxcr2 null HSC show a defect in functional activity with the results in this thesis. 
However, the data indicates there may be difference between samples. If this is the case, it 
is unclear from this experiment whether the HSC derived from the Cxcr2-/- donor show a 
trend towards a decrease in engraftment due to a defect in homing or due to a problem 
within the BM niche. Indeed, CD45.2+ cells derived from the Cxcr2-/- donors were found to 
produce multilineage reconstitution and a percentage of CD45.2+ cells from the Cxcr2-/- 
recipients were found in all mature cells, stem and progenitor cells. Furthermore, the 
percentage engraftment from donor Cxcr2-/- HSC increased over time which suggests the 
HSC were capable of self renewal. It is known that Cxcr2 signalling plays a role in 
neutrophil mobilisation and it is possible that this receptor may play a role in HSC 
mobilisation (Eash et al., 2010). Indeed, a variety of studies have shown that 
administration of Cxcr2 ligands results in the immediate mobilisation of HSC from the BM 
into the periphery which is Cxcr2 dependent (Pelus and Fukuda, 2006). Furthermore, 
previous research reported that Cxcr2 signalling in combination with Cxcr4 (a key HSC 
mobilisation gene) regulated neutrophil mobilisation (Eash et al., 2010). Whether these 
genes may play a role together in HSC mobilisation has not been assessed. To support this 
idea, the evidence that CFU are found in extramedullary sites of haemopoiesis in Cxcr2-/- 
animals does indicate that there may be a defect in HSC mobilisation. The results show 
that Cxcr2-/- HSC do not locate to the PB or spleen instead of the BM as a reduction in 
engraftment was found in all haemopoietic sites. Therefore if the HSC cannot home to the 
BM it is likely that they undergo apoptosis.  
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Data from this chapter showed that mouse HSC populations, including the most primitive 
LSKCD150+CD48- fraction express the receptor, Cxcr2. However due to limited cell 
numbers and time constraints in this study, although mRNA data is available on the 
receptor. To strengthen this result, protein expression should be assayed. To date, very few 
chemokine receptors have been reported on HSC. The majority of research has been on 
CXCR4 which responds to CXCL12 resulting in HSC migration to and from the BM. Gene 
expression analysis for CXCR2 binding ligands on HSC showed no positive expression for 
the ligands tested. This could be technical, or that they are expressed on a less primitive 
stem cell population. It cannot be concluded from the experiments conducted in this study 
what is the mechanism of action of CXCR2 signalling. This presents a future avenue of 
research. 
226 
5 Results III: Human and mouse HSC express 
CXCL4 which regulates HSC self renewal 
5.1 Introduction 
The results shown in chapters 4 and 5 provide evidence to support that CXCR2 signalling 
plays a role in stem cell properties including survival and proliferation in both human and 
mouse systems. However, a discrepancy between the human and mouse experiments 
exists. In chapter 4, it was shown that CXCR2 binding ligands (Cxcl1, Cxcl2 and Cxcl5/6) 
mRNA transcripts were found in human HSC. However, in chapter 5 it was shown that the 
mouse homologs of these specific genes were not expressed by the mouse HSC 
populations tested. Explanations for this result were previously discussed. In addition to 
Cxcr2 binding ligands, another member within the CXC family of chemokines (Cxcl4) was 
examined for expression on mouse HSC populations. We investigated Cxcl4 expression on 
mouse HSC for several reasons; 1. Cxcl4 is within the CXC family of chemokine ligands 
and is structurally similar to Cxcr2 binding ligands; 2. Examination of previously 
unpublished microarray data from our lab identified Cxcl4 as being highly expressed in 
mouse HSC populations at levels comparable to stem cell gene Cxcr4 (data not shown, 
unpublished data); 3. Literature searching identified that Cxcl4 supports human HSC 
survival and adhesion (reviewed in the introduction section). This chemokine therefore 
seemed to be an ideal candidate to further pursuit. The experiments in this chapter were 
designed to elucidate the biological role of Cxcl4 in mouse HSC behaviour. Furthermore, 
we wanted to examine CXCL4 expression in human HSC to examine whether this is a 
novel stem cell factor highly expressed in both mouse and human HSC populations.  
Cxcl4 is a chemokine belonging to the CXC group, which is predominantly expressed by 
activated platelets and promotes blood coagulation (reviewed in the introduction section). 
There is some literature available on the role of Cxcl4 signalling in human stem/progenitor 
cells (reviewed in introduction section) with evidence that Cxcl4 inhibits haemopoeisis and 
promotes stem/progenitor survival, however this is not well understood. Furthermore, as 
far as we have understood, there are no data on mouse Cxcl4 in terms of HSC behaviour. 
In this chapter, expression of the chemokine was examined in both mouse and human HSC 
systems. In addition, the functional role was investigated in the mouse system using 
transgenic Cxcl4-Cre driven reporter mice, Cxcl4 null mice (Cxcl4-/-) and reduction of 
Cxcl4 expression in vitro using shRNA mediated lentiviral transduction. 
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5.2 Aims and Objectives 
The specific aims of this chapter were: 
I  To examine Cxcl4 expression on mouse HSC populations 
It was hypothesised that this chemokine may play a role in HSC properties therefore 
mRNA expression was analysed in mouse HSC populations using Q-PCR. 
II To examine whether a Cxcl4-Cre driven reporter mouse model activity 
correlates with gene expression in HSC populations 
A reporter mouse model in which Cxcl4 drives RFPexpression is available. We wanted to 
use this mouse model to validate the gene expression data. Furthermore, it was aimed to 
use this mouse model to elucidate the biological function of Cxcl4. 
III To investigate how a lack of Cxcl4 alters stem/progenitor cell behaviour 
We wanted to use different approaches to modulate Cxcl4 expression in an aim to 
understand the role of this chemokine in HSC behaviour. We used animals lacking Cxcl4 
(Cxcl4-/-) and examined whether these animals displayed differences in stem/progenitor 
cell frequency, properties and function. As an alternative approach we aimed to reduce 
Cxcl4 expression in vitro using shRNA and to examine the resulting phenotype. 
V To examine the expression of CXCL4 on human HSC 
The microarray study used for this thesis was not conclusive for CXCL4 expression on 
human HSC, therefore this objective was to assess whether this gene is also expressed in 
human HSC and may play a role in human HSC properties. 
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5.3 Results 
5.3.1 CXCL4 is expressed on mouse HSC  
Data in chapter 3 showed that Cxcr2 is expressed on mouse HSC populations, however 
Cxcr2 binding ligands were not detected by Q-PCR analysis. Other chemokines in the 
same functional group were examined for expression, in particular Cxcl4 (also known as 
platelet factor 4). This chemokine is not a known ligand for Cxcr2, but is part of the CXC 
functional group and is structurally related to other CXC chemokine ligands. Furthermore 
there is evidence that Cxcl4 can bind Cxcl8 in vitro (Dudek et al., 2003). In addition, Cxcl4 
was reported to be highly expressed in mouse HSC from a search in unpublished 
microarrays from our group (data not shown). The experiment in this section was carried 
out with Dr Amelie Guitart. 
Q-PCR using the Fluidigm™ platform was used to examine Cxcl4 expression in mouse 
HSC populations. Gene expression was examined in the LSK fraction sorted using CD150 
and CD48 using the terminology described in chapter 4. Data showed detectable 
expression of Cxcl4 in the LT-HSC (CD150+CD48-), ST-HSC (CD150-CD48-) and MPP 
(CD150+CD48+ and CD150-CD48+) populations. Examination of differences between 
populations revealed a trend towards decrease in the CD150-CD48- fraction (n.s.), an 
increase in the CD150+CD48+ population (P <0.01) and a decrease in the CD150-CD48+ 
fraction (P <0.01) with the fold change calculated using the CD150+CD48- fraction as the 
calibrator and set to the value of 1 (n = 3) (Figure 5-1). Gene expression of Pf4 is 
compared to a gene highly expressed in HSC populations (P21) to demonstrate expression 
at relatively high levels (Cheng et al., 2000).  
In summary, results show that Cxcl4 is highly expressed on mouse HSC populations with 
the highest expression found in the MPP population. The observation that Cxcl4 is highly 
expressed in mouse HSC populations including the LT-HSC population merited further 
investigation into the role of this chemokine in stem cell activity. As Cxcl4 is well known 
to be expressed in cell types of megakaryocyte/platelet lineage, it is possible that Cxcl4 is 
actively transcribed in the MPP population and marks cells destined for a particular lineage 
at an early stage in lineage differentiation. However, this is speculation as was not 
investigated further.  
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Figure 5-1 Cxcl4 is expressed on mouse HSC at the mRNA level. 
Normal BM was freshly isolated and stained for antibodies against LSK, CD150 and 
CD48. 500 cells were sorted, RT, preamplified and Q-PCR was carried out to assess Cxcl4 
mRNA expression. Results are shown relative to housekeeping control β2M fold change 
using the CD150+CD48- population as a calibrator set to 1 (A) and displayed as relative 
expression levels (2-DeltaCT) (B). Results displays the mean expression level from three 
independent experiments performed in triplicate (A). Panel B shows relative expression 
levels (2-DeltaCT) with a stem cell gene to compare expression levels. Each dot represents 
average expression from three (Cxcl4) and two (p21) independent experiments (B). 
Animals were 6-12 weeks of age and males. Statistical test carried out was a repeated 
measures one-way ANOVA using Dunnett’s multiple comparison test to compare 
differences between the LT-HSC fraction and each population for panel A only as P21 
expression was examined in two samples only (n = 3, ** P <0.01).   
  
A B 
230 
5.3.2 Lineage tracing of Cxcl4 marks a proportion of HSC with 
enhanced colony formation activity 
The gene expression data identifies that Cxcl4 is highly expressed in HSC populations 
including the LT-HSC fraction. Cxcl4-Cre (commonly referred to as Pf4-Cre) is a widely 
used transgenic model which has been studied extensively previously (Tiedt et al., 2007). 
In this study, we used this reporter model to demonstrate that Cxcl4-Cre recombines in a 
proportion of BM derived HSC. This transgenic mouse model expresses Cre-recombinase 
in cells in which endogenous Cxcl4 is expressed. The cross of Cxcl4-Cre with a reporter 
strain allows cells in which Cre-recombinase activity is active, to be identified and 
isolated. Briefly, Cxcl4-Cre mice were crossed with a tandem repeat RFP under the 
Rosa26 promoter which should show RFP expression in cells expressing Cxcl4 and their 
progeny. The Rosa26-RFP+;Cxcl4-Cre+ transgenic mouse model was used with Rosa26-
RFP+;Cxcl4-Cre- and Rosa26-RFP-;Cxcl4-Cre- models used as controls which showed no 
difference in phenotype and were used interchangeably. The experiments in this section 
were carried out in collaboration with Dr Simon Calaminus.  
5.3.2.1 Cxcl4-Cre is expressed in HSC and subsequent 
progeny 
The transgenic model has been used previously to show RFP expression in cells positive 
for Cxcl4 expression including megakaryocytes and platelets (Tiedt et al., 2007). However, 
an in depth analysis of the reporter model in HSC populations has not been examined to 
date. Results from section 5.3.1 demonstrate that endogenous Cxcl4 is expressed in mouse 
HSC. We wanted to use the reporter mouse model to 1. Provide validation endogenous 
Cxcl4 is expressed in HSC and 2. Elucidate the biological function of Cxcl4. Mice were 
analysed for expression of Cxcl4 using RFP as a marker with flow cytometry analysis in 
combination with antibodies to identify HSC populations. 
Firstly, it was noted that positive RFP expression was found within the haemopoietic 
organs tested (BM, spleen and thymi) with the highest expression in the BM followed by 
the spleen and thymi (n = 3, Figure 5-2). The controls were negative for RFP expression as 
expected (data not shown). Representative plots can be visualised in (Figure 5-3). 
Examination of the stem cell compartment showed that RFP+ cells were found in HSC 
populations. Results showed a proportion of RFP+ cells in the BM, LSK and HSC 
compartments including the most primitive CD150+CD48- fraction (n = 9) (Figure 5-2).  
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As a positive control, BM derived megakaryocytes and PB derived platelets were isolated 
and examined for RFP expression within CD41+ cells. Megakaryocyte and platelets are 
CD41+ and are known to express Cxcl4 therefore should show positive expression for RFP. 
Results showed RFP+ cells in platelets (94.3%) and the majority of megakaryocytes 
(50.2%) (n = 3) (Figure 5-4). This result is as expected and has been shown previously 
suggesting that the transgenic model functions correctly. Although all of the platelets are 
positive for RFP expression, only 50% of megakaryocytes were found to be positive for 
RFP. However, previous results have shown that immature megakaryocytes may have 
incomplete recombination and therefore RFP expression which reflects the cell type and 
not the model (Tiedt et al., 2007). As a technical control, RFP+ and RFP- cells were sorted 
from Rosa26-RFP+;Cxcl4-Cre+ mice and examined for the presence of genomic Cre. 
Results showed the presence of Cre in both RFP+ and RFP- fractions using standard PCR 
(Figure 5-2).  
The Cxcl4-Cre model has been used previously for megakaryocyte and platelet biology but 
Cxcl4 expression in the HSC population has not been identified. This is likely due to 
differences in the techniques with previous research using histology which is not as 
sensitive as flow cytometry for RFP expression. The combination of detection of 
endogenous Cxcl4 mRNA in HSC (Figure 5-1) and the positive RFP expression in HSC 
(Figure 5-2) suggests that Cxcl4-Cre reflects transcriptional activity of Cxcl4 promoter in 
these populations.  
As described in section 2.3.7.2.1, the BAC used to create the transgenic mice in this study 
also contained other genes, one of which is known to play a role in stem cell maintenance. 
Therefore, the results should be concluded with caution. 
Gender was not noted for the animals used in this section. Without knowing whether the 
gender was similar or different between groups does not allow a valid conclusion to be 
drawn. Experiments should be repeated with the gender variable controlled. 
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Figure 5-2 Mature haemopoietic organs and HSC populations express RFP which is under 
the control of the Cxcl4 promoter. 
BM, spleen and thymi were isolated, stained for HSC populations and examined for RFP 
expression using flow cytometry. Data are presented as the mean percentage of RFP+ cells 
in mature haemopoietic organs BM, spleen and thymi (A) in BM and HSC populations 
LSK and LSK,CD150+CD48- from three independent experiments (n = 3) (B). Image 
represents the presence of Cre in DNA isolated from LSK sorted cells which are RFP+ (+) 
and RFP- (-).  Animals were 6-12 weeks of age. Animals were given by Dr Simon 
Calaminus (Beatson Institute for Cancer Research) and gender was not noted.  
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Figure 5-3  Representative plots of RFP expression in organs in Pf4-Cre+-Rosa26-RFP+ mice. 
BM, spleen and thymi were isolated, stained for HSC populations and examined for RFP 
expression using flow cytometry. Data shows representative image of plot for RFP 
expression of cells in mature haemopoietic organs BM, spleen and thymi in BM and HSC 
populations LSK and LSK,CD150+CD48- from three independent experiments (B). Panel 
A demonstrates staining profile for all controls used in this study (A). Animals were given 
by Dr Simon Calaminus (Beatson Institute for Cancer Research) and gender was not noted. 
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Figure 5-4 Positive control cells megakaryocytes and platelets express RFP which is under 
the control of the Cxcl4 promoter. 
BM derived megakaryocytes and PB derived platelets were isolated, stained for CD41 and 
analysed for RFP expression using flow cytometry. Data are presented as the mean 
percentage of RFP+ cells within the CD41+ fraction from three independent experiments (n 
= 3) (B). Representative flow cytometry plots show CD41 and RFP expression in cell 
populations between strains (A). Animals were given by Dr Simon Calaminus (Beatson 
Institute for Cancer Research) and gender was not noted. 
  
A 
B 
235 
5.3.2.2 Lineage tracing of Cxcl4 marks a stem/progenitor 
population with increased colony formation activity 
Interestingly, experiments in section 5.3.2.1 showed that only a proportion of HSC 
expressed RFP. Technical controls were carried out to suggest that this was a true 
biological result (Figure 5-2). It can be inferred from the data that Cxcl4 is only 
transcriptionally active in a subset of cells. Therefore, the question arose, why are only a 
proportion of cells positive for Cxcl4 expression in the HSC? RFP+ and RFP- negative cells 
were isolated from the BM from the Cxcl4-Cre and seeded into a CFC assay to get an 
indication of how these populations differ in terms of differentiation and proliferation 
capacity.  
Results showed an increase in the number of colonies obtained in RFP+ sorted cells in 
comparison to cells lacking RFP expression in a primary CFC assay (P <0.05, n = 3) 
(Figure 5-5). To get an indication of self renewal activity, cells were replated into a 
secondary colony formation assay and results showed a trend towards a decrease in colony 
numbers between RFP+ versus RFP- cells, which was not statistically significant and likely 
represents sample variation (n.s., n = 3) (Figure 5-5).  
The results indicate that Cxcl4+ cells have enhanced colony formation capability in 
comparison to negative cells. This infers that Cxcl4+ cells exhibit an increase in viability, 
differentiation or proliferation in comparison to the negative counterparts. Previous 
literature has shown that human haemopoietic cells respond to exogenous Cxcl4 which 
results in an enhancement in cell viability, therefore this result would be in accordance 
with literature available (Han et al., 1997). It might be expected that an increase in primary 
colonies would result in an increase in colonies in a secondary plating, however this was 
not found. One explanation is that Cxcl4+ cells are more proliferative and exhaust therefore 
produce less colonies in a replating assay. However, this cannot be concluded. 
Furthermore, the transgenic model used does not mark active transcription. Therefore, it is 
possible that Cxcl4 is modulated in response to culture conditions which could skew the 
results in a secondary plating assay. It is also possible that RFP expression is not solely 
dependent on Cxcl4 transcriptional activity due to the random integration of the Cxcl4-Cre 
transgene. 
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Figure 5-5 Cxcl4+ BM cells show enhanced colony capability in a primary plating assay over 
Cxcl4- counterparts. 
Representative flow cytometry plots display the RFP status of cells prior to plating into a 
CFC assay (A). Data are presented as the mean total colony number from cells sorted for 
RFP expression. Results show primary (B) and secondary (B) plating assays (n = 3). A 
ratio paired t test was carried out to assess statistical significance (** P <0.01). Animals 
were given by Dr Simon Calaminus (Beatson Institute for Cancer Research) and gender 
was not noted. 
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5.3.3 Cxcl4 reduction in vitro reduces colony formation activity in 
mouse stem/progenitor cells 
The results from section 5.3.2.2 implicate that Cxcl4 may mark a stem/progenitor 
population with enhanced colony formation activity. To validate this, Cxcl4 expression 
was reduced using a vector with a shRNA hairpin targeting the mouse Cxcl4 coding 
sequence. Positively transduced cells were plated in a colony formation assay and colony 
growth was compared with a non-targeting shRNA control.  
5.3.3.1 Optimisation of construct for Cxcl4 reduction in 
vitro 
As described in chapter 3, different shRNA sequences against a target gene can result in 
varying levels of gene modification. A set of 5 pLKO.1 vectors each with a different 
shRNA sequence were tested for their knock down efficiency in Cxcl4 expressing mouse 
cell lines. Cell lines used were c-Kit positive mouse BM cells which were immortalised for 
long term culture using integration of oncogenes (Gil Smith, data not shown). These cells 
were chosen for optimisation experiments for two reasons: 1. These cells were shown to be 
positive for Cxcl4 expression and 2. Their immortalisation using oncogenes transformed 
them into cell lines allowing an abundance of cells to carry out the required experiments. 
Cells were transduced using lentivirus particles and subsequently cultured in puro for 
several days before RNA was extracted and Q-PCR was used to test for Cxcl4 expression. 
Each vector resulted in the following fold change decrease in comparison to the control 
which was set to the value of 1; sh1 (0.70, n.s.), sh2 (0.60, P <0.01), sh3 (0.80, n.s.), sh4 
(0.33, P <0.01) and sh5 (0.14, P <0.001) (n = 3) (Figure 5-6). An interesting observation 
was that all vectors resulted in some amount of Cxcl4 reduction and fewer cells were 
obtained in comparison to the control cells (data not shown). The construct which resulted 
in the best reduction in Cxcl4 expression (sh5) was sub cloned into a pLKO.1 vector with a 
GFP reporter tag. The Cxcl4-pLKO.1-GFP vector will be described as sh1 for simplicity. 
This vector was tested in cell lines and confirmed to show a reduction in gene expression 
of Cxcl4 (n = 3, P <0.001) in comparison to a control which was set to the value of 1 
(Figure 5-6). Ideally, protein expression would be examined for the effect of the shRNA on 
Cxcl4 protein reduction. However, due to difficulties with antibodies against mouse Cxcl4 
and time constraints, this experiment was not carried out. 
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5.3.3.2 Reduction of Cxcl4 in c-Kit+ cells reduces colony 
formation capability 
A stem/progenitor population (c-Kit enriched mouse BM) was transduced with the shRNA 
vector (sh1) described in section 5.3.3.1. C-Kit enriched mouse BM cells were deemed 
appropriate for this study as a more primitive fraction would have provided fewer cells for 
the assay. Furthermore, primitive HSC are known to be difficult to transduce due to their 
non proliferative status. After transduction, the GFP+ cells were sorted and subsequently 
cultured in a colony formation assay. Results showed a significant decrease in colonies in a 
primary assay with Cxcl4 reduction in comparison to the number of colonies obtained in 
the control arm (P <0.05, n = 3) (Figure 5-7). No differences in the different colony types 
between conditions were observed therefore data was acquired as the total colony number 
obtained. This data suggests that Cxcl4 reduction reduces colony formation therefore Cxcl4 
plays a role in stem/progenitor survival and proliferation. To examine self renewal 
potential, cells from a primary plating assay were plated into a secondary assay. In a 
secondary replating assay, Cxcl4 reduction showed a significant reduction in colony 
numbers in comparison to the control (P <0.01, n = 3) (Figure 5-7). To ensure that the 
shRNA vector reduced Cxcl4 expression in primary mouse cells, cells were harvested from 
the primary plating assay and examined for gene expression levels of Cxcl4 using Q-PCR. 
Results showed a mean 0.50 reduction in Cxcl4 gene expression levels in comparison to 
the control cells which was set to the value of 1. The decrease in gene expression was not 
statistically significant due to variation that was present in technical triplicates derived 
from 3 independent samples (n.s., n = 3) (Figure 5-7). This result indicates that Cxcl4 
controls stem/progenitor cell survival, proliferation and self renewal. A more in depth 
analysis of apoptosis and cell cycle status in response to Cxcl4 reduction is needed to 
confirm these results, however was not completed due to time constraints. 
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Figure 5-6 Reduction of Cxcl4 using shRNA results in a reduction in Cxcl4 expression in 
mouse cell lines. 
Cell lines were transduced using lentivirus for Cxcl4 shRNA or a control hairpin. 
Subsequently RNA was extracted, RT and Q-PCR carried out for Cxcl4 expression. Data 
are presented as the mean fold change in Cxcl4 expression in transduced cell lines with 5 
vectors in a pLKO.1 puro background (A) and 1 vector in a pLKO.1-GFP background (C) 
compared to the control which is set to the value of 1. Data was calculated using 
housekeeping gene Gapdh and using the DeltaDeltaCT method. Relative expression is 
displayed in panels B and D with each individual dot as an average of technical triplicates 
in three independent experiments. A one-way repeated measures ANOVA with Dunnett’s 
multiple comparisons test was used to assess statistical significance between each shRNA 
vector and the Scr control (A) and a ratio paired t test was used for panel C (* P <0.05; ** 
P <0.01; *** P <0.001, n = 3). Animals were 6-12 weeks of age and males were used.  
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Figure 5-7 Cxcl4 reduction in c-Kit+ mouse BM cells reduces colony formation in primary 
and secondary plating assays.  
C-Kit+ BM cells were transduced with shRNA against Cxcl4 or a control hairpin. GFP+ 
cells were sorted into Methocult™ and cultured for 10-14 days and colonies were counted. 
Subsequently, cells were put into a replating assay, cultured and colonies were counted. 
Data are presented as the mean fold change in Cxcl4 expression in the Cxcl4 shRNA 
condition in comparison to the control, which is set to the value of 1 (A). Standard 
deviation represents 3 independent experiments, each with 3 technical replicates. Data 
were calculated using the DeltaDeltaCT method and housekeeping gene Gapdh. Data is 
also presented as relative expression with each dot representing an average of three 
technical replicates from three independent experiments (B). Data are presented as mean 
colony numbers in shRNA condition and control in primary (C) and secondary (D) colony 
formation assays. Statistical analysis carried out was a ratio paired two-tailed t test (A, B & 
C) and a paired two-tailed t test (B) (* P <0.05; ** P <0.01, n = 3). Animals were 6-12 
weeks of age and males were used.  
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5.3.4 Analysis of haemopoiesis in Cxcl4-/- animals 
The results in sections 5.3.2.2 and 5.3.3.2 provide evidence that Cxcl4 controls colony 
formation and self renewal in mouse stem/progenitor populations. To compliment these 
experiments, analysis of animals lacking the Cxcl4 gene were analysed (Cxcl4-/-). Cxcl4-/- 
mice have been generated previously and shown to exhibit an increase in platelet counts 
and defects in blood coagulation in comparison to WT controls (Zhang et al., 2001) 
(Lambert et al., 2007). However, to date the HSC compartment and functional activity of 
these populations has not been assessed. In this study, the Cxcl4-/- mouse model was used 
to examine the frequency of stem and progenitor populations and to examine their 
functional activity in in vitro and in vivo assays. As the previous results show Cxcl4 
supports the survival and self renewal of HSC, experiments were designed to test whether 
similar results could be obtained in cells lacking Cxcl4. 
Cxcl4-/- animals and age/sex matched WT controls were analysed (C57/BL6 background). 
Animals were genotyped prior to use using optimised PCR conditions for primers to detect 
endogenous Cxcl4 or Neomycin (Figure 5-8). The haemopoietic system was assessed by 
measuring the frequency of mature cells/HSC/progenitor cells in the haemopoietic organs 
(BM, spleen, PB and thymus). Functional activity of the HSC populations was 
experimentally tested using in vitro and in vivo assays including colony formation assays 
with replates and BM reconstitution assays. These methods were described previously in 
chapter 4. 
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Figure 5-8 Genotyping analysis of WT and Cxcl4-/-animals. 
Genomic DNA was extracted from tail tips/ear notch samples from animals and PCR was 
carried out using two sets of primers against mouse endogenous Cxcl4 and Neomycin. 
Image shows a representative image of PCR products in WT and Cxcl4-/- DNA. DNA 
derived from WT cells shows the presence of endogenous Cxcl4 (800bp), while DNA 
derived from cells lacking Cxcl4 show the presence of a band corresponding to Neomycin 
expression (620bp). Genotyping was performed to identify whether animals were WT, 
Cxcl4-/- or Cxcl4+/-. Positive (known WT and Cxcl4-/- DNA) and negative controls (no 
DNA template) were run to ensure the PCR reaction worked correctly and no 
contamination of reagents was present. Animals were only used in this study if genotyping 
gave a clear result of a single band for either Cxcl4 or Neomycin to ensure that 
heterozygotes were not included in any experiments. 
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5.3.4.1 Mature cell types in haemopoietic organs 
The frequency of mature cell types was examined in the BM, spleen, PB and thymi as 
described previously. 
5.3.4.1.1 BM 
 
BM analysis showed no difference in the cellularity in the Cxcl4-/- animals in comparison 
to the controls (n.s., n = 6, 7) (Figure 5-9). There were no differences in the numbers of 
erythroid cells, granulocytes or B cells in the BM between the strains (n.s., n = 6, 7) 
(Figure 5-9).  
5.3.4.1.2 Spleen 
 
Spleen analysis showed no difference in cellularity between the strains (n.s., n = 6, 7) 
(Figure 5-10). No differences in erythroid, granulocytes, B or T cells was found between 
strains (n.s., n = 6, 7) (Figure 5-10). 
5.3.4.1.3 PB 
 
PB analysis showed no difference in the cellularity in the Cxcl4-/- animals in comparison to 
the WT animals (n.s., n = 6, 8) (Figure 5-11). A trend towards an increase was noted in 
platelet counts in the Cxcl4-/- animals (n.s., n = 6, 8). Finally, no differences were noted in 
the numbers of mature cells in the PB between strains (n.s., n = 6, 7) (Figure 5-11). 
 
5.3.4.1.4 Thymi 
 
Analysis of the thymi showed no difference in the cellularity between strains (n.s., n = 6, 
7) with no difference in T cells between strains (n.s., n = 6, 7) (Figure 5-12).  
In summary, results showed no differences in the cellularity or numbers of mature cell 
types in the haemopoietic organs between Cxcl4-/- animals and WT controls. This infers 
that Cxcl4 is not involved in the regulation of mature haemopoietic cells. An increase in 
platelet count found in the Cxcl4-/- animals is in accordance with previous literature and the 
lack of significance likely reflects small sample size with previous research examining a 
much larger sample size  
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Figure 5-9 Cellularity and absolute numbers of mature cells in the BM between WT and 
Cxcl4-/-animals. 
BM was isolated, assessed for cellularity, stained against mature markers and examined 
using flow cytometry. Data are presented as the mean cellularity (A) and absolute numbers 
of erythroid cells (TER119+), granulocytes (GR1+CD11B+) and B (CD19+B220+) cells (B) 
in the BM between WT and Cxcl4-/- animals. A Mann Whitney U test showed no statistical 
significance between conditions (n.s., n = 6, 7). Animals were 6-12 weeks of age and 
gender was the same (WT 6 females; Cxcl4-/- 7 females). 
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Figure 5-10 Cellularity and absolute numbers of mature cells in the spleen between WT and 
Cxcl4-/- animals.  
Spleen cells were isolated, assessed for cellularity and stained with antibodies against 
mature cell types and analysed using flow cytometry. Data are presented as the mean 
cellularity (A) and absolute numbers of erythroid cells (TER119+), granulocytes 
(GR1+CD11B+), B (CD19+B220+) (B) and T cell subsets (CD4+CD8+, CD4-CD8-, 
CD4+CD8- and CD4-CD8+) (C) in the spleen between WT and Cxcl4-/- animals. No 
statistical differences were reported using a two-tailed unpaired t test (A) and two-tailed 
unpaired t test with Welch’s correction for unequal variance (B & C) (n.s., n = 6, 7). 
Animals were 6-12 weeks of age and gender was the same (WT 6 females; Cxcl4-/- 7 
females). 
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Figure 5-11 Cellularity and absolute numbers of mature cells in the PB between WT and 
Cxcl4-/-animals.  
PB was harvested, assessed for cellularity, RBC were lysed and stained with antibodies to 
identify mature cell populations. extracted with an anticoagulant and assessed for 
cellularity neat and platelet count. Data are presented as the mean cellularity (A), absolute 
numbers of erythroid cells (TER119+), granulocytes (GR1+CD11B+), B (CD19+B220+) 
(B), T cell subsets (CD4+CD8+, CD4-CD8-, CD4+CD8- and CD4-CD8+) (C) and platelet 
counts (D) in the PB between WT and Cxcl4-/- animals. No statistical differences were 
reported using a student’s unpaired t test with Welch’s correction for unequal variance 
(n.s., n = 6, 7 (A-C), n = 6, 8 (D)). Animals were 6-12 weeks of age and gender was the 
same (WT 6 females; Cxcl4-/- 7 females).  
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Figure 5-12 Cellularity and absolute numbers of mature cells in the thymi between WT and 
Cxcl4-/-animals. 
Thymi were isolated, assessed for cellularity and stained with antibodies against mature 
cell types and analysed using flow cytometry. Data are presented as the mean cellularity 
(A) and absolute numbers of T cell subsets (CD4+CD8+, CD4-CD8-, CD4+CD8- and CD4-
CD8+) (B) in the thymi between WT and Cxcl4-/- animals. No statistical differences were 
reported using a student’s unpaired t test with Welch’s correction for unequal variance 
(n.s., n = 6, 7). Animals were 6-12 weeks of age and gender was the same (WT 6 females; 
Cxcl4-/- 7 females).  
 
  
A B 
248 
 
5.3.4.2 The numbers of stem and progenitor populations in 
mice lacking Cxcl4 
Assessment of the frequency of stem and progenitor populations in Cxcl4-/- mice has not 
previously been carried out. The frequency of stem and progenitor populations was 
examined using antibody staining against a variety of cell surface markers and analysed 
using flow cytometry as mentioned previously.  
5.3.4.2.1 BM 
5.3.4.2.1.1 HSC populations 
 
No difference was found in the number of lineage negative cells in the Cxcl4-/-animals in 
comparison to controls (n.s., n = 6, 7) (Figure 5-13).Within the lineage negative fraction, 
the LSK and further enriched stem cell populations were examined. There was no 
difference in the LSK cells between strains (n.s., n = 6, 7) (Figure 5-13). There were no 
differences noted between HSC populations between strains (n.s., n = 6, 7) (Figure 5-13).  
5.3.4.2.1.2 Progenitor populations 
 
In terms of progenitors, the LK fraction contains progenitor cells and showed no 
differences between strains (n.s., n = 6, 7) (Figure 5-14). There were no statistically 
significant differences between GMP, CMP and MEP populations in terms of absolute 
numbers (n.s., n = 6, 7) (Figure 5-14).  
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5.3.4.2.2 Spleen 
 
5.3.4.2.2.1 HSC populations 
 
A trend towards an increase in the number of lineage negative cells in the Cxcl4-/-animals 
was reported which was not statistically significant (n.s., n = 6) (Figure 5-15). There was a 
trend towards increase in the number of LSK cells in the Cxcl4-/-condition which was not 
statistically significant (n.s., n = 6) (Figure 5-15). All HSC fractions showed no differences 
in the absolute number of HSC populations between conditions (n.s., n = 6) (Figure 5-15).  
 
5.3.4.2.2.2 Progenitor populations 
 
In terms of progenitor cells in the spleen, the LK fraction showed a trend towards an 
increase in the Cxcl4-/-animals which was not statistically significant (n.s., n = 6). There 
were no differences in the progenitor populations including the GMP, CMP and MEP 
populations (n.s., n = 3) (Figure 5-16).  
In summary, the data collectively shows that a lack of Cxcl4 in animals does not alter stem 
or progenitor frequency in either the BM or spleen. As only female animals were 
examined, future experiments should compare stem cell function in male animals in case 
the effects are gender specific. Frequency does not always confer to stem cell function, 
therefore experiments were designed to test functionality of stem/progenitor cells in Cxcl4-
/-
 animals. 
  
250 
 
Figure 5-13 The numbers of HSC in the BM of WT and Cxcl4-/-animals. 
BM was isolated and stained for antibodies against HSC markers and examined using flow 
cytometry. Data are presented as the mean absolute numbers of lineage negative (A), LSK 
(B) and HSC populations (C) in the BM between WT and Cxcl4-/- animals. No statistical 
differences were reported using a student’s unpaired t test with Welch’s correction for 
unequal variance (n.s., n = 6, 7). Animals were 6-12 weeks of age and gender was the same 
(WT 6 females; Cxcl4-/- 7 females). 
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Figure 5-14 The numbers of progenitor cells in the BM of WT and Cxcl4-/-animals. 
BM was isolated and stained against progenitor markers and examined using flow 
cytometry. Data are presented as the mean absolute numbers of LK (A) and progenitor 
populations (B) in the BM between WT and Cxcl4-/- animals. No statistical differences 
were reported using a student’s unpaired t test with Welch’s correction for unequal 
variance (n.s., n = 6, 7). Animals were 6-12 weeks of age and gender was the same (WT 6 
females; Cxcl4-/- 7 females). 
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Figure 5-15 The numbers of HSC in the spleen of WT and Cxcl4-/-animals. 
The spleen was isolated and stained with antibodies against HSC markers and examined 
using flow cytometry. Data are presented as the mean absolute numbers of lineage negative 
(A), LSK (B) and HSC populations (C) in the spleen between WT and Cxcl4-/-animals. No 
statistical differences were reported using a student’s unpaired t test assuming equal 
variance between conditions (n.s., n = 6, 7). Animals were 6-12 weeks of age and gender 
was the same (WT 6 females; Cxcl4-/- 7 females). 
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Figure 5-16 The numbers of progenitors in the spleen of WT and Cxcl4-/-animals. 
The spleen was isolated and stained with antibodies against HSC markers and examined 
using flow cytometry. Data are presented as the mean absolute numbers of LK (A) and 
progenitor populations (B) in the spleen between WT and Cxcl4-/- animals. No statistical 
differences were reported using a student’s unpaired t test assuming equal variance (n.s., n 
= 6, 7 (A), n = 3 (B)). Animals were 6-12 weeks of age and gender was the same (WT 6 
females; Cxcl4-/- 7 females). 
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5.3.4.3 WT and Cxcl4-/- stem/progenitors show no difference 
in viability or cell cycle status 
Although results in section 5.3.4.2 show animals lacking Cxcl4 do not show different 
frequencies of stem or progenitor cells, we wanted to examine stem cell functionality. We 
examined viability and cell cycle status in HSC as described in chapter 4. 
BM cells harvested from WT and Cxcl4-/- animals were stained for LSK and Annexin-V. 
Results showed no difference in Annexin-V+ cells between different populations between 
strains (n.s., n = 3) (Figure 5-17). 
Ki-67 staining showed no differences in Ki-67+ cells between strains (n.s., n = 3) (Figure 
5-17). However, a trend towards an increase is noted in all populations.  
The staining pattern obtained suggests that the assay was technically sound with the 
highest percentage of viable and quiescent cells in the HSC compartments. Therefore, it 
can be inferred from the data that there are no differences in cell viability or proliferation 
in HSC populations between WT and Cxcl4-/- conditions. As there is trend towards an 
increase in Ki-67+ cells in the Cxcl4-/- cells, it suggests that this experiment should be 
repeated with more animals and perhaps examining male animals. 
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Figure 5-17 Viability and cell cycle status in HSC derived from WT and Cxcl4-/- animals. 
BM cells were stained with antibodies against lineage, Sca-1, c-Kit, CD150 and CD48 and 
Annexin-V or Ki-67 and analysed using flow cytometry (LSK only for panel A). Data are 
presented as the mean percentage of Annexin-V+ (A)  cells in BM, lineage negative, LK 
and LSK cells (A) or the percentage of Ki-67+ cells in BM, lineage negative, LK, LSK and 
HSC populations (B) between strains. Statistical test carried out was a student’s unpaired t 
test assuming equal variances (B) and with Welch’s correction (A) (n.s., n = 3). Animals 
were 6-12 weeks of age and gender was the same (WT 3 females; Cxcl4-/- 3 females). 
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5.3.4.4 Cxcl4-/- BM cells show no difference in colony 
numbers compared to controls  
Colony formation primary and secondary replating assays were used to get an indication of 
whether stem/progenitor cell function is impaired in cells lacking Cxcl4. 
5.3.4.4.1 BM 
 
Results showed no difference in colony numbers in cells derived from the BM in a primary 
plating assay (n.s., n = 6) (Figure 5-18). In a secondary replating assay, results showed a 
trend towards a decrease in the Cxcl4-/- condition which was not statistically significant due 
to high variation between samples (n.s, n = 5) (Figure 5-18). 
High variation found between individual samples resulted in a lack of statistical 
significance. However, this result in combination with data obtained in section 5.3.3.2 
provides evidence to support that Cxcl4 reduction reduces colony formation capability. 
This could be due to a role of Cxcl4 in differentiation, survival or proliferation. This could 
also infer Cxcl4 plays a role in stem cell self renewal. However, the CFC assay is a more 
progenitor assay and more in depth experiments are required to confirm the role of Cxcl4 
in stem cell properties. 
5.3.4.4.2 Spleen 
 
Results showed no difference in colony numbers in cells derived from the spleen in a 
primary plating assay, however a trend towards an increase in the CFU-GM colony types 
was noted (n.s., n = 4) Figure 5-19). No difference in the CFU-E or CFU-GEMM colonies 
was found (n.s., n = 4) (Figure 5-19). When the colony types were counted collectively, a 
trend towards an increase in the number in the Cxcl4-/-condition was noted which was not 
statistically significant (n.s., n = 4) (Figure 5-19).  
The trend towards increase in the number of colonies in the spleen cells in the Cxcl4-/-
condition suggests there is increased stem/progenitor activity in the absence of Cxcl4. This 
is in accordance with the trend towards an increase reported in the frequency of LK and 
LSK populations in the Cxcl4-/-condition (Figure 5-15; Figure 5-16). However, the results 
were not statistically significant. 
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Figure 5-18 Cxcl4-/- BM cells show no difference in colony numbers in primary or secondary 
replating assays in comparison to WT cells. 
BM cells harvested from WT and Cxcl4-/- animals were cultured in Methocult™ for 10-14 
days and colonies were counted, cells harvested and plated in a secondary plating assay. 
Data are presented as the mean number of total colonies between strains in a primary (A) 
(n.s., n = 6) and secondary replating assay (B) (n.s., n = 5). Statistical test carried out was a 
student’s unpaired t test with the assumption of equal variance (A) and with Welch’s 
correction (B).  Animals were 6-12 weeks of age and gender was the same (CFC1 WT 6 
females; Cxcl4-/- 6 females; CFC2 WT 5 females; Cxcl4-/- 5 females). 
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Figure 5-19 Cxcl4-/- spleen cells show no difference in colony numbers in comparison to WT 
cells. 
Spleen cells harvested from WT and Cxcl4-/- animals were cultured in Methocult™ for 10-
14 days and colonies were counted. Data are presented as the mean number of different 
colony types (A) and total colonies between strains (B) in a primary assay. Statistical test 
carried out was a student’s two-tailed unpaired t test assuming equal variance (n.s., n = 4). 
Animals were 6-12 weeks of age and gender was the same (WT 4 females; Cxcl4-/- 4 
females). 
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5.3.4.5 WT and Cxcl4-/- show no difference in BM 
reconstitution potential 
Collectively, the results show that cells in which Cxcl4 is reduced show a reduction in 
colony formation. The gold standard technique for assaying HSC activity is the BM 
reconstitution assay. LT-HSC were isolated from WT or Cxcl4-/- BM and examined for the 
ability to engraft in a recipient with a lethally ablated BM as described previously in 
chapter 4. 
PB from irradiated recipient animals were examined for the percentages of CD45.1+ versus 
CD45.2+ cells to track engraftment as described previously in chapter 4. Furthermore, 
within the CD45.2+ fraction, the percentage of myeloid (GR1+ and CD11B+), B (CD19+) 
and T (CD4+ and CD8+) cells were examined to assess the donor contribution to 
multilineage differentiation. Due to availability of mice, different sexes were used in this 
assay. This should be noted as same sex would make the experiment more reliable. 
At up to 16 weeks post transplant, no differences in the percentage of donor cells in the PB 
was found between WT and Cxcl4-/- groups (n.s., n = 7, 6) (Figure 5-20). Panel B in Figure 
5-20 shows engraftment levels obtained in individual animals from each group and it can 
be seen that although some inter group variation exists, the means are similar.  
Within the CD45.2+ cells, the percentage of cells positive for mature cells was examined at 
16 weeks post transplant. Data showed no difference in the ability of the recipient animals 
to produce mature cell types at 16 weeks post transplant (n.s., n = 7, 6) for WT and Cxcl4-/-
conditions (Figure 5-20). The data trended towards an increase in myeloid cells and 
decrease in T cells in Cxcl4-/- derived cells, however this was not statistically significant 
and likely represents heterogeneity between samples. 
Primary recipients were sacrificed at 16 weeks post transplant and the engraftment of 
donor cells was examined in the mature cell types (myeloid, erythroid and B cells) and 
stem cells within the BM and spleen. No differences were found in the engraftment of any 
cell types in the BM or spleen between WT and Cxcl4-/-conditions (n.s., n = 7, 6).  
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In terms of the stem cell populations, no differences were found in CD45.2+ cells between 
groups in the BM (n.s., n = 7, 6). Similar results were obtained with the spleen between 
conditions (n.s., n = 7, 6).  
If Cxcl4 was regulating self renewal, the assay to conclude this is a secondary BM 
transplantation assay. In this assay, donor derived stem cells are harvested from primary 
recipients and transplanted into secondary recipients and examined for engraftment. Due to 
time constraints in this study, this experiment could not be completed. It can be seen in 
Figure 5-20 that an increase in CD45.2+ cells over 16 weeks is found in the recipients 
transplanted with WT HSC. This is as expected as it indicates that the HSC are self 
renewing over time and able to contribute to haemopoiesis. A defect in self renewal 
activity would reduce the ability of the donor cells to contribute to haemopoiesis. In the 
recipients transplanted with Cxcl4-/- HSC, an increase in CD45.2+ cells are found up to 12 
weeks. However, at the 16 week time-point, a reduction/no change in engraftment is found 
in comparison to the 12 week time-point (Figure 5-20). This could potentially represent a 
defect in self renewal which would complement the previous results, however this is not 
conclusive. To assess defects in self-renewal conclusively, engraftment in secondary 
transplantation assays needs to be assessed.  
Donor cells from animals were aged matched (6-12 weeks) but differed in sex due to 
availability (WT F, KO M). Recipient animals were age matched (6-12 weeks) and were 
gender matched but due to toxicity related deaths final analysed animals were skewed (WT 
3M, 4F; and Cxcl4-/- 1M, 5 F). This experiment should be repeated with cells derived from 
donors matched for gender. This is important in stem cell biology and there is evidence to 
support that HSC behave differently in response to gender (Nakada et al., 2014). 
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Figure 5-20 WT and Cxcl4-/  HSC-show no difference in the engraftment or multilineage 
differentiation capacity after BM transplantation.  
LT-HSC (102) were sorted from BM from WT or Cxcl4-/-animals and mixed with 2.0x105 
BM cells from mice on a CD45.1 background. Data are presented as the mean percentage 
of CD45.2+ cells in recipient mice transplanted with either WT or Cxcl4-/-HSC in the PB 
across 16 weeks (A). Each recipient animal is displayed as a single symbol on the graph at 
16 weeks post transplant to demonstrate heterogeneity in engraftment between samples 
(B). A representative flow cytometry plot is used to demonstrate engraftment between 
conditions (C). Within the CD45.2+ cells, the percentage of mature cell types was 
examined in the PB including myeloid (GR1+CD11B+), B (CD19+) and T (CD4+CD8+) 
cells (D). Antibodies against CD4 and CD8 were used in the same fluorophore therefore T 
cells are labelled as double positive cells (CD4+, CD8+ ) only. Data are presented as the 
mean percentage of mature cell types within the CD45.2 + fraction (n = 7, 6) (B). A two-
way ANOVA was used with Sidak’s multiple comparisons to compare differences between 
WT and Cxcl4-/- null animals at each time point (A). A two tailed unpaired t test was used 
to compare differences in percentage of mature cells within CD45.2+ cells between WT 
and Cxcl4-/- conditions (D). Animals were 6-12 weeks of age and mixed gender (donor WT 
2 females; Cxcl4-/- 2 males; recipient WT 3 males, 4 females; Cxcl4-/- 1 male and 5 
females). 
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Figure 5-21 WT and Cxcl4-/- show no differences in the contribution to mature, stem and 
progenitors in a BM reconstitution assay. 
LT-HSC (102) were sorted from BM from WT or Cxcl4-/-animals and mixed with 2.0x105 
BM cells from mice on a CD45.1 background. Animals were sacrificed at 16 weeks post 
transplant and examined for the percentage of CD45.2+ cells within the BM and spleen 
HSC and progenitor cell types (A-D). Data are presented as the mean percentage of 
CD45.2+ cells within each cell fraction stated (n = 7). No statistically significant 
differences were reported using a student’s unpaired t test with Welch’s correction for 
unequal variance (n.s.). Animals were 6-12 weeks of age and mixed gender (donor WT 2 
females; Cxcl4-/- 2 males; recipient WT 3 males, 4 females; Cxcl4-/- 1 male and 5 females). 
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5.3.5 CXCL4 is highly expressed on human HSC and up regulated 
on the most primitive, quiescent fraction 
To relate the mouse work to the human system, CXCL4 expression was examined on 
human HSC populations. Data from a published microarray on human HSC populations 
was shown to be inconclusive for CXCL4 expression ((Graham et al., 2007); data not 
shown). Furthermore, there was no literature to suggest CXCL4 is expressed by human 
HSC. To examine this, human HSC populations were sorted and examined for CXCL4 
expression at the mRNA and protein level. 
5.3.5.1 CXCL4 gene expression 
Primitive HSC (CD34+CD38-) and more proliferative progenitor (CD34+CD38+) fractions 
in BM and PB derived human samples were stained, sorted and examined for CXCL4 
expression. Results showed high levels of expression in the HSC populations from both 
sources, with an up regulation in the most primitive fraction (CD34+CD38-). The results 
showed a 0.03 and 0.12 fold change in CXCL4 levels in the BM and PB respectively in the 
CD34+CD38+ fraction using the CD34+CD38- fraction which was set to the value of 1 
(Figure 5-22). This suggests that CXCL4 is highly expressed in human HSC in comparison 
to progenitor populations. The CD34+CD38- HSC fraction can be further enriched for a 
purer, more primitive population. Gene expression was examined in CD34+CD38+ versus 
CD34+CD38-CD90- and CD34+CD38-CD90+ fractions. PB derived samples were used due 
to the availability of material. Results showed an up regulation in the CD34+CD38-CD90- 
and the CD34+CD38+ fraction in comparison to the CD34+CD38-CD90+ fraction which 
was set to the value of 1 (n = 3) (Figure 5-22). Collectively, the results show that CXCL4 is 
expressed in human HSC populations with highest expression in the most primitive, 
quiescent HSC fraction (CD34+CD38-CD90+). 
5.3.5.2 CXCL4 protein expression 
To ensure that the CXCL4 protein was translated, protein expression was examined using 
intracellular flow cytometry. PB derived HSC were stained to assess HSC (CD34+CD38-
CD90+) and progenitor (CD34+CD38+) fractions with the addition of a monoclonal 
antibody against CXCL4. 
Results showed that all HSC populations stained positive for CXCL4 in comparison to 
isotype control stained cells (CD34+; CD34+CD38- and CD34+CD38+). This was not in 
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accordance with the gene expression data and the flow cytometry plots suggest this is non 
specific staining due to a shift in the whole population (Figure 5-23). It is understood that 
there can be technical problems associated with chemokine antibodies using intracellular 
staining and this was not further pursued due to time constraints. Ideally western blotting 
or immunofluorescence should be used for conclusive evidence of CXCL4 protein 
expression in human HSC. 
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Figure 5-22 CXCL4 is highly expressed in human HSC with an up regulation in the more 
primitive fraction. 
BM or PB derived cells were sorted for CD34, CD38 and CD90 cell populations (500 
cells), RT and Q-PCR was carried out. Gene expression was calculated using expression 
levels of housekeeping control GAPDH and using the DeltaDeltaCT method. Data are 
presented as the mean fold change in CXCL4 expression in BM and PB derived 
CD34+CD38+ fraction using the CD34+CD38- as a calibrator set to the value of 1 (A) (*** 
P <0.001) (n = 3). Panel C displays the fold change in CXCL4 expression in the 
CD34+CD38-CD90- and CD34+CD38+ fraction using the CD34+CD38-CD90+ as a 
calibrator set to the value of 1 (C) (** P <0.01; *** P <0.001) (n = 3). Panels B and D 
show relative expression using 2-DeltaCT. Each dot represents the average of technical 
triplicates from three independent experiments. A paired t test (A) and a repeated measures 
one-way ANOVA with Dunnett’s test for multiple comparisons (C) was used to analyse 
statistical differences between the CD34+CD38-CD90+ population against the other 
populations. Patient samples used were of mixed age, gender and health status. 
  
A B 
C D 
266 
 
Figure 5-23 CXCL4 flow cytometry monoclonal antibody is not appropriate to detect CXCL4 
in human HSC. 
Human PB samples were stained with antibodies for CD34, CD38, CD90, fixed, 
permeabilised and analysed for CXCL4 expression. Data are presented as the flow 
cytometry plots for the gating strategy used for different human HSC populations (A) and 
the observed histogram for CXCL4+ expression in each population (B) (n = 1). Gates are 
set according to isotype control which correlated with unstained cells.  
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5.4 Discussion 
Collectively, the data from this chapter show that human and mouse HSC express CXCL4 
and the chemokine may play a role in stem cell properties, such as stem cell self renewal.  
The Cxcl4-Cre reporter model was previously used to study platelet biology as it was 
originally thought that Cxcl4 was expressed solely on platelets and megakaryocytes. 
However, data from this study identifies that Cxcl4 is also expressed on HSC populations 
and subsequent mature cells in haemopoiesis. The question arises, why was this not 
identified in previous studies?  Previously this model has been shown to be specific for 
platelet and megakaryocyte cells (Bertozzi et al., 2010) (Tiedt et al., 2007). However, other 
studies have shown that Cxcl4 driven reporter models show expression outside these cells 
(Chagraoui et al., 2011). It is possible that technical reasons and differences in data 
analysis are responsible for discrepancies between studies. More specifically, previous 
studies have used immunohistochemistry, while flow cytometry is thought to be more 
sensitive. Secondly, varying reporter genes have been used, such as lacZ, which possibly 
show variations in expression. As data in this chapter showed endogenous Cxcl4 
expression in HSC populations at the mRNA level, this provides further evidence that 
Cxcl4 is expressed in HSC populations. The identification that Cxcl4-Cre is expressed in 
HSC is important, not only for the study of Cxcl4 in HSC biology, but also for those who 
use the Cxcl4-Cre models. Although these models have provided invaluable data regarding 
platelet biology, any HSC phenotype, for example using these mice, may be misinterpreted 
as involving platelet and megakaryocyte biology, which may not be the case and should be 
interpreted with care. As a positive control using the Cxcl4-Cre model, platelets and 
megakaryocytes were examined for RFP expression and it was predicted these cell types 
should show maximum RFP expression. The results showed that approximately 100% of 
platelets showed RFP+ expression and approximately 50% of the megakaryocytes were 
RFP+. This is perhaps due to the presence of immature megakaryocytes which have yet to 
produce Cxcl4 and subsequently RFP expression, which has been noted in another study 
with integrin β1. In contrast, the Cxcl4-Cre transgene, although useful, has its pitfalls. 
Integration can be random therefore an active model for lineage tracing would be better.  
In addition, a proportion of RFP+ cells are noted in thymocytes which cannot be explained 
by megakaryocytes and platelets. This suggests that Cxcl4 becomes transcriptionally active 
in stem cells which then results in a proportion of positive cells in all lineages including 
thymocytes. The reason only a proportion of mature cells are RFP+ suggests that only a 
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subset of HSC switch on Cxcl4 therefore mature cell types contain a mix of both positive 
and negative cells. Indeed, HSC analysis shows not all HSC are RFP+. Again, cells which 
are marked with Cxcl4 transcription with a dynamic reporter would help address these 
questions. 
As Cxcl4 is thought to be a ‘platelet specific’ gene, it is surprising that expression was 
found in a stem cell population. In support of this, genes thought to be associated solely 
with platelet biology or other lineage specific paths have been identified to be expressed in 
stem cell populations (Pina et al., 2012). Indeed, platelets are a major source of CXCL12 
and CXCR4 (Chatterjee and Gawaz, 2013). One example to support this has been reported 
in a previous study in which another ‘platelet associated’ gene (Vwf) was noted to be 
expressed in HSC in the mouse system (Kent et al., 2009). Furthermore, this particular 
gene was noted to be highest and consistently expressed in the self renewing HSC fraction 
which supports the results and conclusions proposed in this chapter. In addition, recent 
research published in Nature by Sten Jacobsen and his group used a Vwf  driven GFP 
reporter mouse model (Sanjuan-Pla et al., 2013). Their research showed only a subset of 
HSC were positive for Vwf transcription. They have data to show that this population 
marks a mouse HSC subset primed for platelet-specific gene expression. They suggest the 
HSC hierarchy starts with platelet primed HSC at the apex. Possibly Cxcl4 is playing a 
similar role in HSC biology, however experiments will need to address this. 
Results using shRNA to knock down Cxcl4 in vitro showed a decrease in colony formation 
in cells with reduced Cxcl4 in primary plating assays, which was more exaggerated in 
secondary replating assays. This result indicates that Cxcl4 is controlling colony formation, 
but to a greater extent self-renewal. This could be supported by the experiments using 
Cxcl4-/- BM which showed a reduction of colonies in a secondary replating assay in the 
cells lacking Cxcl4 however it should be noted that this result was not statistically 
significant. It is possible that Cxcl4-/-mice are less sensitive than WT cells with Cxcl4 
reduction in vitro. Furthermore, a transgenic reporter mouse model under the promoter of 
Cxcl4-Cre showed that Cxcl4 negative cells showed decreased colony formation in a 
primary plating assay. In the secondary replate, no difference was found between 
conditions. One possibility for the discrepancy in these results is that the transgenic 
reporter model does not mark active Cxcl4 expression and only reports expression in which 
a Cxcl4 transcription was active at some point. It is possible that the cells respond to 
culture conditions and switch on or switch off Cxcl4 transcription and show skewed 
results. Therefore more conclusive evidence was obtained using Cxcl4 reduction in vitro 
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and from Cxcl4-/- cells. Possible future work will be to study a transgenic model which 
marks active Cxcl4 transcription with a reporter gene. In this way, the expression pattern of 
Cxcl4 and its activity can be traced over time. In addition, the Cxcl4-/-mice were all female 
and the transplantation assays had mixed genders. It is possible that the Cxcl4 is gender 
specific and further experiments should address this. This could be explained by the 
experiment in which Cxcl4 is reduced in vitro as these animals were male. 
The key experiment to investigate self renewal is to examine the ability of a HSC 
population to reconstitute a lethally ablated BM in a secondary transplantation assay. This 
experiment is currently under way and it is hypothesised that a decrease in engraftment 
will be noted in recipients engrafted with Cxcl4-/- HSC populations, however this was 
outside the timeframe of this study. An experiment to compliment this could use WT HSC 
transduced with Cxcl4 shRNA and the engraftment in secondary recipients should be 
examined. However, this experiment was outside the time frame in this study. 
The data in this chapter examines the role of Cxcl4 in adult haemopoiesis. It is possible 
that the chemokine may play a role in early haemopoiesis in addition to adult 
haemopoiesis, however this should be further investigated. 
The results in this chapter showed that CXCL4 is highly expressed in a primitive human 
HSC population, however the role is unclear. Data from mouse studies suggested that it 
was playing a role in self renewal and this should be examined in human studies. There is 
little literature on the expression of CXCL4 on human HSC populations. One study 
examined expression between BM, CB and G-CSF mobilised PB and noted a much higher 
expression in BM derived cells (Ng et al., 2004). Results in this chapter showed both BM 
and PB derived samples had an up regulation in expression in the CD34+CD38- fraction, 
however expression between samples was not compared. It is possible that BM derived 
cells express higher levels due to the increase in quiescence in these cells in comparison to 
PB sources. The data in this chapter investigated a more in depth analysis of Cxcl4 
expression in the stem cell compartment. Although there is little literature currently to 
suggest human HSC express CXCL4, there is evidence to support that the cells can respond 
to the chemokine. Studies have shown that recombinant CXCL4 (rCXCL4) supports the 
viability of BM cells, including the CD34+ fraction, and provides a protective effect from 
cytotoxic drugs (Han et al., 1997). Furthermore, rCXCL4 was found to increase quiescence 
in CD34+ cells in comparison to the control (Huang et al., 2000). Another study noted that 
CXCL4 enhanced the adhesion of CD34+ cells to intact stroma (Dudek et al., 2003). 
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However, self renewal has not been assessed. It is possible that cells respond to the 
chemokine and plays several functions in these cells, including promoting cell viability and 
self renewal. This also suggested that CXCL4 may be acting in an autocrine fashion, with 
evidence that human HSC express and respond to the chemokine. This is in accordance 
with data from the mouse system, in which the mouse stem/progenitor cells expressed 
CXCL4 and also responded to modulation. 
To extend this research in a possible future avenue, the mechanism of action can be 
examined. CXCL4 is a curious chemokine and in the literature it is not well understood 
which receptor it binds to or how it elicits its effects. Although there are various proposed 
mechanisms of action, currently it is unclear in the literature therefore future experiments 
are required to address this, particularly in the context of HSC properties. 
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6 Conclusion 
6.1 Concluding remarks and future work 
The haemopoietic system is an elegant hierarchical organisation in which a stem cell 
population is responsible for producing and maintaining all the mature haemopoietic cell 
types over the period of a lifetime (Weissman, 2000). The biological decisions of the HSC 
population are tightly controlled for the maintenance of the stem cell pool and the 
production of multi-lineage differentiated cells for basal haemopoiesis and when required 
in response to haemopoietic stress or injury (Passegue et al., 2005). HSC respond to 
intrinsic and extrinsic factors in the BM niche (Zon, 2008, Pietras et al., 2011, Blank et al., 
2008). The deregulation of cellular fate decisions consequently disrupts stem cell 
maintenance and subsequently results in defects in the haemopoietic system. There is 
evidence to suggest that stem cell fate decisions are deregulated in response to ageing and 
in malignant transformation, including diseases of the haemopoietic system, such as 
leukaemia (Geiger et al., 2013) (Warr et al., 2011). However to begin to understand cancer 
and cancer stem cell properties in particular, it is essential to first understand the regulation 
of normal stem cells. It is therefore fundamental that the molecular mechanisms underlying 
cellular fate decisions are well understood.  
A variety of studies have aimed to understand the molecular mechanisms of HSC cellular 
fate regulation. Studies have used a combination of data driven approaches using high-
throughput expression studies and hypothesis driven research for the identification of novel 
candidates in the regulation of HSC fate. One of these studies compared the global gene 
expression profile between quiescent and proliferating HSC populations through a 
microarray that aimed to identify novel transcriptional targets that may be key to HSC 
regulation (Graham et al., 2007). However, the nature of a microarray alone does not allow 
for interpretation of the biological role of these chemokine ligands within the haemopoietic 
hierarchy. Therefore, it was aimed to expand current knowledge that is critical to the 
current understanding of HSC fate regulation. The aim of this present study was to validate 
findings from the study conducted by Graham et al. as well as focus on the biological role 
of CXC chemokines within haemopoiesis, including cell cycle regulation. In this 
conclusion chapter, the results obtained from this study are discussed in accordance with 
previous literature and possible future avenues for research are proposed. 
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6.1.1 High-throughput screening as a tool to identify novel 
candidates in biological processes 
The genes examined in this study were identified from a microarray screen comparing 
gene expression in quiescent (G0) and dividing (G1, G2, S and M) normal HSC populations 
(Graham et al., 2007). This highlights the advantages of using a high-throughput approach 
to identify novel candidates in biological processes. Systems biology is a field of study 
which combines biology with informatics in an aim to understand complex interactions 
within biological systems. Systems biology has emerged over the past several years as a 
novel high-throughput approach to compare expression patterns between different cell 
populations which has aided biological and biomedical research (Soon et al., 2013). 
Systems biology approaches allow global expression patterns to be compared between 
different cell populations at the epigenetic, genetic, protein and phospho-protein levels. 
This approach allows a data driven method which has the ability to identify several 
differentially regulated components in a variety of cellular processes. This can be applied 
to studying genes involved in biological processes, such as HSC cellular fates or disease 
populations. Furthermore, analysis can identify candidates for further study that can prove 
useful for drug discovery research. In terms of stem cell biology, these techniques have 
allowed us to increase our understanding of the biological system.  
Various studies have employed this approach to examine the differential expression 
between HSC populations. However, only one previous study to date has identified 
CXCR2 signalling in this context. This is likely due to differences in samples used, method 
of cell isolation, culture conditions, data acquisition and the informatics analysis. This 
highlights an important issue in which although high-throughput screening has increased 
our understanding, there are disadvantages involved.  The main limiting factors are 
expense and the need for large amounts of material for screens which is sometimes not 
possible when studying rare populations, including stem cell populations. Importantly, the 
expression data obtained is combined with bioinformatics analysis and there are several 
different approaches in the analysis step (Slonim, 2002). Consequently, it is possible that 
significant and biologically relevant candidates are neglected due to the particular 
threshold values used in the analysis step or even due to technical problems with the assay. 
As an example, in this study the chemokine CXCL4 was investigated due to its structural 
similarity to the candidates identified from the screen and from unpublished data and 
evidence in the literature. However, CXCL4 was not originally identified as differentially 
expressed between quiescent and proliferating normal human HSC in the original 
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microarray.  On the contrary, it is understood that there is a high level of ‘noise’ obtained 
from global expression studies, leading to the identification of candidates which are not 
biologically significant. Therefore, it is crucial for candidates to be validated after the array 
step. Collectively these points highlight that there is the need for data driven expression 
data in combination with hypothesis driven research approaches. This includes the use of 
appropriate bioinformatics analysis, a comprehensive review of the literature and most 
importantly experimental validation. 
6.1.2 The role of CXCR2 signalling in HSC properties 
The aim of this study was to extend previous research with the main question addressing  
what is the biological role of particular CXC chemokines in terms of HSC properties? 
Importantly, the current study corroborated the microarray data from the Graham et al, 
study to show that CXCL1 and its receptor CXCR2 are expressed by human HSC 
populations. Furthermore through inhibition experiments, the current study demonstrated 
that CXCL1 and CXCR2 may play a pro survival role in human HSC. However, it is 
important that these experiments are repeated to obtain an appropriate number of biological 
replicates so that proper conclusions can be made. In addition, as discussed in section 3.3.2 
further experiments are required to conclude that human HSC express CXCL1 due to 
technical issues with antibodies. 
CXCR2 is a promiscuous receptor, which is capable of binding several ligands, which are 
structurally very similar, thus suggesting redundancy between them (Rossi and Zlotnik, 
2000). It was therefore surprising that one key ligand for the receptor showed such a 
dramatic effect on the viability of HSC, considering several other ligands for the receptor 
were also found to be expressed on HSC. However, the results obtained in this study were 
supported by evidence in the literature which shows that although CXCR2 ligands share 
similar roles in some processes, in other processes, such as autocrine driven viability and 
proliferation, CXCL1 and CXCR2 pathways play clearly distinct roles. This has been 
reported in various cell types, including oligodendrocyte precursor cells and epithelial 
ovarian carcinoma cells (Bolitho et al., 2010, Filipovic and Zecevic, 2008, Botton et al., 
2011, Tsai et al., 2002). To extend this research, future experiments should validate this 
research. In addition, experiments to extend this research might examine the mechanism of 
action with examination of signalling pathways involved. Experiments from other cell 
types implicate the involvement of ERK1/2 and epidermal growth factor (EGF) in CXCR2 
signalling (Miyake et al., 2013). These have been shown to influence cell proliferation in 
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human ES cells and could therefore be potential candidate pathways to explore (Schuldiner 
et al., 2000). It is not surprising that a pro survival signalling pathway is expressed in 
normal HSC and up regulated in the quiescent sub population as stem cells are designed to 
be robust and viable in order to protect the haemopoietic system. Indeed, this is supported 
by the evidence that a variety of pro survival genes and pathways are up regulated in the 
most primitive HSC population. Survival is an important feature of HSC as the balance of 
survival and programmed cell death in the HSC population is tightly regulated to control 
the numbers of the stem cell pool (Wagers et al., 2002). 
For experimental research, it should be considered that HSC do not exist in isolation in 
vivo, they reside in the BM where complex signalling occurs, with both intrinsic and 
extrinsic factors involving several diverse cell types. Examining human signalling 
pathways in vitro gives a good indication of human function. However, in vivo assays can 
add the advantage of examining the HSC population in the presence of complex signalling 
in the niche. This is important to this particular study as there is evidence that other cell 
types in the niche can contribute to determining HSC cell fate (Yin and Li, 2006). To 
extend the human research in this study, possible future experiments could examine the 
CXCL1 and CXCR2 interaction on human HSC in the context of the niche. Several 
approaches to modelling the niche interaction have been developed which could be used. 
Furthermore, human HSC could be transduced with plasmids to inhibit CXCL1 or CXCR2 
expression and the effect in vivo observed using BM transplantation assays. 
The majority of experiments examining stem cell function have used mouse models. The 
advantages are the availability of more material and more elegant in vivo models of HSC 
function. The availability of a Cxcr2-/- mouse model allowed the human work to be 
strengthened and to give a more in depth analysis of the role of this signalling pathway in 
HSC biological properties in vivo.  
Briefly, the results in this study show that Cxcr2-/- animals exhibit extramedullary 
haemopoiesis amd an expansion of viable LT-HSC in the BM. The data indicates Cxcr2-/- 
HSC may display a reduced ability of LT-HSC to engraft the BM of an irradiated host. 
However, this result needs to be repeated due to variation between replicates.  
To strengthen these results, in addition to repetition of the experiments in this thesis, future 
work could examine which cell types Cxcr2 expressing HSC signal to. From the results in 
this thesis it is therefore currently unclear in the animal system which ligands are involved 
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in Cxcr2 signalling and in addition, which cell types are expressing these ligands. One 
possibility is that CXCR2 binding ligands are expressed by the HSC which were not 
examined in this study. A well-studied chemokine signalling pathway in haemopoiesis is 
CXCR4 and ligand CXCL12, which involves signalling between the HSC and stromal 
cells (Sugiyama et al., 2006). There is literature to show that CXCR2 ligands are expressed 
by cell types residing in the BM niche, including EC and the possibility of a HSC/stromal 
cell interaction is also possible (Miyake et al., 2013). Alternatively, it is possible that 
CXCR2 ligands are expressed by a more proliferative progenitor population which signals 
to LT-HSC. Figure 6-1 highlights possibilities of how CXCR2 signalling is mediated in the 
mouse system which future experiments can assess. 
For future research, it will be essential to repeat the transplantation experiments with the 
adidition of serial transplantation assays. If repetition shows that Cxcr2 expressing HSC 
show a disadvantage in transplantation ability in comparison to the WT controls, 
experiments should aim to test why. Two hypotheses are proposed from this result in 
which either the Cxcr2-/- HSC exhaust faster than the WT cells, subsequently losing 
reconstitution potential, or alternatively the Cxcr2-/- HSC have a defect in migration and 
cannot home to the BM for engraftment. If we first consider the first hypothesis that the 
Cxcr2-/- HSC are exhausting faster than the control counterparts. The tight regulation of 
self renewal and multilineage differentiation is responsible for the maintenance of 
haemopoiesis and deregulation in these properties can result in stem cell exhaustion. Cell 
cycle blocking can inhibit self renewal and in contrast, cell cycle activation can lead to 
stem cell exhaustion which has been elegantly shown using manipulation of these 
properties (Yoshida et al., 2008). Deregulation of key self renewal genes results in the 
activation of cell cycle and consequently results in stem cell exhaustion and therefore 
reconstitution potential. Future work to further examine this should analyse the cell cycle 
status of WT and Cxcr2-/- HSC populations. Analysis ex vivo shows that there is no 
difference in proliferation as measured using Ki-67 staining in HSC populations between 
Cxcr2-/- cohorts and their control counterparts. However, possible future experiments to 
conclude this involve in vivo cell cycle assays, including the treatment and subsequent 
analysis of Brd-U to track proliferation of the cells in vivo or administrating 5-FU that will 
introduce stress to the system, which can be analysed between strains. In addition, to 
compare the self renewal capacity between Cxcr2-/- HSC and their WT counterparts, 
secondary transplantations can be examined and these experiments are currently underway. 
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In contrast, Cxcr2 is well-studied for its effects on cellular migration and there is evidence 
to support this hypothesis in the HSC system. The Cxcr2-/- mouse model shows the 
presence of circulating HSC in the periphery and enhanced numbers of HSC in the spleen. 
Furthermore, CXCR2 binding ligands have been identified as factors which, when added 
exogenously to mice, results in mobilisation (Pelus and Fukuda, 2006). In addition, G-CSF 
treatment, which also leads to HSC mobilisation, has been shown to modulate the 
expression of Cxcl1 and Cxcl2 in the BM niche (Pelus, 2008). Future work should examine 
the ability of HSC from WT and Cxcr2-/- HSC to home to the BM immediately post 
injection into irradiated hosts which will address this hypothesis.  
 
 
Figure 6-1 Potential mechanisms of CXCR2 signalling within mouse BM. 
The schematic diagram illustrates potential mechanisms mediating CXCR2 signalling in 
mouse HSC. It is unknown from experiments in this thesis how CXCR2 ligands are 
binding to the receptor and which cell types are involved are in the mouse system. It is 
possible that an autocrine loop exists with ligands (panel A). Alternatively, paracrine 
signalling could be involved with ligands expressed by more mature progenitor cells or 
mature cells within the BM niche including EC (panel B). 
6.1.3 The role of CXCL4 signalling in HSC properties 
A key gene identified in this study as important in HSC regulation is CXCL4. The current 
study shows that CXCL4 is expressed by both human and mouse primitive HSC 
populations. Furthermore, experiments using transgenic mouse models in combination 
with knock down, collectively identifies CXCL4 alters stem cell colony formation ability 
and indicate CXCL4 may play a role in stem cell properties. The observation that CXCL4 
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is up regulated in the most primitive fraction of human HSC supports this hypothesis as it 
is predicted a key stem cell gene would be highly expressed in this HSC population. The 
results are fortified by evidence in the literature in which human CD34+ cells have been 
shown to respond to exogenous CXCL4 with effects on cell viability, adhesion and stem 
cell expansion (Dudek et al., 2003, Lu et al., 2003, Li et al., 2006, Han et al., 1997). 
Importantly, the expression of CXCL4 on human and mouse HSC and its role in stem cell 
properties are novel. One possibility is that CXCL4 is involved in self renewal. HSC self 
renewal is a fundamental process of HSC and to date a variety of self renewal genes have 
been identified (Zon, 2008). However, there is still much left to be discovered in this field 
and the results in this study identify a novel gene involved in the process of self renewal. 
However, as discussed in chapter 5, serial BM transplantations are required to confirm this 
result and cannot be concluded with the results in this thesis. 
CXCL4 was originally thought of as a lineage specific gene. A variety of studies have 
identified this gene as expressed solely on megakaryocytes and platelets, however the 
current study identifies that this gene is expressed by HSC populations. This finding is 
corroborated by emerging literature that suggests that genes associated with lineage 
commitment, in particular megakaryocyte/platelet expression, are expressed by HSC and 
involved in biological roles. An example of this is Vwf  which shows expression in self 
renewing mouse HSC populations (Kent et al., 2009). Alternatively, it is possible that 
CXCL4 is active in a population of HSC which are destined for a particular lineage, 
however this would require future investigation.  
As a possible avenue for future research, the mechanism of action of CXCL4 activity is 
currently not well understood in the literature and could be investigated (Kasper and 
Petersen, 2011). As the results show HSC express CXCL4 and modulation of the protein 
demonstrates a phenotype in vitro, this suggests the signalling is occurring in an autocrine 
manner. However, CXCL4 signalling is complex and not standard as exhibited by the other 
structurally similar chemokine ligands with ‘classical’ GPCR signalling (Rossi and 
Zlotnik, 2000). As detailed in the introduction, CXCL4 signalling is complicated. 
Expression of CXCR3B to date is not known on human/mouse HSC and could be a 
possible avenue of future work. Similarly, it is possible CXCL4 is functioning through 
binding to integrin receptors which have indeed been shown to be important for HSC 
behaviour (Yin and Li, 2006). Additionally, CXCL4 can heterodimerise with other 
chemokine ligands (Slungaard, 2005). In the context of HSC, an interesting study has 
observed the ability of CXCL4 to adhere and bind to CD34+ cells through binding of 
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CXCL8 and with a CD34+ chondroitin sulphate-containing moiety (Dudek et al., 2003). 
This would suggest a link between CXCL4 and CXCR2 in HSC biology. Furthermore, 
CXCL4 can bind GAG which may also transducer the signal. I think that understanding the 
mechanism of action of CXCL4 signalling in stem cells is particularly important and 
requires further examination. Figure 6-2 demonstrates possible mechanisms of CXCL4 
signalling which can be studied further in future research. Understanding the mechanism of 
action will not only be important for furthering our understanding of haemopoiesis, but 
also for the other roles of the protein, including in megakaryocytic/platelet research.  
 
 
Figure 6-2 Potential signalling mechanisms for CXCL4. 
The schematic diagram illustrates potential mechanisms mediating CXCL4 signalling in 
human and mouse HSC. It is unknown from experiments in this thesis how CXCL4 
mediates its effects. It is possible that an autocrine loop exists with ligands including 
CXCR3B, integrin receptors or GAG (panels A and C). Alternatively, CXCL4 could elicit 
its effects through binding other ligands such as CXCL8 (panel B). 
Finally, in this thesis we have identified a role for CXCL4 in mouse HSC biology. Gene 
expression analyses have shown that this ligand is expressed by human HSC and indeed is 
up regulated in the most primitive subsets. This would infer that CXCL4 is important for 
stem cell behaviour in human HSC. However, due to time constraints, an investigation into 
the function in human HSC could not be carried out. Future experiments could use 
inhibitors or shRNA plasmids to block/reduce CXCL4 signalling and examine the 
phenotype in human HSC. 
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6.1.4 Understanding normal HSC regulation can be applied to 
studying disease models 
Currently, HSC cellular fates are not well understood and understanding this process in 
normal HSC is essential before understanding how the process is deregulated in response 
to disease. Global gene expression studies have been used as an approach for investigating 
the differences between normal and cancer cells. This approach has provided a starting 
point for many important discoveries for potential future therapies. A well understood 
chemokine signalling pathway in HSC biology is CXCR4 and CXCL12, which is shown to 
exhibit roles in normal HSC, but also is deregulated in leukaemia.  Based on experimental 
data, research is examining the therapeutic advantage of CXCR4 inhibitors in cancer 
(Burger and Burkle, 2007). The modulation of chemokine signalling can therefore 
represent a novel therapy in haematological malignancies. 
The role of chemokines in malignancies was described in the introduction section. 
Although the role of CXC chemokines in haematological malignancies was outside the 
scope of this particular study, the previously published microarray was used to compare 
normal dividing and proliferating HSC, but also to examine transcriptional differences 
between normal and leukaemic HSC populations (Graham et al., 2007). This was carried 
out using CML patient samples which were analysed in comparison to normal HSC 
populations. Briefly, CML is a disease in which the HSC compartment is transformed with 
a fusion oncogene (BCR-ABL) which allows the HSC to show deregulated cell fate, 
including increased survival and proliferation, which are responsible for the disease 
pathogenesis (Calabretta and Perrotti, 2004, Sawyers, 1999, Rowley, 1973) (panel A, 
Figure 6-3). CML therefore represents an ideal model in which the leukemic HSC are 
responsible for the pathogenesis of the disease and therefore should be targeted for the 
eradication of the disease. Indeed, studies have shown that it is the HSC fraction that is less 
sensitive to standard therapy both in vitro and in vivo and which consequently prevents the 
eradication of the disease (Jiang et al., 2007, Holtz et al., 2002, Bhatia et al., 2003, Graham 
et al., 2002). It is therefore fundamental that we understand how these leukaemic stem cells 
(LSC) are deregulated for future novel candidates for therapy to be identified. Informatic 
analyses were used to show that chemokine ligands were down regulated in quiescent 
leukaemic HSC in comparison to normal counterparts (Graham et al., 2007) (panel B, 
Figure 6-3). The data from this study suggests CXCL1/CXCR2 and CXCL4 signalling is a 
pro survival pathway in human HSC, therefore it is surprising that this would be down 
regulated in leukaemia. LSC are known to up regulate survival pathways in comparison to 
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their normal counterparts. However, this was not further examined in this study. Results 
from an unpublished study indicate that CML LSC up regulate chemokine ligands after 
treatment with standard therapy drugs, therefore it can be speculated that these genes may 
indeed play a role in the survival of LSC (unpublished data) (panel C, Figure 6-3). In 
addition, the data from the microarray identified that chemokine ligands were expressed at 
higher levels in quiescent CML cells in comparison to proliferating cells. The 
identification of genes up regulated in quiescent CML LSC is important as this population 
is less sensitive to current therapy (panel D, Figure 6-3). 
 
Figure 6-3 CXC chemokines are deregulated in CML and may provide a novel therapy. 
CML occurs due to mutation resulting in the juxtaposition of BCR and ABL genes in a 
novel chromosome. The result of this mutation in a stem cell population results in the 
generation of a LSC and the pathogenesis of the disease (A). A previously published 
microarray identified that chemokines (CXCL1, CXCL2 and CXCL6) are up regulated in 
CML G0 versus dividing, however expression is down regulated in CML G0 in comparison 
to normal G0 (B). Interestingly, treatment of LSC with standard therapy has been shown to 
increase chemokine expression (C). It is possible that this is due to up regulation of this 
chemokine as a survival pathway. Consequently, inhibition of chemokine signalling may 
represent a novel future therapy (D).  
Interestingly, both CXCL1 and CXCR2 have been implicated in playing a biological role 
in diseases, including solid tumours. Tumours in a preclinical lung cancer model have been 
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noted to be decreased on a Cxcr2-/- background (Keane et al., 2004). Similar results have 
been obtained for CXCR2 in prostate and breast cancer models (Waugh and Wilson, 2008, 
Snoussi et al., 2010). In terms of a possible mechanism, previous research suggests 
primary MSC express CXCR2 and facilitate the metastasis of mammary cancer cells to the 
BM (Halpern et al., 2011). Furthermore, CXCL1 has also been identified to play a role in 
promoting tumourigenesis, tumour migration and angiogenesis (Dhawan and Richmond, 
2002, Halpern et al., 2011). Based on the abundance of the literature, CXCR2 inhibitors 
have emerged as a useful pharmaceutical target. In contrast, there is also evidence that 
CXCR2 signalling is involved in tumour prevention with evidence to show that CXCR2 
ligands, including CXCL1, are involved in the recruitment of immune cells to clear tumour 
cells (Acosta and Gil, 2009). Future research could examine whether CXCL1 and CXCR2 
is a survival pathway in CML HSC. 
Focusing on CXCL4, a previous study shows that CXCL4 can inhibit tumour growth 
(Vandercappellen et al., 2011). Although there is little literature available on CXCL4 in 
leukaemia, a recent study notes that the gene is expressed in murine HSC populations in a 
CML model (Zhang et al., 2012). Furthermore, CXCL4 expression is reported to be 
modulated in the absence of hypoxia gene HIF1a, which has previously been shown to 
mediate cellular responses to hypoxia within the BM niche and is essential for HSC 
maintenance (Miyamoto et al., 2007, Kranc et al., 2009, Takubo et al., 2010, Zhang et al., 
2012). Hypoxia related genes have also been implicated in haemopoietic malignancies 
therefore are an important avenue for leukaemia research. As an example, in human AML, 
targeting HIF genes compromises AML functions, implicating these genes in future 
therapies and HIF genes have been shown to be essential in CML (Zhang et al., 2012, 
Wang et al., 2011). In addition, CXCL4 has been shown to regulate adhesion of both 
normal and leukaemic HSC to EC (Zhang et al., 2004). Therefore, CXCL4 in normal HSC 
biology and leukaemia may be interesting for further pursuit. Furthermore, experiments in 
this thesis show that CXCL4 is expressed in mouse HSC which was validated using Cxcl4-
Cre. As discussed in chapter 5, this therefore raises concerns in studies using this model 
for megakaryocyte/platelet biology. This observation also opens up new possibilities for 
the use of this mouse model in haemopoietic studies including disease. Cxcl4-Cre can 
therefore be used in combination with other mouse strains to examine disease. As an 
example, experiments using Cxcl4-Cre coupled to inhibition/activation of β-catenin have 
shown this drives a myelofibrosis phenotype (data not shown).  
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A possible future avenue to extend the research in this study would be to explore the 
biological roles of CXCL1/CXCR2 and CXCL4 signalling in disease models, including 
leukaemia, however this was not within the scope of this study. Possible future 
experiments should examine expression and function of these genes and pathways in 
leukaemic HSC in comparison to normal HSC. Several mouse models of CML are 
currently available and could provide insight into whether these chemokines play a role in 
leukaemia initiation and maintenance and could provide a novel therapy (Koschmieder and 
Schemionek, 2011). Future experiments could examine disease initiation and maintenance 
in animals lacking Cxcr2 or Cxcl4. Animals on a Cxcr2-/- or Cxcl4-/- background could be 
crossed with animal models of CML or alternatively, BCR-ABL+ cells can be generated 
using retroviral transduction which can be transplanted into Cxcr2-/- or Cxcl4-/- hosts. 
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7 Supplementary 
7.1 Western blotting images 
Original western blot images from the following figures are shown below (Figure 3-4, 
Figure 3-7 and Figure 3-10). Images can be found in Figure 7-2, Figure 7-4 and Figure 7-4 
respectively. In addition, a western blot image of human rCXCL1 is displayed (Figure 
7-1). Original, full blots are provided with an overlay of the molecular weight marker with 
sizes of bands. 
 
 
Figure 7-1 Raw western blot image of human rCXCL1. 
Raw image of western blot with human rCXCL1 protein which has been run on a 15% gel. 
L = molecular marker ladder. 1 = rCXCL1. Approximate sizes of the marker are shown on 
the left of the image in kD. Three bands were found with the protein at ~8kD, ~12kD and 
~16kD. 
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Figure 7-2 Raw western blot image for primary human cells sorted for CD34+CD38- and 
CD34+CD38+ populations. 
Raw image of western blot with human primary CD34+ cells which has been run on a 15% 
gel. L = molecular marker ladder, 1 = PB CD34+CD38+, 2 = PB CD34+CD38-, 3 = BM 
CD34+CD38+, 4 = BM CD34+CD38- with both CXCL1 and β-Tubulin antibodies. 
Approximate sizes of the marker are shown on the right of the image (kD). Several bands 
were found with the CXCL1 antibody with the most prominent at ~16kD. A single band 
was found in the housekeeping control at the estimated size of 50kD. 
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Figure 7-3 Raw western blot image for HT1080 cells transduced with plasmids to reduce 
CXCL1 or control.  
Raw image of western blot with HT1080 cells which have been transduced with plamids to 
knock down CXCL1 (sh) or the control (Scr). The gel has been run on a 15% gel. L = 
molecular marker ladder, 1 = unstransduced, 2 = Scr, 3 = sh1, 4 = sh2, 5 = sh3, 6 = sh4 and 
7 = sh5 with CXCL1 antibody (A) and β-Tubulin (B) antibodies. Approximate sizes of the 
marker are shown on the left of each panel (kD). Several bands were found with the 
CXCL1 antibody with the most prominent at ~16kD. A single band was found in the 
housekeeping control at the estimated size of 50kD. 
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Figure 7-4 Raw western blot image for HT1080 cells transduced with empty vector or CXCL1 
over expression vector. 
Raw image of western blot with human HT1080 cell lines which has been run on a 15% 
gel. L = molecular marker ladder, 1 = Empty Vector, 2 = CXCL1-PRRL with CXCL1 
antibody (A) or β-Tubulin antibody (B). Approximate sizes of the marker are shown on the 
left of each panel (kD). Several bands were found with the CXCL1 antibody with the most 
prominent at ~16kD (A). A single band was found in the housekeeping control at the 
estimated size of 50kD (B). 
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